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Background: The purpose of this study was to compare centralized reimbursement/coverage 
decision-making processes for health technologies in 23 European countries, according to: 
mandate, authority, structure, and policy options; mechanisms for identifying, selecting, and 
evaluating technologies; clinical and economic evidence expectations; committee composition, 
procedures, and factors considered; available conditional reimbursement options for promising 
new technologies; and the manufacturers’ roles in the process.
Methods: A comprehensive review of publicly available information from peer-reviewed 
literature (using a variety of bibliographic databases) and gray literature (eg, working papers, 
committee reports, presentations, and government documents) was conducted. Policy experts 
in each of the 23 countries were also contacted. All information collected was reviewed by two 
independent researchers.
Results: Most European countries have established centralized reimbursement systems for 
making decisions on health technologies. However, the scope of technologies considered, as 
well as processes for identifying, selecting, and reviewing them varies. All systems include an 
assessment of clinical evidence, compiled in accordance with their own guidelines or interna-
tionally recognized published ones. In addition, most systems require an economic evaluation. 
The quality of such information is typically assessed by content and methodological experts. 
Committees responsible for formulating recommendations or decisions are multidisciplinary. 
While criteria used by committees appear transparent, how they are operationalized during 
deliberations remains unclear. Increasingly, reimbursement systems are expressing interest in 
and/or implementing reimbursement policy options that extend beyond the traditional “yes,” 
“no,” or “yes with restrictions” options. Such options typically require greater involvement of 
manufacturers which, to date, has been limited.
Conclusion: Centralized reimbursement systems have become an important policy tool in many 
European countries. Nevertheless, there remains a lack of transparency around critical elements, 
such as how multiple factors or criteria are weighed during committee deliberations.
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Introduction
The past decade has seen unprecedented growth in the number of new, often high-cost, 
health technologies and consumer demand for access to them. It has also seen increased 
public awareness and scrutiny of decisions about which technologies to include in the 
basket of publicly insured services.1–3 To improve the legitimacy of such decisions 
and optimize health outcomes through the effective use of increasingly strained health 
care resources, many payers, particularly those in Europe, have established central-
ized systems for determining the reimbursement status of new health technologies.4,5 ClinicoEconomics and Outcomes Research 2011:3 submit your manuscript | www.dovepress.com
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In this invited review, we compare these systems across 
selected countries in Northern, Southern, Western, Eastern, 
and Central Europe, examining:
•	 Their mandate, authority, organizational structure, and 
policy options
•	 Mechanisms for identifying, selecting, and evaluating 
technologies
•	 Clinical and economic evidence expectations
•	 Review committee composition, procedures, and key 
factors considered during deliberations
•	 Use of conditional reimbursement options for enabling 
access to promising new technologies around which con-
siderable uncertainty related to clinical and/or economic 
value exists
•	 The role of manufacturers in steps comprising the reim-
bursement review process.
Methods
This review is based upon findings from a comprehensive 
search for publicly available information on centralized 
reimbursement systems in selected European countries. 
Peer-reviewed literature published in English over the 
past decade (ending in January 2011) was located using a 
structured search strategy that combined relevant controlled 
vocabulary terms, ie, MeSH and EMTREE (eg, “technology, 
medical,” “reimbursement mechanisms,” “decision-making,” 
“technology assessment,” “health policy”) and free text 
terms (eg, “pharmaceuticals,” “medical devices,” “cover-
age,” “funding,” “centralized review,” “health technology 
assessment,” and “reimbursement,” the full search strategy 
being available from the authors). Such terms were identi-
fied through an analysis of words used to index references 
familiar to the authors. The strategy was applied to several 
health-related electronic bibliographic databases, including 
PubMed, MEDLINE, EMBASE, HealthSTAR, CINAHL, 
EconLit, PASCAL, SCOPUS, International Pharmaceutical 
Abstracts, Web of Science, and the UK Centre for Reviews 
and Dissemination databases (Database of Abstracts of 
Reviews of Effects, National Health Service Economic 
Evaluation Database, and Health Technology Assessment). 
For comprehensiveness, reference lists of retrieved papers 
and the most recent issues of health policy-related journals 
were hand-searched.
A search for gray (unpublished) literature (eg, work-
ing papers, conference abstracts, reports, presentations, 
  government documents) was also performed using the 
Google® search engine and terms from the main search 
strategy. In addition, the following dedicated gray   literature 
databases were scanned: the New York Academy of 
  Medicine’s Gray Literature database, Knowledge Utiliza-
tion database,   Systematic Reviews for Management and 
Policy Making, and National Health Service Evidence in 
Health and Social Care. Separate searches for information 
on centralized reimbursement processes within health care 
systems of the top 30 European countries ranked accord-
ing to gross domestic product per capita by the World 
Bank were also conducted. This number was considered 
sufficient to capture the full spectrum of such processes. 
For each country, the websites of relevant ministries (eg, 
health, social affairs, economics), translated into English 
with Google Translate®, were scanned for documents 
describing legislation and other policies and processes 
for making reimbursement decisions on new health tech-
nologies, including pharmaceuticals, medical devices, 
diagnostic tests, and procedures.
Documents retrieved from the various searches were 
reviewed independently by two of the authors. Published 
papers unrelated to the introduction of individual health 
technologies (eg, those on macrolevel priority setting) were 
excluded. Because the purpose of this review was to examine 
current actual processes, papers proposing specific decision-
making tools or discussing one component of decision-
making were also excluded. Information on process-related 
characteristics of the centralized reimbursement systems, 
including perceived strengths and weaknesses, was extracted 
using a standardized, pretested data abstraction form. To 
ensure it reflected the current policy environment, the fol-
lowing individuals were consulted: corresponding authors of 
published papers, contacts listed on organizations’ websites, 
and European policy experts with whom the authors were 
already acquainted.
Extracted information was tabulated to facilitate the 
identification of patterns or trends across country-specific 
reimbursement processes, and subsequently analyzed 
qualitatively using content analysis and constant comparison 
techniques.
Results
Of the 30 European countries initially identified for the 
review, information on centralized reimbursement processes 
could only be found for 23. Therefore, the review included the 
following 23 countries: Austria, Belgium, Czech Republic, 
Denmark, Estonia, Finland, France, Germany, Greece, 
Hungary, Ireland, Italy, Norway, Poland, Portugal, Scotland, 
Slovakia, Spain, Sweden, Switzerland, the Netherlands, the 
United Kingdom, and Wales.ClinicoEconomics and Outcomes Research 2011:3 submit your manuscript | www.dovepress.com
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Mandate of centralized reimbursement 
systems
The majority (18/23) of countries have established central-
ized reimbursement processes to support coverage decision-
making for either pharmaceuticals or pharmaceuticals and 
devices needed for their delivery. In general, eligible phar-
maceuticals comprise those requiring a prescription. Two-
thirds of such processes review both inpatient and outpatient 
pharmaceuticals (12/18), while one-third (6/18) considers 
those administered in outpatient settings only (Table 1). 
The remaining five countries have invested in centralized 
reimbursement systems that span medical devices, proce-
dures, and pharmaceuticals (Table 1). Despite differences 
in the scope of technologies included, such processes share 
a similar mandate to determine the reimbursement status of 
new technologies. In most of the countries, this amounts to 
a decision on whether to add the technology to a “positive 
list” (ie, list of insured services). However, a small propor-
tion of the countries also maintain a “negative list” (ie, a 
list of nonreimbursable services), broadening the mandate 
of their centralized reimbursement systems to include deci-
sions resulting in active exclusion of some technologies 
from the benefit plan (Table 1). In legislation governing 
most systems (13/23), decisions are authoritative (ie, must be 
implemented), rather than advisory (ie,   recommendations). 
Given that the price of a technology can significantly influ-
ence assessments of value for money and affordability, 
many of the countries have also incorporated pricing into 
the mandates of such systems (discussed in detail later). 
Finally, all consider at least three funding decision options, 
ie, provide, do not provide, and provide with restrictions or 
conditions (ie, restrict use to specific providers or patients 
meeting certain criteria, Table 1). In addition, approximately 
one-third have introduced a fourth option, ie, provide while 
additional evidence is collected. The latter comprises a 
provisional funding arrangement in which the technology is 
reimbursed in the interim while information needed to reduce 
uncertainties in existing evidence is collected to support a 
definitive decision.
Assessment of health technologies  
in centralized reimbursement systems
Approaches to the identification of technologies for review 
by centralized reimbursement systems vary across countries 
(Table 2). Broadly, there are three strategies: technologies 
may be submitted by manufacturers seeking coverage for 
newly licensed pharmaceuticals (13/23); they may be referred 
by potential payers (eg, government, sickness funds) or users 
(eg, hospitals, providers, patients), as well as manufacturers 
(8/23); or they may be identified by payers or users only 
(2/23). Systems limited to consideration of reimbursement 
applications from manufacturers alone typically review sub-
missions in order of receipt, unless a technology is eligible 
for “fast tracking,” which moves it to the front of the queue. 
In countries with such mechanisms (eg, the Netherlands), 
eligibility criteria include technologies (mainly pharma-
ceuticals) used to treat rare or life-threatening conditions 
for which no alternatives beyond best supportive care exist. 
Some countries (eg, Scotland and Norway) have more closely 
linked centralized regulatory and reimbursement processes 
in order to reduce overall inefficiencies in technology policy. 
Specifically, pharmaceuticals are automatically sent to the 
centralized reimbursement system for review upon market 
approval. In systems that accept referrals from multiple 
stakeholders, technology selection and/or prioritization cri-
teria have been established. For example, Germany’s Federal 
Joint Committee, which determines which technologies to 
review, takes into account clinical relevance, cost implica-
tions, and potential “risks” related to the technology and its 
introduction into the health care system.6 In the UK, the topic 
selection panel of the National Institute of Health and Clinical 
Excellence, whose members include health care providers 
and patient representatives, formulate recommendations fol-
lowing consideration of: the burden of disease for which the 
technology targets; anticipated clinical impact (ie, whether 
the technology represents a significant medical advance that 
could yield substantial health benefits); potential impact on 
National Health Service costs and resources; alignment of 
the technology with broader government priority areas; con-
cerns over appropriateness of use in practice; and potential 
for national guidance to add value.7 Recommendations are 
forwarded to the Department of Health, which makes the 
final decision.
Across centralized reimbursement systems, technology 
identification and selection is followed by some form of 
health technology assessment (Table 2). This involves col-
lection and synthesis of evidence (clinical and, in most cases, 
economic), the findings of which are presented in an assess-
ment report, and critical appraisal of the relevance, quality, 
and generalizability of that evidence. The results of the latter 
are summarized in an evaluation report.   Responsibility for 
the preparation of these reports varies. In systems where 
a manufacturer’s submission initiates the reimbursement 
review process, the assessment report is part of the sub-
mission (Table 2). Therefore, its preparation rests with the ClinicoEconomics and Outcomes Research 2011:3 submit your manuscript | www.dovepress.com
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Table 1 Centralized reimbursement system and mandate
Country Centralized reimbursement  
review/decision-making body (role)
Technology scope Decision problem Decision “scope” Available decision options
Reimbursement Linkage to pricing Provide Do not provide Provide with restrictions Provide while additional   
evidence is collected
Austria •   Association of Austrian Social  
Security institutions (decisions)55
•   Pharmaceutical Evaluation Board/ 
Austrian Medicines Evaluation  
Commission (recommendations)21,56–58
•   Pharmaceuticals 
– Outpatient55
•   Provide as publicly insured  
service (reimbursable)55
•   Do not provide as publicly  
insured service (nonreimbursable)55
Yes56,59 Yes21,56,59 Yes56 Yes56 Yes56 not specified
Belgium •   Minister of Social Affairs (decisions)
•   Commission on reimbursement  
of medicines/Drug Reimbursement  
Committee (recommendations)9,60–63
•   Pharmaceuticals 
– Outpatient 
– inpatient21,64
•   Provide as publicly insured  
service (reimbursable)21
Yes21 Yes21 Yes21 Yes21 Yes21 Yes21
Czech Republic •   State institute for Drug  
Control (decisions)65–67
•   Pharmaceuticals 
– Outpatient65
•   Provide as publicly insured  
service (reimbursable)65
Yes67 Yes67 Yes65 Yes65 Yes65 not specified
Denmark •   Danish Medicines Agency  
(decisions).68–70 Reimbursement  
Committee (recommendations)68,70
•   Pharmaceuticals 
– Outpatient71
•   Provide as publicly  
insured service38,46,69,71
Yes68 no68 Yes38,69 Yes38,69 Yes38,69 not specified
Estonia • Ministry of Social Affairs (decisions)72 
•   Pharmaceuticals Committee  
(recommendations)72
•   Pharmaceuticals 
– Outpatient72
•   Provide as publicly  
insured service (reimbursable)72
Yes72 Yes72 Yes72 Yes72 Yes72 no67
Finland •   Pharmaceuticals Pricing  
Board (decisions)64,73,74
•   Pharmaceuticals Pricing Board  
Expert group (recommendations)75
•   Pharmaceuticals 
– Outpatient76
•   Provide as publicly insured  
service (reimbursable)76
•   Do not provide as publicly  
funded service (nonreimbursable)76
Yes76 Yes76 Yes77 Yes73 Yes73 no74
France •   Ministry for health and  
Social Security (decisions)20,78
•   French national Authority  
for health (recommendations)78
•   Pharmaceuticals 
– Outpatient 
– inpatient79
• Devices79 
• Procedures79
•   Provide as publicly insured  
service (reimbursable)80
Yes16,20,22,78 Yes16,20,22,78 Yes20 Yes20 Yes20 Yes16,20
germany •   Federal Joint Committee 
(decisions)19
•   institute for Quality and Efficiency  
in health Care (recommendations)19
•   Pharmaceuticals 
– Outpatient 
– inpatient81,82
• Devices18 
• Procedures83
•   Provide as publicly insured  
service (reimbursable)55
•   Do not provide as publicly  
funded service (nonreimbursable)55 
note: Must not exclude technologies   
for which there is no alternative18,81
Yes19 Yes82,84 Yes19 Yes19 Yes19 Yes19
greece •   Transparency Committee in  
the Reimbursement and Medicinal  
Products (makes decisions)85,86
•   Pharmaceuticals 
– Outpatient85
•   Classify pharmaceutical  
into therapeutic category85
Yes85 Yes87 n/A n/A n/A n/A
hungary • Ministers of health and Finance (decisions) 
•   national health insurance Fund  
Administration health Technology  
Assessment Committee (recommendations)88,89
•   Pharmaceuticals 
– Outpatient 
– inpatient90
• Provide as publicly insured service88 
•   Do not provide as publicly  
funded service (nonreimbursable)26
Yes88 not specified Yes90 Yes90 Yes90 not specified
ireland • health Service Executive (decisions)91,92 •   Pharmaceuticals 
– Outpatient 
– inpatient
• Devices 
• Procedures91,92
•   Provide as publicly insured  
service (reimbursable)92
Yes91 no91 Yes91 Yes91 Yes91 no93
italy •   italian Medicines Agency Technical  
Scientific Committee (decisions)94
•   italian Medicines Agency Pricing and  
Reimbursement Committee  
(recommendations)95
•   Pharmaceuticals 
– Outpatient 
– inpatient21
•   Provide as publicly insured  
service (reimbursable)21
Yes96,97 Yes96,97 Yes96 Yes96 Yes96 Yes96
norway • norwegian Medicines Agency (decisions)98
•   Department of Pharmacoeconomics 
(recommendations)98
•   Pharmaceuticals 
– Outpatient 
– inpatient34
•   Provide as publicly insured  
service (reimbursable)98
Yes98 Yes98 Yes98 Yes98 Yes98 not specified
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Table 1 Centralized reimbursement system and mandate
Country Centralized reimbursement  
review/decision-making body (role)
Technology scope Decision problem Decision “scope” Available decision options
Reimbursement Linkage to pricing Provide Do not provide Provide with restrictions Provide while additional   
evidence is collected
Austria •   Association of Austrian Social  
Security institutions (decisions)55
•   Pharmaceutical Evaluation Board/ 
Austrian Medicines Evaluation  
Commission (recommendations)21,56–58
•   Pharmaceuticals 
– Outpatient55
•   Provide as publicly insured  
service (reimbursable)55
•   Do not provide as publicly  
insured service (nonreimbursable)55
Yes56,59 Yes21,56,59 Yes56 Yes56 Yes56 not specified
Belgium •   Minister of Social Affairs (decisions)
•   Commission on reimbursement  
of medicines/Drug Reimbursement  
Committee (recommendations)9,60–63
•   Pharmaceuticals 
– Outpatient 
– inpatient21,64
•   Provide as publicly insured  
service (reimbursable)21
Yes21 Yes21 Yes21 Yes21 Yes21 Yes21
Czech Republic •   State institute for Drug  
Control (decisions)65–67
•   Pharmaceuticals 
– Outpatient65
•   Provide as publicly insured  
service (reimbursable)65
Yes67 Yes67 Yes65 Yes65 Yes65 not specified
Denmark •   Danish Medicines Agency  
(decisions).68–70 Reimbursement  
Committee (recommendations)68,70
•   Pharmaceuticals 
– Outpatient71
•   Provide as publicly  
insured service38,46,69,71
Yes68 no68 Yes38,69 Yes38,69 Yes38,69 not specified
Estonia • Ministry of Social Affairs (decisions)72 
•   Pharmaceuticals Committee  
(recommendations)72
•   Pharmaceuticals 
– Outpatient72
•   Provide as publicly  
insured service (reimbursable)72
Yes72 Yes72 Yes72 Yes72 Yes72 no67
Finland •   Pharmaceuticals Pricing  
Board (decisions)64,73,74
•   Pharmaceuticals Pricing Board  
Expert group (recommendations)75
•   Pharmaceuticals 
– Outpatient76
•   Provide as publicly insured  
service (reimbursable)76
•   Do not provide as publicly  
funded service (nonreimbursable)76
Yes76 Yes76 Yes77 Yes73 Yes73 no74
France •   Ministry for health and  
Social Security (decisions)20,78
•   French national Authority  
for health (recommendations)78
•   Pharmaceuticals 
– Outpatient 
– inpatient79
• Devices79 
• Procedures79
•   Provide as publicly insured  
service (reimbursable)80
Yes16,20,22,78 Yes16,20,22,78 Yes20 Yes20 Yes20 Yes16,20
germany •   Federal Joint Committee 
(decisions)19
•   institute for Quality and Efficiency  
in health Care (recommendations)19
•   Pharmaceuticals 
– Outpatient 
– inpatient81,82
• Devices18 
• Procedures83
•   Provide as publicly insured  
service (reimbursable)55
•   Do not provide as publicly  
funded service (nonreimbursable)55 
note: Must not exclude technologies   
for which there is no alternative18,81
Yes19 Yes82,84 Yes19 Yes19 Yes19 Yes19
greece •   Transparency Committee in  
the Reimbursement and Medicinal  
Products (makes decisions)85,86
•   Pharmaceuticals 
– Outpatient85
•   Classify pharmaceutical  
into therapeutic category85
Yes85 Yes87 n/A n/A n/A n/A
hungary • Ministers of health and Finance (decisions) 
•   national health insurance Fund  
Administration health Technology  
Assessment Committee (recommendations)88,89
•   Pharmaceuticals 
– Outpatient 
– inpatient90
• Provide as publicly insured service88 
•   Do not provide as publicly  
funded service (nonreimbursable)26
Yes88 not specified Yes90 Yes90 Yes90 not specified
ireland • health Service Executive (decisions)91,92 •   Pharmaceuticals 
– Outpatient 
– inpatient
• Devices 
• Procedures91,92
•   Provide as publicly insured  
service (reimbursable)92
Yes91 no91 Yes91 Yes91 Yes91 no93
italy •   italian Medicines Agency Technical  
Scientific Committee (decisions)94
•   italian Medicines Agency Pricing and  
Reimbursement Committee  
(recommendations)95
•   Pharmaceuticals 
– Outpatient 
– inpatient21
•   Provide as publicly insured  
service (reimbursable)21
Yes96,97 Yes96,97 Yes96 Yes96 Yes96 Yes96
norway • norwegian Medicines Agency (decisions)98
•   Department of Pharmacoeconomics 
(recommendations)98
•   Pharmaceuticals 
– Outpatient 
– inpatient34
•   Provide as publicly insured  
service (reimbursable)98
Yes98 Yes98 Yes98 Yes98 Yes98 not specified
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Table 1 (Continued)
Country Centralized reimbursement  
review/decision-making body (role)
Technology scope Decision problem Decision “scope” Available decision options
Reimbursement Linkage to pricing Provide Do not provide Provide with restrictions Provide while additional   
evidence is collected
Poland • Ministry of health (decisions)99 •   Pharmaceuticals 
– Outpatient 
– inpatient100
•   Provide as publicly insured  
service (reimbursable)100
Yes100 Yes100 Yes100 Yes100 Yes100 not specified
Portugal • Ministry of health (decisions)
• inFARMED (recommendations)44,101
•   Pharmaceuticals 
– Outpatient 
– inpatient102
•   Provide as publicly  
insured service (reimbursable)44
Yes103 Yes99 Yes99 Yes99 Yes99 no99
Scotland •   national health Service Scotland (decisions)30
•   Scottish Medicines Consortium  
(recommendations)
•   Pharmaceuticals 
– Outpatient 
– inpatient30
•   Provide as publicly insured  
service (reimbursable)30
Yes104 no104 Yes104 Yes104 Yes99 no99
Slovakia • Ministry of health (decisions) 
•   Reimbursement Committee for  
Medicinal Products (recommendations)105–107
•   Pharmaceuticals 
– Outpatient 
– inpatient102
•   Provide as publicly  
insured service (reimbursable)102
•   Do not provide as publicly  
funded service (nonreimbursable)102
Yes106 Yes106 Yes102 Yes102 Yes102 not specified
Spain •   Ministry of health Directorate  
general of Pharmacy and health  
Products (decisions)21,108
•   Pharmaceuticals 
– Outpatient 
– inpatient108
•   Provide as publicly funded  
service (reimbursable)108
•   Do not provide as publicly  
funded service (non-reimbursable)108
Yes21 Yes21 Yes21 Yes21 Yes21 no21
Sweden •   Dental and Pharmaceutical  
Benefits Board (decisions)15,109,110
•   Pharmaceuticals 
– Outpatient
•   Devices (for administration  
of pharmaceuticals)15,21,33,109
•   Provide as publicly  
funded service (reimbursable)15
Yes111 Yes112 Yes109 Yes109 Yes109 Yes109
Switzerland •   Swiss Federal Office of Public  
health (decisions)
•   Federal Drug Commission  
(recommendations)113–115
•   Pharmaceuticals 
– Outpatient 
– inpatient113
•   Provide as publicly funded  
service (reimbursable)113
Yes113,114 Yes113,114 Yes113,114 Yes113,114 Yes113,114 not specified
The netherlands •   Ministry of health, Welfare and  
Sport (decisions)
•   Medicinal Products Reimbursement  
Committee of the Dutch healthcare  
insurance Board (recommendations)116
•   Pharmaceuticals 
– Outpatient 
– high cost 
inpatient49
• Procedures117
•   Provide as publicly funded  
service (reimbursable)49
Yes117,118 no31 Yes31 Yes31 Yes119 Yes119
United Kingdom •   national institute for health and  
Clinical Excellence (decisions)
•   Technology Appraisals  
Committee (recommendations)7
•   Pharmaceuticals 
– Outpatient 
– inpatient7
• Devices7 
• Procedures7
•   Provide as publicly  
funded service (reimbursable)7
Yes7 no7 Yes7 Yes7 Yes7 Yes7
Wales •   Ministry for health and  
Social Services (decisions)
•   All Wales Medicines Strategy  
group (recommendations)120
•   Pharmaceuticals 
– Outpatient 
– inpatient120
•   Provide as publicly funded service 
(reimbursable)120
Yes120 no120 Yes120 Yes120 Yes120 Yes120
manufacturer. Most systems have developed a standard tem-
plate/structure for the report and submission guidelines to 
which manufacturers must adhere. These guidelines largely 
include content/information requirements and internationally 
accepted methods for synthesizing and analyzing evidence. In 
two of the countries, responsibility for the assessment depends 
upon the type of review (“appraisal”). Both France and the 
UK have created “single technology appraisal” and “mul-
tiple technology appraisal” processes. “Single technology 
appraisals” compare the candidate technology with a limited 
number of alternatives for a specific, well-defined indica-
tion (eg, disease stage). Their scope most closely resembles 
processes based upon manufacturers’   submissions. “Multiple 
technology appraisals” consider either several indications for 
a candidate technology or several technologies (along with 
the candidate technology) for a condition at one or more 
points in its course, taking a disease management approach. 
The assessment report for a single technology appraisal is 
prepared by the manufacturer. For a multiple technology 
appraisal, the report is drafted either internally with support ClinicoEconomics and Outcomes Research 2011:3 submit your manuscript | www.dovepress.com
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Table 1 (Continued)
Country Centralized reimbursement  
review/decision-making body (role)
Technology scope Decision problem Decision “scope” Available decision options
Reimbursement Linkage to pricing Provide Do not provide Provide with restrictions Provide while additional   
evidence is collected
Poland • Ministry of health (decisions)99 •   Pharmaceuticals 
– Outpatient 
– inpatient100
•   Provide as publicly insured  
service (reimbursable)100
Yes100 Yes100 Yes100 Yes100 Yes100 not specified
Portugal • Ministry of health (decisions)
• inFARMED (recommendations)44,101
•   Pharmaceuticals 
– Outpatient 
– inpatient102
•   Provide as publicly  
insured service (reimbursable)44
Yes103 Yes99 Yes99 Yes99 Yes99 no99
Scotland •   national health Service Scotland (decisions)30
•   Scottish Medicines Consortium  
(recommendations)
•   Pharmaceuticals 
– Outpatient 
– inpatient30
•   Provide as publicly insured  
service (reimbursable)30
Yes104 no104 Yes104 Yes104 Yes99 no99
Slovakia • Ministry of health (decisions) 
•   Reimbursement Committee for  
Medicinal Products (recommendations)105–107
•   Pharmaceuticals 
– Outpatient 
– inpatient102
•   Provide as publicly  
insured service (reimbursable)102
•   Do not provide as publicly  
funded service (nonreimbursable)102
Yes106 Yes106 Yes102 Yes102 Yes102 not specified
Spain •   Ministry of health Directorate  
general of Pharmacy and health  
Products (decisions)21,108
•   Pharmaceuticals 
– Outpatient 
– inpatient108
•   Provide as publicly funded  
service (reimbursable)108
•   Do not provide as publicly  
funded service (non-reimbursable)108
Yes21 Yes21 Yes21 Yes21 Yes21 no21
Sweden •   Dental and Pharmaceutical  
Benefits Board (decisions)15,109,110
•   Pharmaceuticals 
– Outpatient
•   Devices (for administration  
of pharmaceuticals)15,21,33,109
•   Provide as publicly  
funded service (reimbursable)15
Yes111 Yes112 Yes109 Yes109 Yes109 Yes109
Switzerland •   Swiss Federal Office of Public  
health (decisions)
•   Federal Drug Commission  
(recommendations)113–115
•   Pharmaceuticals 
– Outpatient 
– inpatient113
•   Provide as publicly funded  
service (reimbursable)113
Yes113,114 Yes113,114 Yes113,114 Yes113,114 Yes113,114 not specified
The netherlands •   Ministry of health, Welfare and  
Sport (decisions)
•   Medicinal Products Reimbursement  
Committee of the Dutch healthcare  
insurance Board (recommendations)116
•   Pharmaceuticals 
– Outpatient 
– high cost 
inpatient49
• Procedures117
•   Provide as publicly funded  
service (reimbursable)49
Yes117,118 no31 Yes31 Yes31 Yes119 Yes119
United Kingdom •   national institute for health and  
Clinical Excellence (decisions)
•   Technology Appraisals  
Committee (recommendations)7
•   Pharmaceuticals 
– Outpatient 
– inpatient7
• Devices7 
• Procedures7
•   Provide as publicly  
funded service (reimbursable)7
Yes7 no7 Yes7 Yes7 Yes7 Yes7
Wales •   Ministry for health and  
Social Services (decisions)
•   All Wales Medicines Strategy  
group (recommendations)120
•   Pharmaceuticals 
– Outpatient 
– inpatient120
•   Provide as publicly funded service 
(reimbursable)120
Yes120 no120 Yes120 Yes120 Yes120 Yes120
from external content and methodological experts (France) 
or by an independent academic group (the UK). Finally, in 
some countries, technical staff of a dedicated health tech-
nology assessment body or the centralized reimbursement 
system itself undertake the assessment report, regardless of 
the scope (eg, Germany).
With one exception (the UK), responsibility for preparing 
the evaluation report that accompanies each assessment also 
lies with technical staff and, if necessary, external experts. 
The National Institute of Health and Clinical Excellence 
commissions independent academic groups to evaluate 
assessments submitted by manufacturers as part of its single 
technology appraisal process.
Clinical and economic evidence 
expectations of centralized 
reimbursement systems
Centralized reimbursement systems have issued their 
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Table 2 Comparison of processes for identifying, selecting, and assessing technologies
Country Centralized reimbursement review/ 
decision-making body (role)
Technologies to be considered for review Health technology assessment
Technology identification Technology selection Synthesis and analysis of  
evidence (assessment report)
Evaluation of evidence provided  
(evaluation report)
Austria •   Association of Austrian Social  
Security institutions (decisions)55
•   Pharmaceutical Evaluation  
Board (recommendations)56
Referred by: 
•   Manufacturers seeking reimbursement for newly approved  
pharmaceuticals58
•   Typically considered in  
order received58
• Manufacturer through submission requirements55
•   Methods should comply with internationally  
recognized systematic review and economic  
guidelines55
•   Technical staff within Association of Austrian  
Social Security institutions (Department of  
Pharmaceutical Affairs – pharmacological  
and medical-therapeutic assessment; health  
Economics Team – economic assessment)55
Belgium • Minister of Social Affairs (decisions)
•   Commission on reimbursement  
of medicines/Drug Reimbursement  
Committee (CRM) (recommendations)9
Referred by:
•   Manufacturers seeking reimbursement  
for newly approved pharmaceuticals17
•   Typically considered in  
order received17
• Manufacturer through submission requirements9
•   Methods should comply with internationally  
recognized systematic review guidelines9
•   Technical staff within CRM supported  
by external experts9
Czech Republic •   State institute for Drug  
Control (decisions)65
Referred by:
•   Manufacturers seeking reimbursement for newly approved  
pharmaceuticals66
•   Typically considered in  
order received65
•   Manufacturer through submission  
requirements66
•   Technical staff within State institute  
for Drug Control65
Denmark •   Danish Medicines  
Agency (decisions)68,69,121
•   Reimbursement Committee  
(recommendations)68,121
Referred by:
•   Manufacturers seeking reimbursement for newly approved 
pharmaceuticals84
•   Typically considered in  
order received84
• Manufacturer through submission requirements68 
•   Methods must comply with “Danish guidelines  
for the socioeconomic analysis of medicines”68
•   Technical staff within Danish Medicines  
Agency supported by external experts,  
if necessary68
Estonia •   Ministry of Social Affairs  
(decisions)72
•   Pharmaceuticals Committee  
(recommendations)72
Referred by:
•   Manufacturers seeking reimbursement for newly approved  
pharmaceuticals72
• not specified •   Manufacturer through  
submission requirements72
•   Technical staff within Estonian health  
insurance Fund and State Agency of Medicines72
Finland •   Pharmaceuticals Pricing  
Board (decisions)73,74,76
•   Pharmaceuticals Pricing Board  
Expert group (recommendations)75
Referred by:
•   Manufacturers seeking reimbursement  
for newly approved pharmaceuticals76
•   Typically considered in  
order received73
•   Manufacturer through  
submission requirements122
•   Methods must comply with guidelines of  
the Ministry of Social Affairs and health122
•   Technical staff within Pharmaceuticals  
Pricing Board supported by external experts122
France •   Ministry for health and  
Social Security (decisions)21,78
•   French national Authority for  
health (recommendations)78
Depends on type of appraisal16,20 
Single technology appraisal 
Referred by:
•   Manufacturers seeking reimbursement for newly approved 
pharmaceuticals and devices
•   health care professional associations seeking reimbursement  
for procedures
Multiple technology appraisals 
Typically classes of pharmaceuticals  
or categories of devices
Referred by:
• health care professional associations
• Ministry of health
• national Union of health insurance Funds
• Patient and/or carer organizations120
 
Single technology appraisals
•   Typically considered in order  
received16 
Multiple technology appraisals
• Selection criteria not specified
 
Single technology appraisals 
•   Manufacturer through submission requirements20
Multiple technology appraisals
•   Technical staff within health and Social  
Security supported by external experts20
•   Methods should comply with  
internationally recognized systematic  
review and economic guidelines20
 
Single technology appraisals 
•   Technical staff within health and Social  
Security supported by external experts20
Multiple technology appraisals
•   Technical staff within health and Social  
Security or independent academic group20
germany • Federal Joint Committee (decisions)19 
•   institute for Quality and Efficiency in health Care  
(recommendations)19
Referred by: 
• Associations represented by Federal Joint Committee 
• Ministry of health 
• institute for Quality and Efficiency in health Care 
• Federal commissioner of patient affairs
• Patient and/or carer organizations18
•   Determined by Federal  
Joint Committee
•   Selection criteria: 
1. Clinical relevance 
2. Cost implications 
3. “Risks”6
•   Technical staff within institute for  
Quality and Efficiency in health  
Care supported by external experts123,124
•   Methods must comply with institute for  
Quality and Efficiency in health Care  
systematic review and economic guidelines124
•   Technical staff within institute for  
Quality and Efficiency in health  
Care supported by external experts123,124
greece •   Transparency Committee in the Reimbursement and  
Medicinal Products (makes decisions)85
Referred by:
•   Manufacturers seeking reimbursement  
for newly approved pharmaceuticals85
• not specified •   Manufacturer through  
submission requirements85
•   Technical staff within Transparency  
Committee in the Reimbursement  
and Medicinal Products85
hungary • Ministers of health and Finance (decisions) 
•   national health insurance Fund Administration 
(recommendations)88,89
Referred by:
•   Manufacturers seeking reimbursement  
for newly approved pharmaceuticals
• national health insurance Fund Administration88
• not specified •   Technical staff within national  
Technology Assessment Office of  
the national institute for Strategic  
health Research90
•   Technical staff within national Technology  
Assessment Office of the national institute  
for Strategic health Research90
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Table 2 Comparison of processes for identifying, selecting, and assessing technologies
Country Centralized reimbursement review/ 
decision-making body (role)
Technologies to be considered for review Health technology assessment
Technology identification Technology selection Synthesis and analysis of  
evidence (assessment report)
Evaluation of evidence provided  
(evaluation report)
Austria •   Association of Austrian Social  
Security institutions (decisions)55
•   Pharmaceutical Evaluation  
Board (recommendations)56
Referred by: 
•   Manufacturers seeking reimbursement for newly approved  
pharmaceuticals58
•   Typically considered in  
order received58
• Manufacturer through submission requirements55
•   Methods should comply with internationally  
recognized systematic review and economic  
guidelines55
•   Technical staff within Association of Austrian  
Social Security institutions (Department of  
Pharmaceutical Affairs – pharmacological  
and medical-therapeutic assessment; health  
Economics Team – economic assessment)55
Belgium • Minister of Social Affairs (decisions)
•   Commission on reimbursement  
of medicines/Drug Reimbursement  
Committee (CRM) (recommendations)9
Referred by:
•   Manufacturers seeking reimbursement  
for newly approved pharmaceuticals17
•   Typically considered in  
order received17
• Manufacturer through submission requirements9
•   Methods should comply with internationally  
recognized systematic review guidelines9
•   Technical staff within CRM supported  
by external experts9
Czech Republic •   State institute for Drug  
Control (decisions)65
Referred by:
•   Manufacturers seeking reimbursement for newly approved  
pharmaceuticals66
•   Typically considered in  
order received65
•   Manufacturer through submission  
requirements66
•   Technical staff within State institute  
for Drug Control65
Denmark •   Danish Medicines  
Agency (decisions)68,69,121
•   Reimbursement Committee  
(recommendations)68,121
Referred by:
•   Manufacturers seeking reimbursement for newly approved 
pharmaceuticals84
•   Typically considered in  
order received84
• Manufacturer through submission requirements68 
•   Methods must comply with “Danish guidelines  
for the socioeconomic analysis of medicines”68
•   Technical staff within Danish Medicines  
Agency supported by external experts,  
if necessary68
Estonia •   Ministry of Social Affairs  
(decisions)72
•   Pharmaceuticals Committee  
(recommendations)72
Referred by:
•   Manufacturers seeking reimbursement for newly approved  
pharmaceuticals72
• not specified •   Manufacturer through  
submission requirements72
•   Technical staff within Estonian health  
insurance Fund and State Agency of Medicines72
Finland •   Pharmaceuticals Pricing  
Board (decisions)73,74,76
•   Pharmaceuticals Pricing Board  
Expert group (recommendations)75
Referred by:
•   Manufacturers seeking reimbursement  
for newly approved pharmaceuticals76
•   Typically considered in  
order received73
•   Manufacturer through  
submission requirements122
•   Methods must comply with guidelines of  
the Ministry of Social Affairs and health122
•   Technical staff within Pharmaceuticals  
Pricing Board supported by external experts122
France •   Ministry for health and  
Social Security (decisions)21,78
•   French national Authority for  
health (recommendations)78
Depends on type of appraisal16,20 
Single technology appraisal 
Referred by:
•   Manufacturers seeking reimbursement for newly approved 
pharmaceuticals and devices
•   health care professional associations seeking reimbursement  
for procedures
Multiple technology appraisals 
Typically classes of pharmaceuticals  
or categories of devices
Referred by:
• health care professional associations
• Ministry of health
• national Union of health insurance Funds
• Patient and/or carer organizations120
 
Single technology appraisals
•   Typically considered in order  
received16 
Multiple technology appraisals
• Selection criteria not specified
 
Single technology appraisals 
•   Manufacturer through submission requirements20
Multiple technology appraisals
•   Technical staff within health and Social  
Security supported by external experts20
•   Methods should comply with  
internationally recognized systematic  
review and economic guidelines20
 
Single technology appraisals 
•   Technical staff within health and Social  
Security supported by external experts20
Multiple technology appraisals
•   Technical staff within health and Social  
Security or independent academic group20
germany • Federal Joint Committee (decisions)19 
•   institute for Quality and Efficiency in health Care  
(recommendations)19
Referred by: 
• Associations represented by Federal Joint Committee 
• Ministry of health 
• institute for Quality and Efficiency in health Care 
• Federal commissioner of patient affairs
• Patient and/or carer organizations18
•   Determined by Federal  
Joint Committee
•   Selection criteria: 
1. Clinical relevance 
2. Cost implications 
3. “Risks”6
•   Technical staff within institute for  
Quality and Efficiency in health  
Care supported by external experts123,124
•   Methods must comply with institute for  
Quality and Efficiency in health Care  
systematic review and economic guidelines124
•   Technical staff within institute for  
Quality and Efficiency in health  
Care supported by external experts123,124
greece •   Transparency Committee in the Reimbursement and  
Medicinal Products (makes decisions)85
Referred by:
•   Manufacturers seeking reimbursement  
for newly approved pharmaceuticals85
• not specified •   Manufacturer through  
submission requirements85
•   Technical staff within Transparency  
Committee in the Reimbursement  
and Medicinal Products85
hungary • Ministers of health and Finance (decisions) 
•   national health insurance Fund Administration 
(recommendations)88,89
Referred by:
•   Manufacturers seeking reimbursement  
for newly approved pharmaceuticals
• national health insurance Fund Administration88
• not specified •   Technical staff within national  
Technology Assessment Office of  
the national institute for Strategic  
health Research90
•   Technical staff within national Technology  
Assessment Office of the national institute  
for Strategic health Research90
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Table 2 (Continued)
Country Centralized reimbursement review/ 
decision-making body (role)
Technologies to be considered for review Health technology assessment
Technology identification Technology selection Synthesis and analysis of  
evidence (assessment report)
Evaluation of evidence provided  
(evaluation report)
ireland • health Service Executive (decisions)91,92 Referred by: 
•   Manufacturers seeking reimbursement  
for newly approved pharmaceuticals91
Referred by:
•   Department of health and Children of the health Services  
Executive for new and existing devices and diagnostic tests that   
might “incur a high cost or have a significant budget impact”91
• not specified •   Manufacturer through submission  
requirements93,125
•   Methods must comply with irish  
health Technology Assessment guidelines93
•   Technical staff within national Centre for 
Pharmacoeconomics, supported by external  
clinical experts93
italy •   italian Medicines Agency Technical  
Scientific Committee (decisions)94
•   italian Medicines Agency Pricing and  
Reimbursement Committee (recommendations)95
Referred by:
•   Manufacturers seeking reimbursement  
for newly approved pharmaceuticals27
•   Typically considered in  
order received27
•   Manufacturer through  
submission requirements126
•   Methods must comply with  
italian submission guidelines27
•   Members of Technical  
Scientific Committee126
norway • norwegian Medicines Agency (decisions)98 
•   Department of Pharmacoeconomics  
(recommendations)98
Referred by: 
•   Manufacturers seeking reimbursement for  
newly approved pharmaceuticals34
• not specified • Manufacturer through submission requirements34
•   Methods should comply with internationally 
recognized systematic review guidelines34
•   Technical staff within norwegian  
Medicines Agency and Department  
of Pharmacoeconomics98
Poland • Ministry of health (decisions)99 Referred by:
•   Manufacturers seeking reimbursement  
for newly approved pharmaceuticals99
• not specified •   Manufacturer through  
submission requirements99
• Technical staff within Ministry of health99 
• Agency for health Technology Assessment127
Portugal • Ministry of health (decisions)
• inFARMED (recommendations)36,45
Referred by:
•   Manufacturers seeking reimbursement  
for newly approved pharmaceuticals36
• not specified •   Manufacturer through  
submission requirements36
•   Technical staff within inFARMED  
supported by external experts36
Scotland • national health Service Scotland (decisions)30
•   Scottish Medicines Consortium  
(recommendations)
Referred by:
•   Manufacturers seeking reimbursement for  
newly approved pharmaceuticals104
• Automatic within 12 weeks of market launch104
•   Exclusion criteria: 
Already appraised by national institute  
of health and Clinical Excellence  
through its multiple technologies  
appraisal process104
•   Manufacturer through  
submission requirements128
•   Methods must comply with Scottish  
Medicines Consortium systematic review  
and economic guidelines34
•   Technical staff within Scottish Medicines 
Consortium supported by external experts128
Slovakia • Ministry of health (decisions) 
•   Reimbursement Committee for  
Medicinal Products (recommendations)105,107,129,106
Referred by:
•   Manufacturers seeking reimbursement for  
newly approved pharmaceuticals104
• not specified •   Manufacturer through  
submission requirements131
•   Working group for pharmacoeconomics  
and outcomes research131
Spain •   Ministry of health Directorate general  
of Pharmacy and health Products
•   inter-Ministerial Pricing Commission 
(decisions)21,108
Referred by:
• Ministry of health (newly approved pharmaceuticals)108
• not specified •   Manufacturer through invitation  
to submit information to inter-Ministerial  
Pricing Commission21
• Technical staff within Ministry of health132
•   inter-Ministerial Pricing  
Commission21
Sweden •   Dental and Pharmaceutical Benefits  
Board (decisions)15,109,110
Referred by: 
•   Manufacturers seeking reimbursement  
for newly approved pharmaceuticals104
•   Dental and Pharmaceutical Benefits Board  
(for pharmaceuticals approved prior to 2002)133,134
•   For new pharmaceuticals: typically  
considered in order received
•   For older pharmaceuticals: 
Overall sales volume134,135
•   For new pharmaceuticals: Manufacturer  
through submission requirements136
•   For older pharmaceuticals: 
Technical staff within Dental and Pharmaceutical  
Benefits Board supported by external experts136
•   Methods must comply with Dental and  
Pharmaceutical Benefits Board systematic  
review and economic guidelines10
•   For new pharmaceuticals: Technical  
staff within Dental and Pharmaceutical  
Benefits Board136
•   For older pharmaceuticals: 
Technical staff within Dental and  
Pharmaceutical Benefits Board  
supported by external experts136
Switzerland •   Swiss Federal Office of  
Public health (decisions)
•   Federal Drug Commission  
(recommendations)114,115
Referred by: 
•   Manufacturers seeking reimbursement  
for newly approved pharmaceuticals114
• Patients and carers 
• hospitals and hospital groups 
• health care professional associations 
• Federal Office of Public health114,137
• not specified •   Manufacturer through  
submission requirements113
• Federal Drug Commission114
The netherlands •   Ministry of health, Welfare  
and Sport (decisions)
•   Medicinal Products Reimbursement  
Committee of the Dutch healthcare  
insurance Board (recommendations)116
Referred by:
•   Manufacturers seeking reimbursement for  
newly approved pharmaceuticals31
•   University hospital federations, health care professional  
associations, and Dutch healthcare insurance Board for  
high-cost inpatient pharmaceuticals
• not specified •   Manufacturer through submission requirements31
•   Technical staff within Dutch  
healthcare insurance Board117
•   Methods must comply with internationally  
recognize systematic review guidelines and Dutch  
healthcare insurance Board economic guidelines117
•   Technical staff within Dutch  
healthcare insurance Board117
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Table 2 (Continued)
Country Centralized reimbursement review/ 
decision-making body (role)
Technologies to be considered for review Health technology assessment
Technology identification Technology selection Synthesis and analysis of  
evidence (assessment report)
Evaluation of evidence provided  
(evaluation report)
ireland • health Service Executive (decisions)91,92 Referred by: 
•   Manufacturers seeking reimbursement  
for newly approved pharmaceuticals91
Referred by:
•   Department of health and Children of the health Services  
Executive for new and existing devices and diagnostic tests that   
might “incur a high cost or have a significant budget impact”91
• not specified •   Manufacturer through submission  
requirements93,125
•   Methods must comply with irish  
health Technology Assessment guidelines93
•   Technical staff within national Centre for 
Pharmacoeconomics, supported by external  
clinical experts93
italy •   italian Medicines Agency Technical  
Scientific Committee (decisions)94
•   italian Medicines Agency Pricing and  
Reimbursement Committee (recommendations)95
Referred by:
•   Manufacturers seeking reimbursement  
for newly approved pharmaceuticals27
•   Typically considered in  
order received27
•   Manufacturer through  
submission requirements126
•   Methods must comply with  
italian submission guidelines27
•   Members of Technical  
Scientific Committee126
norway • norwegian Medicines Agency (decisions)98 
•   Department of Pharmacoeconomics  
(recommendations)98
Referred by: 
•   Manufacturers seeking reimbursement for  
newly approved pharmaceuticals34
• not specified • Manufacturer through submission requirements34
•   Methods should comply with internationally 
recognized systematic review guidelines34
•   Technical staff within norwegian  
Medicines Agency and Department  
of Pharmacoeconomics98
Poland • Ministry of health (decisions)99 Referred by:
•   Manufacturers seeking reimbursement  
for newly approved pharmaceuticals99
• not specified •   Manufacturer through  
submission requirements99
• Technical staff within Ministry of health99 
• Agency for health Technology Assessment127
Portugal • Ministry of health (decisions)
• inFARMED (recommendations)36,45
Referred by:
•   Manufacturers seeking reimbursement  
for newly approved pharmaceuticals36
• not specified •   Manufacturer through  
submission requirements36
•   Technical staff within inFARMED  
supported by external experts36
Scotland • national health Service Scotland (decisions)30
•   Scottish Medicines Consortium  
(recommendations)
Referred by:
•   Manufacturers seeking reimbursement for  
newly approved pharmaceuticals104
• Automatic within 12 weeks of market launch104
•   Exclusion criteria: 
Already appraised by national institute  
of health and Clinical Excellence  
through its multiple technologies  
appraisal process104
•   Manufacturer through  
submission requirements128
•   Methods must comply with Scottish  
Medicines Consortium systematic review  
and economic guidelines34
•   Technical staff within Scottish Medicines 
Consortium supported by external experts128
Slovakia • Ministry of health (decisions) 
•   Reimbursement Committee for  
Medicinal Products (recommendations)105,107,129,106
Referred by:
•   Manufacturers seeking reimbursement for  
newly approved pharmaceuticals104
• not specified •   Manufacturer through  
submission requirements131
•   Working group for pharmacoeconomics  
and outcomes research131
Spain •   Ministry of health Directorate general  
of Pharmacy and health Products
•   inter-Ministerial Pricing Commission 
(decisions)21,108
Referred by:
• Ministry of health (newly approved pharmaceuticals)108
• not specified •   Manufacturer through invitation  
to submit information to inter-Ministerial  
Pricing Commission21
• Technical staff within Ministry of health132
•   inter-Ministerial Pricing  
Commission21
Sweden •   Dental and Pharmaceutical Benefits  
Board (decisions)15,109,110
Referred by: 
•   Manufacturers seeking reimbursement  
for newly approved pharmaceuticals104
•   Dental and Pharmaceutical Benefits Board  
(for pharmaceuticals approved prior to 2002)133,134
•   For new pharmaceuticals: typically  
considered in order received
•   For older pharmaceuticals: 
Overall sales volume134,135
•   For new pharmaceuticals: Manufacturer  
through submission requirements136
•   For older pharmaceuticals: 
Technical staff within Dental and Pharmaceutical  
Benefits Board supported by external experts136
•   Methods must comply with Dental and  
Pharmaceutical Benefits Board systematic  
review and economic guidelines10
•   For new pharmaceuticals: Technical  
staff within Dental and Pharmaceutical  
Benefits Board136
•   For older pharmaceuticals: 
Technical staff within Dental and  
Pharmaceutical Benefits Board  
supported by external experts136
Switzerland •   Swiss Federal Office of  
Public health (decisions)
•   Federal Drug Commission  
(recommendations)114,115
Referred by: 
•   Manufacturers seeking reimbursement  
for newly approved pharmaceuticals114
• Patients and carers 
• hospitals and hospital groups 
• health care professional associations 
• Federal Office of Public health114,137
• not specified •   Manufacturer through  
submission requirements113
• Federal Drug Commission114
The netherlands •   Ministry of health, Welfare  
and Sport (decisions)
•   Medicinal Products Reimbursement  
Committee of the Dutch healthcare  
insurance Board (recommendations)116
Referred by:
•   Manufacturers seeking reimbursement for  
newly approved pharmaceuticals31
•   University hospital federations, health care professional  
associations, and Dutch healthcare insurance Board for  
high-cost inpatient pharmaceuticals
• not specified •   Manufacturer through submission requirements31
•   Technical staff within Dutch  
healthcare insurance Board117
•   Methods must comply with internationally  
recognize systematic review guidelines and Dutch  
healthcare insurance Board economic guidelines117
•   Technical staff within Dutch  
healthcare insurance Board117
(Continued)ClinicoEconomics and Outcomes Research 2011:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
128
Stafinski et al
Table 2 (Continued)
Country Centralized reimbursement review/ 
decision-making body (role)
Technologies to be considered for review Health technology assessment
Technology identification Technology selection Synthesis and analysis of  
evidence (assessment report)
Evaluation of evidence provided  
(evaluation report)
United Kingdom •   national institute for health and  
Clinical Excellence (decisions)
•   Technology Appraisals  
Committee (recommendations)7
Referred by: 
•   Manufacturers seeking reimbursement  
for newly approved pharmaceuticals
• Patients and carers
• health care providers
• health care professional associations
• general Public
• national horizon Scanning Centre120
Selection criteria: 
•   Burden of disease (population affected,  
mortality, and morbidity)
•   Resource impact (on national health  
Service costs and resources)
• Clinical importance 
•   Policy importance (alignment with  
government priority areas)
•   inappropriate variations in practice
•   Likelihood of national guidance adding  
value7
Technology selection panel composition: 
•   health care providers (specialists,  
general practitioners, and public  
health professionals)
•   Patient representatives 
Technology selection panel makes  
recommendations. Final decisions  
made by Department of health7
Single technology appraisals
•   Manufacturer through submission  
requirements120
Multiple technology appraisals 
•   independent academic group120
•   Methods must comply with national institute  
for health and Clinical Excellence systematic  
review and economic guidelines120
Single technology appraisals 
•   independent academic group120
Multiple technology appraisals
• independent academic group120
Wales •   Ministry for health and Social  
Services (decisions)
•   All Wales Medicines Strategy  
group (recommendations)28
Referred by: 
•   Manufacturers seeking reimbursement for  
newly approved pharmaceuticals28
•   Welsh Medicines Partnership horizon scanning process  
for identifying pharmaceuticals expected to receive market  
approval within 18 months28
•   Typically considered in  
order received28
• Manufacturer through submission requirements28 
• Welsh Medicines Partnership28 
•   Methods must comply with All Wales Medicines  
Strategy group systematic review and economic  
guidelines28
• Welsh Medicines Partnership28
requirements for assessment reports (Tables 3 and 4). These 
guidelines state topics to be addressed and the types of infor-
mation accepted for addressing them. In most cases (16/23), 
specified clinically-related topics are similar and include: 
burden of illness and/or characteristics of the target patient 
population; therapeutic claim of the candidate technology; 
safety; efficacy; and effectiveness (preferably comparative 
effectiveness) across relevant patient subgroups (Table 3). 
Additionally, several require information on current man-
agement or the place of the candidate technology within 
existing treatment pathways (eg, France and the UK), and 
its proposed frequency and duration of use (eg, Austria). 
Across systems and where reported, there is a shared prefer-
ence for information on health outcomes that represent final 
clinical endpoints related to mortality, morbidity, and qual-
ity of life. Less frequently, information on adverse events/
complications is also required. This may be explained 
by the fact that a prerequisite for reimbursement review 
is typically regulatory approval. Therefore, systems may 
view reconsideration of adverse events, which relate to the 
safety of a technology, unnecessary. In systems proposing 
or stipulating the use of quality-adjusted life-years (7/23), 
change in health-related quality of life is to be measured in 
patients and then valued in the public or general population 
(eg, the UK). Surrogate outcomes are discouraged or not 
accepted unless well validated (eg, Germany). Lastly, some 
systems elicit the views of patients and or carers in identify-
ing topic specific outcomes and their relative importance 
(eg, Germany).
In general, centralized reimbursement systems state a 
preference for head-to-head randomized controlled trials 
comparing the candidate technology with standard care, 
no active treatment/best supportive care, or placebo (if no 
alternatives exist, Table 3). However, increased interest in 
evidence of “comparative effectiveness” over “comparative 
efficacy” among most reimbursement systems has led to 
requests for inclusion of head-to-head randomized controlled 
trials conducted in “naturalistic settings” (ie, pragmatic trials, 
in the UK) and other direct comparative studies (observa-
tional and experimental in design), the collective findings of 
which may offer a more accurate prediction of the behavior 
of the technology in general clinical practice (eg, France, 
Germany, and Sweden). Also, there appears to be emerging 
recognition of the need for flexibility in evidence expectations 
under certain circumstances. Recently, Germany’s Institute 
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Table 2 (Continued)
Country Centralized reimbursement review/ 
decision-making body (role)
Technologies to be considered for review Health technology assessment
Technology identification Technology selection Synthesis and analysis of  
evidence (assessment report)
Evaluation of evidence provided  
(evaluation report)
United Kingdom •   national institute for health and  
Clinical Excellence (decisions)
•   Technology Appraisals  
Committee (recommendations)7
Referred by: 
•   Manufacturers seeking reimbursement  
for newly approved pharmaceuticals
• Patients and carers
• health care providers
• health care professional associations
• general Public
• national horizon Scanning Centre120
Selection criteria: 
•   Burden of disease (population affected,  
mortality, and morbidity)
•   Resource impact (on national health  
Service costs and resources)
• Clinical importance 
•   Policy importance (alignment with  
government priority areas)
•   inappropriate variations in practice
•   Likelihood of national guidance adding  
value7
Technology selection panel composition: 
•   health care providers (specialists,  
general practitioners, and public  
health professionals)
•   Patient representatives 
Technology selection panel makes  
recommendations. Final decisions  
made by Department of health7
Single technology appraisals
•   Manufacturer through submission  
requirements120
Multiple technology appraisals 
•   independent academic group120
•   Methods must comply with national institute  
for health and Clinical Excellence systematic  
review and economic guidelines120
Single technology appraisals 
•   independent academic group120
Multiple technology appraisals
• independent academic group120
Wales •   Ministry for health and Social  
Services (decisions)
•   All Wales Medicines Strategy  
group (recommendations)28
Referred by: 
•   Manufacturers seeking reimbursement for  
newly approved pharmaceuticals28
•   Welsh Medicines Partnership horizon scanning process  
for identifying pharmaceuticals expected to receive market  
approval within 18 months28
•   Typically considered in  
order received28
• Manufacturer through submission requirements28 
• Welsh Medicines Partnership28 
•   Methods must comply with All Wales Medicines  
Strategy group systematic review and economic  
guidelines28
• Welsh Medicines Partnership28
health technology assessments and makes reimbursement 
recommendations on selected health technologies to the 
Federal Joint Committee, issued methodological guidelines 
suggesting that when no active alternative treatment exists, 
well designed case series would be deemed adequate.8
While across systems, the preferred source of such 
clinical evidence is published, peer-reviewed studies, many 
encourage, and in several cases require if available, inclusion 
of unpublished or ongoing studies (eg, Austria, Belgium, 
Norway, Poland, Slovakia, Sweden, the Netherlands, and the 
UK), commercial in-confidence data (eg, Austria, France, 
Sweden, and the UK) and/or current national and interna-
tional clinical practice guidelines (eg, France) in assessment 
reports. In recent years, some systems have incorporated 
submissions from patient and/or carer organizations into 
their processes (eg, Scotland, Sweden, and the UK). Such 
submissions are increasingly viewed as an important source 
of information regarding the relative value of outcome mea-
sures employed in clinical studies and the meaningfulness or 
significance of findings to patients and carers. Finally, while 
systems tend not to explicitly exclude sources of informa-
tion, Belgium’s Drug Reimbursement Committee states that 
abstracts are not accepted.9
Most centralized reimbursement systems (20/23) 
have made mandatory the inclusion of a formal economic 
  evaluation/analysis for either some (ie, those for which 
alternative(s) exist(s), eg, Germany, or those offering “added 
therapeutic value,” eg, Austria and Belgium, or all candidate 
technologies to inform deliberations around “value for money” 
and/or “efficiency.” In the latter case, the type of evaluation 
is rarely stipulated, because options available depend, in part, 
on the magnitude of the incremental benefit of the technology 
over its comparators. However, a rationale must be presented, 
and methods adopted must comply with economic guidelines 
developed or endorsed by the centralized reimbursement 
system (Table 4). For technologies that appear to offer “added 
therapeutic value” (ie, are more effective), some systems 
indicate a preference for certain types of evaluations, such as 
cost-utility analysis by Ireland’s Health Service Executive.10 
Others state explicitly which types will not be accepted, such 
as cost-benefit analysis by Belgium’s Drug Reimbursement 
Committee.11 In addition to a formal economic evaluation, 
the Institute for Quality and Efficiency in Health Care in Ger-
many requires an efficiency frontier analysis, which assesses 
the relative value of different technologies within a given 
therapeutic area.12 Regarding the perspective to be taken for ClinicoEconomics and Outcomes Research 2011:3 submit your manuscript | www.dovepress.com
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Table 3 Comparison of clinical evidence requirements
Country Centralized reimbursement  
review/decision-making body (role)
Clinical evidence requirements
Topic Preferred clinical outcomes Type Source
Austria •   Association of Austrian Social Security institutions  
(decisions)55
•   Pharmaceutical Evaluation Board (recommendations)56
•   Target patient population and indications  
(therapeutic claim)
• Pharmacology 
• Safety 
• Efficacy 
• Effectiveness (across population subgroups) 
• Frequency and duration of treatment55
• not specified Preference for: 
• Double-blind randomized controlled trials 
•   Systematic reviews and meta-analyses of randomized  
controlled trials complying with internationally  
recognized guidelines55
• Published, peer-reviewed studies 
•   Unpublished reports and studies may be  
accepted in exceptional circumstances55
• Commercial, in-confidence data55
Belgium • Minister of Social Affairs (decisions) 
•   Commission on reimbursement of medicines/Drug  
Reimbursement Committee (recommendations)9,60
• Target patient population and indications (therapeutic claim) 
• Safety 
• Efficacy 
• Effectiveness (across population subgroups)11
• Morbidity 
• Adverse events/complications 
• Quality of life 
•   Overall survival/mortality  
(life-years gained)
•   Quality-adjusted life years  
(QALYs) – measured in patients  
but valued by public/society
•   Other relevant disease-specific  
outcomes4
• Final endpoints11
Preference for: 
• Randomized controlled trials 
• Observational head-to-head comparative studies11,17 
• Effectiveness studies (over efficacy studies)17 
•   Minimum of one positive superiority trial on primary  
endpoints against active control or placebo  
(if no alternative treatments exist)17
• Published, peer-reviewed studies
• Unpublished reports and studies17
• Abstracts not accepted9
Czech Republic •   State institute for Drug Control (decisions)65 • Safety 
• Efficacy 
• Effectiveness66
• not specified • All clinical trials138 • not specified
Denmark • Danish Medicines Agency (decisions)68,69,121
• Reimbursement Committee (recommendations)68,121
• Target patient population and indications (therapeutic claim) 
• Safety 
• Efficacy 
• Effectiveness (across population subgroups)38
• not specified Preference for:
•   Randomized controlled trials comparing  
pharmaceutical to standard care38
• not specified
Estonia • Ministry of Social Affairs (decisions)72
• Pharmaceuticals Committee (recommendations)67
• Safety 
• Efficacy 
• Effectiveness139
• Adverse events/complications 
• Side effects 
• Overall survival/mortality139,140
Preference for: 
• Randomized controlled trials84
• Published, peer-reviewed studies84
Finland • Pharmaceuticals Pricing Board (decisions)73,74,76
•   Pharmaceuticals Pricing Board Expert group  
(recommendations)75
• Target patient population and indications (therapeutic claim) 
• Severity and burden of illness 
• Effectiveness (across population subgroups)76
• not specified Preference for: 
•   Randomized controlled trials comparing  
pharmaceutical to standard care76
Evidence from other available direct comparative  
experimental and observational studies, as well  
as meta-analyses, should be included76
• Published, peer-reviewed studies76
France •   Ministry for health and Social Security  
(decisions)20,78
•   French national Authority for health  
(recommendations)20,78
• Target patient population and indications (therapeutic claim) 
• Current management 
• Place of technology in care pathway 
• Safety 
• Efficacy 
• Effectiveness (across population subgroups)16
• Morbidity 
• Overall survival/mortality 
• Quality of life16
Preference for:
• head-to-head, double-blind randomized controlled trials 
• Other direct comparative studies 
• Post-market studies 
•   Systematic reviews and meta-analyses of randomized  
controlled trials complying with internationally  
recognized guidelines16
• Published, peer-reviewed studies 
•   Current national and international clinical 
practice guidelines
• Expert opinion 
• Surveys of practice 
• Commercial, in-confidence data16
germany • Federal Joint Committee (decisions)19 
•   institute for Quality and Efficiency in health Care  
(recommendations)19,141
• Target patient population and indications (therapeutic claim) 
• Severity and burden of illness 
• Safety 
• Efficacy 
• Effectiveness (across population subgroups)8
• Morbidity 
• Overall survival/mortality 
• Quality of life 
• Adverse events/complications 
• Side effects 
• Duration of illness 
• health status8,83,142–144 
•   Topic specific outcomes identified  
in consultation with patient  
organizations18
• Validated surrogate outcomes83
Preference for:
•   Randomized controlled trials comparing pharmaceutical  
to placebo, standard care, or no active treatment8
Evidence from other available direct comparative  
experimental and observational studies, as well as  
systematic reviews and meta-analyses complying  
with internationally recognized guidelines,  
should also be included8
•   if no treatment alternative exists,  
well-documented case series acceptable8
• Published, peer-reviewed studies 
•   Commercial, in-confidence data not  
accepted unless it can be published18
greece •   Transparency Committee in the Reimbursement  
and Medicinal Products (makes decisions)85
• Safety 
• Efficacy 
• Effectiveness145
• not specified • not specified • not specified
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Table 3 Comparison of clinical evidence requirements
Country Centralized reimbursement  
review/decision-making body (role)
Clinical evidence requirements
Topic Preferred clinical outcomes Type Source
Austria •   Association of Austrian Social Security institutions  
(decisions)55
•   Pharmaceutical Evaluation Board (recommendations)56
•   Target patient population and indications  
(therapeutic claim)
• Pharmacology 
• Safety 
• Efficacy 
• Effectiveness (across population subgroups) 
• Frequency and duration of treatment55
• not specified Preference for: 
• Double-blind randomized controlled trials 
•   Systematic reviews and meta-analyses of randomized  
controlled trials complying with internationally  
recognized guidelines55
• Published, peer-reviewed studies 
•   Unpublished reports and studies may be  
accepted in exceptional circumstances55
• Commercial, in-confidence data55
Belgium • Minister of Social Affairs (decisions) 
•   Commission on reimbursement of medicines/Drug  
Reimbursement Committee (recommendations)9,60
• Target patient population and indications (therapeutic claim) 
• Safety 
• Efficacy 
• Effectiveness (across population subgroups)11
• Morbidity 
• Adverse events/complications 
• Quality of life 
•   Overall survival/mortality  
(life-years gained)
•   Quality-adjusted life years  
(QALYs) – measured in patients  
but valued by public/society
•   Other relevant disease-specific  
outcomes4
• Final endpoints11
Preference for: 
• Randomized controlled trials 
• Observational head-to-head comparative studies11,17 
• Effectiveness studies (over efficacy studies)17 
•   Minimum of one positive superiority trial on primary  
endpoints against active control or placebo  
(if no alternative treatments exist)17
• Published, peer-reviewed studies
• Unpublished reports and studies17
• Abstracts not accepted9
Czech Republic •   State institute for Drug Control (decisions)65 • Safety 
• Efficacy 
• Effectiveness66
• not specified • All clinical trials138 • not specified
Denmark • Danish Medicines Agency (decisions)68,69,121
• Reimbursement Committee (recommendations)68,121
• Target patient population and indications (therapeutic claim) 
• Safety 
• Efficacy 
• Effectiveness (across population subgroups)38
• not specified Preference for:
•   Randomized controlled trials comparing  
pharmaceutical to standard care38
• not specified
Estonia • Ministry of Social Affairs (decisions)72
• Pharmaceuticals Committee (recommendations)67
• Safety 
• Efficacy 
• Effectiveness139
• Adverse events/complications 
• Side effects 
• Overall survival/mortality139,140
Preference for: 
• Randomized controlled trials84
• Published, peer-reviewed studies84
Finland • Pharmaceuticals Pricing Board (decisions)73,74,76
•   Pharmaceuticals Pricing Board Expert group  
(recommendations)75
• Target patient population and indications (therapeutic claim) 
• Severity and burden of illness 
• Effectiveness (across population subgroups)76
• not specified Preference for: 
•   Randomized controlled trials comparing  
pharmaceutical to standard care76
Evidence from other available direct comparative  
experimental and observational studies, as well  
as meta-analyses, should be included76
• Published, peer-reviewed studies76
France •   Ministry for health and Social Security  
(decisions)20,78
•   French national Authority for health  
(recommendations)20,78
• Target patient population and indications (therapeutic claim) 
• Current management 
• Place of technology in care pathway 
• Safety 
• Efficacy 
• Effectiveness (across population subgroups)16
• Morbidity 
• Overall survival/mortality 
• Quality of life16
Preference for:
• head-to-head, double-blind randomized controlled trials 
• Other direct comparative studies 
• Post-market studies 
•   Systematic reviews and meta-analyses of randomized  
controlled trials complying with internationally  
recognized guidelines16
• Published, peer-reviewed studies 
•   Current national and international clinical 
practice guidelines
• Expert opinion 
• Surveys of practice 
• Commercial, in-confidence data16
germany • Federal Joint Committee (decisions)19 
•   institute for Quality and Efficiency in health Care  
(recommendations)19,141
• Target patient population and indications (therapeutic claim) 
• Severity and burden of illness 
• Safety 
• Efficacy 
• Effectiveness (across population subgroups)8
• Morbidity 
• Overall survival/mortality 
• Quality of life 
• Adverse events/complications 
• Side effects 
• Duration of illness 
• health status8,83,142–144 
•   Topic specific outcomes identified  
in consultation with patient  
organizations18
• Validated surrogate outcomes83
Preference for:
•   Randomized controlled trials comparing pharmaceutical  
to placebo, standard care, or no active treatment8
Evidence from other available direct comparative  
experimental and observational studies, as well as  
systematic reviews and meta-analyses complying  
with internationally recognized guidelines,  
should also be included8
•   if no treatment alternative exists,  
well-documented case series acceptable8
• Published, peer-reviewed studies 
•   Commercial, in-confidence data not  
accepted unless it can be published18
greece •   Transparency Committee in the Reimbursement  
and Medicinal Products (makes decisions)85
• Safety 
• Efficacy 
• Effectiveness145
• not specified • not specified • not specified
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Table 3 (Continued)
Country Centralized reimbursement  
review/decision-making body (role)
Clinical evidence requirements
Topic Preferred clinical outcomes Type Source
hungary • Ministers of health and Finance (decisions)
•   national health insurance Fund Administration  
(recommendations)88
• Severity and burden of illness 
• Current management 
• Safety 
• Efficacy 
• Effectiveness (across population subgroups)90
• not specified Preference for: 
• Randomized controlled trials84
• Published, peer-reviewed studies90
ireland • health Service Executive (decisions)91,92 • Safety 
• Efficacy 
• Effectiveness (across population subgroups)146
• Morbidity 
• Overall survival/mortality 
• Quality of life 
•   QALYs – measured in patients  
but valued by public/society146
•   All other health benefits accrued  
by individuals147
Preference for: 
•   Randomized controlled trials147
Evidence from other available direct comparative  
experimental and observational studies, as well  
as systematic reviews and meta-analyses complying  
with Irish Health Technology Assessment  
Guidelines, should also be included146
• not specified
italy •   italian Medicines Agency Technical Scientific  
Committee (decisions)94
•   italian Medicines Agency Pricing and Reimbursement  
Committee (recommendations)95
• Target patient population and indications (therapeutic claim) 
• Severity and burden of illness 
• Current management 
• Safety 
• Efficacy 
• Effectiveness (across population subgroups)148
• Morbidity 
• Overall survival/mortality 
• Quality of life149
Preference for: 
•   Randomized controlled trials comparing  
pharmaceutical to standard care97
•   Evidence from other available direct experimental  
and observational studies comparing pharmaceutical  
with standard care148
• not specified
norway • norwegian Medicines Agency (decisions)98 
• Department of Pharmacoeconomics (recommendations)98
• Target patient population and indications (therapeutic claim) 
• Severity and burden of illness 
• Current management 
• Place of technology in care pathway 
• Safety 
• Efficacy 
• Effectiveness (across population subgroups)34,149
• Morbidity 
• Overall survival/mortality 
• Quality of life144
Preference for: 
• head-to-head, double-blind randomized controlled trials 
• Other direct comparative studies 
•   Systematic reviews and meta-analyses complying  
with internationally recognized guidelines149,150
• Published, peer-reviewed studies 
• Unpublished reports and studies149,150
Poland • Ministry of health (decisions)99,100 • Severity and burden of illness 
• Current management 
• Safety 
• Efficacy 
• Effectiveness (across population subgroups)151
• Morbidity 
• Overall survival/mortality 
• Quality of life151
Preference for: 
• Randomized controlled trials151
• Published, peer-reviewed studies 
• Unpublished reports and studies151
Portugal • Ministry of health (decisions) 
• inFARMED (recommendations)44
• Safety 
• Efficacy 
• Effectiveness (across population subgroups)101
• Morbidity 
• Overall survival/mortality 
• Quality of life101
Preference for: 
•   Effectiveness studies of target population (over efficacy studies)101
• Comparative clinical trials 
•   Other study designs accepted, but rationale  
must be provided101
• not specified
Scotland • national health Service Scotland (decisions)50 
• Scottish Medicines Consortium (recommendations)
• Target patient population and indications (therapeutic claim) 
• Severity and burden of illness 
• Current management 
• Place of technology in care pathway 
• “Comparative” safety 
• Efficacy 
• Effectiveness (across population subgroups)128
• Morbidity 
• Overall survival/mortality 
• Quality of life 
• QALYs (strongly preferred)50
• Randomized controlled trials required 
• Comparative observational studies accepted50 
•   if no head-to head studies available,  
indirect comparison required50
• Published, peer-reviewed studies 
• Unpublished reports and studies 
• Expert opinion 
•   Submissions from patient and carer  
organizations128
Slovakia • Ministry of health (decisions) 
•   Reimbursement Committee for Medicinal Products  
(recommendations)105,107,130
• Target patient population and indications (therapeutic claim) 
• Severity and burden of illness 
• Current management 
• Patient acceptance 
• Safety 
• Efficacy 
• Effectiveness 
• Frequency and duration of treatment106
• Morbidity 
• Overall survival/mortality 
• Adverse events/complications 
• Quality of life106
Preference for: 
• Comparative studies84
• Published, peer-reviewed studies 
•   Unpublished reports and studies with  
negative findings152
Spain •   Ministry of health Directorate general of  
Pharmacy and health Products; inter-Ministerial  
Pricing Commission (decisions)21,108
• Target patient population and indications (therapeutic claim) 
• Severity and burden of illness 
• Current management 
• Safety 
• Efficacy 
• Effectiveness132
• Morbidity 
• Overall survival/mortality 
• Quality of life 
• QALYs132
Preference for: 
•   Randomized controlled trials
Evidence from other available direct comparative  
experimental and observational studies should  
also be included132
• not specified
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Table 3 (Continued)
Country Centralized reimbursement  
review/decision-making body (role)
Clinical evidence requirements
Topic Preferred clinical outcomes Type Source
hungary • Ministers of health and Finance (decisions)
•   national health insurance Fund Administration  
(recommendations)88
• Severity and burden of illness 
• Current management 
• Safety 
• Efficacy 
• Effectiveness (across population subgroups)90
• not specified Preference for: 
• Randomized controlled trials84
• Published, peer-reviewed studies90
ireland • health Service Executive (decisions)91,92 • Safety 
• Efficacy 
• Effectiveness (across population subgroups)146
• Morbidity 
• Overall survival/mortality 
• Quality of life 
•   QALYs – measured in patients  
but valued by public/society146
•   All other health benefits accrued  
by individuals147
Preference for: 
•   Randomized controlled trials147
Evidence from other available direct comparative  
experimental and observational studies, as well  
as systematic reviews and meta-analyses complying  
with Irish Health Technology Assessment  
Guidelines, should also be included146
• not specified
italy •   italian Medicines Agency Technical Scientific  
Committee (decisions)94
•   italian Medicines Agency Pricing and Reimbursement  
Committee (recommendations)95
• Target patient population and indications (therapeutic claim) 
• Severity and burden of illness 
• Current management 
• Safety 
• Efficacy 
• Effectiveness (across population subgroups)148
• Morbidity 
• Overall survival/mortality 
• Quality of life149
Preference for: 
•   Randomized controlled trials comparing  
pharmaceutical to standard care97
•   Evidence from other available direct experimental  
and observational studies comparing pharmaceutical  
with standard care148
• not specified
norway • norwegian Medicines Agency (decisions)98 
• Department of Pharmacoeconomics (recommendations)98
• Target patient population and indications (therapeutic claim) 
• Severity and burden of illness 
• Current management 
• Place of technology in care pathway 
• Safety 
• Efficacy 
• Effectiveness (across population subgroups)34,149
• Morbidity 
• Overall survival/mortality 
• Quality of life144
Preference for: 
• head-to-head, double-blind randomized controlled trials 
• Other direct comparative studies 
•   Systematic reviews and meta-analyses complying  
with internationally recognized guidelines149,150
• Published, peer-reviewed studies 
• Unpublished reports and studies149,150
Poland • Ministry of health (decisions)99,100 • Severity and burden of illness 
• Current management 
• Safety 
• Efficacy 
• Effectiveness (across population subgroups)151
• Morbidity 
• Overall survival/mortality 
• Quality of life151
Preference for: 
• Randomized controlled trials151
• Published, peer-reviewed studies 
• Unpublished reports and studies151
Portugal • Ministry of health (decisions) 
• inFARMED (recommendations)44
• Safety 
• Efficacy 
• Effectiveness (across population subgroups)101
• Morbidity 
• Overall survival/mortality 
• Quality of life101
Preference for: 
•   Effectiveness studies of target population (over efficacy studies)101
• Comparative clinical trials 
•   Other study designs accepted, but rationale  
must be provided101
• not specified
Scotland • national health Service Scotland (decisions)50 
• Scottish Medicines Consortium (recommendations)
• Target patient population and indications (therapeutic claim) 
• Severity and burden of illness 
• Current management 
• Place of technology in care pathway 
• “Comparative” safety 
• Efficacy 
• Effectiveness (across population subgroups)128
• Morbidity 
• Overall survival/mortality 
• Quality of life 
• QALYs (strongly preferred)50
• Randomized controlled trials required 
• Comparative observational studies accepted50 
•   if no head-to head studies available,  
indirect comparison required50
• Published, peer-reviewed studies 
• Unpublished reports and studies 
• Expert opinion 
•   Submissions from patient and carer  
organizations128
Slovakia • Ministry of health (decisions) 
•   Reimbursement Committee for Medicinal Products  
(recommendations)105,107,130
• Target patient population and indications (therapeutic claim) 
• Severity and burden of illness 
• Current management 
• Patient acceptance 
• Safety 
• Efficacy 
• Effectiveness 
• Frequency and duration of treatment106
• Morbidity 
• Overall survival/mortality 
• Adverse events/complications 
• Quality of life106
Preference for: 
• Comparative studies84
• Published, peer-reviewed studies 
•   Unpublished reports and studies with  
negative findings152
Spain •   Ministry of health Directorate general of  
Pharmacy and health Products; inter-Ministerial  
Pricing Commission (decisions)21,108
• Target patient population and indications (therapeutic claim) 
• Severity and burden of illness 
• Current management 
• Safety 
• Efficacy 
• Effectiveness132
• Morbidity 
• Overall survival/mortality 
• Quality of life 
• QALYs132
Preference for: 
•   Randomized controlled trials
Evidence from other available direct comparative  
experimental and observational studies should  
also be included132
• not specified
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Table 3 (Continued)
Country Centralized reimbursement  
review/decision-making body (role)
Clinical evidence requirements
Topic Preferred clinical outcomes Type Source
Sweden • Dental and Pharmaceutical Benefits Board (decisions)15,109 • Target patient population and indications (therapeutic claim) 
• Severity and burden of illness 
• Current management 
• Safety 
• Efficacy 
• Effectiveness153
• Morbidity 
• Overall survival/mortality 
• Quality of life 
• QALYs (preferred)109
Preference for: 
•   Randomized controlled trials comparing  
pharmaceutical to standard care109
Evidence from other available direct comparative  
experimental and observational studies should  
also be included15
• Commercial, in-confidence data109 
• Published, peer-reviewed studies 
• Unpublished reports and studies 
• Ongoing studies 
•   Submissions from patient and carer 
organizations51
Switzerland • Swiss Federal Office of Public health (decisions) 
• Federal Drug Commission (recommendations)113–115
• Safety 
• Efficacy 
• Effectiveness113
• not specified • not specified • not specified
The netherlands • Ministry of health, Welfare and Sport (decisions) 
•   Medicinal Products Reimbursement Committee of  
the Dutch healthcare insurance Board  
(recommendations)116
• Target patient population and indications (therapeutic claim) 
• Severity and burden of illness 
• Safety 
• Efficacy 
• Effectiveness154
• Morbidity 
• Overall survival/mortality 
• Quality of life36,155
Preference for: 
• head-to-head randomized controlled trials 
•   Systematic reviews or meta-analyses complying  
with internationally recognized guidelines35,156
• Published, peer-reviewed studies 
• Unpublished reports and studies 
• Commercial, in-confidence data 
• Expert opinion154
United Kingdom •   national institute for health and Clinical  
Excellence (decisions)
• Technology Appraisals Committee (recommendations)7
• Target patient population and indications (therapeutic claim) 
• Severity and burden of illness 
• Current management 
• Place of technology in care pathway 
• “Comparative” safety 
• Efficacy 
• Effectiveness (across population subgroups)29
• Morbidity 
•   Overall survival/mortality  
(life years)
• Quality of life157 
•   QALYs – measured in patients  
but valued by public/society29,158
Preference for: 
•   head-to-head randomized controlled trials conducted  
in “naturalistic” settings
•   Effectiveness studies of target population  
(over efficacy studies)
•   Systematic reviews or meta-analyses complying  
with internationally recognized guidelines159
Evidence from other available direct comparative experimental  
and observational studies should also be included159 
Registries, case series, and follow-up studies also accepted159
• Published, peer-reviewed studies 
• Unpublished reports and studies 
• Commercial, in-confidence data159 
•   Submissions from patient and carer 
organizations159
•   information from health care professional 
associations, administrators, government, 
and manufacturers157
Wales • Ministry for health and Social Services (decisions) 
• All Wales Medicines Strategy group (recommendations)120
• Target patient population and indications (therapeutic claim) 
• Severity and burden of illness 
• Current management 
• Place of technology in care pathway 
• “Comparative” safety 
• Efficacy 
• Effectiveness (across population subgroups)28
• Morbidity 
• Overall survival/mortality 
• Quality of life 
• QALYs (preferred)28
•   All types of clinical studies accepted, but  
greater importance given to high quality ones28
• Published, peer-reviewed studies 
• Unpublished reports and studies 
• Expert opinion 
•   Submissions from patient and carer  
organizations describing experiences  
of those who have taken the  
pharmaceutical28
the economic evaluation, the proportion of systems adopting a 
“payer,” “societal,” or both “payer” and “societal” perspective 
is similar. Among systems considering a payer’s perspective 
only, costs to be captured are often restricted to those directly 
related to care associated with the use of the candidate technol-
ogy throughout the course of a disease or condition (ie, direct 
costs to the health care system). One exception is the National 
Institute of Health and Clinical Excellence, which specifies 
inclusion of direct and indirect costs to the National Health 
Service and Personal Social Services.13 In systems requiring 
a societal perspective, costs specified comprise direct costs to 
not only the health care system, but also services beyond health 
care and indirect (lost productivity) costs. However, they must 
be reported separately (eg, Finland, Portugal, and the Nether-
lands). In Sweden, The Dental and Pharmaceutical Benefits 
Board has taken a wider view on indirect costs, requesting that 
time lost by patients and carers be considered, along with lost 
productivity.14,15 Thus, its methods broadly resemble those of 
“holistic” economic analysis, a technique initially developed for 
economic evaluations of public programs, the costs and benefits 
of which are often complex. Nevertheless, considerable debate 
over the valuation of items such as “time lost” within academic 
and policy communities remains. This may be why other sys-
tems employing a societal perspective have assumed a narrower 
position on eligible indirect costs. With respect to the choice 
of comparator for the economic evaluation, almost all systems 
specify use of one of the following: “standard care,” “the 
most commonly used alternative,” or “alternative most likely 
to be replaced.” France also requires separate analyses with 
two additional comparators, ie, the most recently reimbursed 
alternative and the least expensive alternative.16 In Belgium, if 
the candidate technology represents an “addon” treatment, the 
  comparator must constitute current treatment without the can-
didate technology.17 Further, the use of “offlabel” treatments 
as the comparator is not permitted.11 All systems rely upon 
sensitivity analyses to assess the stability of estimates generated 
through the economic evaluation, but few stipulate the type. 
Among those that do, probabilistic sensitivity analysis is the 
most commonly prescribed (eg, Belgium, Germany, Scotland, 
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Table 3 (Continued)
Country Centralized reimbursement  
review/decision-making body (role)
Clinical evidence requirements
Topic Preferred clinical outcomes Type Source
Sweden • Dental and Pharmaceutical Benefits Board (decisions)15,109 • Target patient population and indications (therapeutic claim) 
• Severity and burden of illness 
• Current management 
• Safety 
• Efficacy 
• Effectiveness153
• Morbidity 
• Overall survival/mortality 
• Quality of life 
• QALYs (preferred)109
Preference for: 
•   Randomized controlled trials comparing  
pharmaceutical to standard care109
Evidence from other available direct comparative  
experimental and observational studies should  
also be included15
• Commercial, in-confidence data109 
• Published, peer-reviewed studies 
• Unpublished reports and studies 
• Ongoing studies 
•   Submissions from patient and carer 
organizations51
Switzerland • Swiss Federal Office of Public health (decisions) 
• Federal Drug Commission (recommendations)113–115
• Safety 
• Efficacy 
• Effectiveness113
• not specified • not specified • not specified
The netherlands • Ministry of health, Welfare and Sport (decisions) 
•   Medicinal Products Reimbursement Committee of  
the Dutch healthcare insurance Board  
(recommendations)116
• Target patient population and indications (therapeutic claim) 
• Severity and burden of illness 
• Safety 
• Efficacy 
• Effectiveness154
• Morbidity 
• Overall survival/mortality 
• Quality of life36,155
Preference for: 
• head-to-head randomized controlled trials 
•   Systematic reviews or meta-analyses complying  
with internationally recognized guidelines35,156
• Published, peer-reviewed studies 
• Unpublished reports and studies 
• Commercial, in-confidence data 
• Expert opinion154
United Kingdom •   national institute for health and Clinical  
Excellence (decisions)
• Technology Appraisals Committee (recommendations)7
• Target patient population and indications (therapeutic claim) 
• Severity and burden of illness 
• Current management 
• Place of technology in care pathway 
• “Comparative” safety 
• Efficacy 
• Effectiveness (across population subgroups)29
• Morbidity 
•   Overall survival/mortality  
(life years)
• Quality of life157 
•   QALYs – measured in patients  
but valued by public/society29,158
Preference for: 
•   head-to-head randomized controlled trials conducted  
in “naturalistic” settings
•   Effectiveness studies of target population  
(over efficacy studies)
•   Systematic reviews or meta-analyses complying  
with internationally recognized guidelines159
Evidence from other available direct comparative experimental  
and observational studies should also be included159 
Registries, case series, and follow-up studies also accepted159
• Published, peer-reviewed studies 
• Unpublished reports and studies 
• Commercial, in-confidence data159 
•   Submissions from patient and carer 
organizations159
•   information from health care professional 
associations, administrators, government, 
and manufacturers157
Wales • Ministry for health and Social Services (decisions) 
• All Wales Medicines Strategy group (recommendations)120
• Target patient population and indications (therapeutic claim) 
• Severity and burden of illness 
• Current management 
• Place of technology in care pathway 
• “Comparative” safety 
• Efficacy 
• Effectiveness (across population subgroups)28
• Morbidity 
• Overall survival/mortality 
• Quality of life 
• QALYs (preferred)28
•   All types of clinical studies accepted, but  
greater importance given to high quality ones28
• Published, peer-reviewed studies 
• Unpublished reports and studies 
• Expert opinion 
•   Submissions from patient and carer  
organizations describing experiences  
of those who have taken the  
pharmaceutical28
In recent years, affordability has become an increasingly 
important consideration for centralized reimbursement sys-
tems, with almost all of those included in this review (where 
information could be found) requiring a budget impact analysis 
(Table 4). However, some waive this analysis in certain circum-
stances, eg, when no alternative treatment exists (Belgium).17 
Although information describing the specific costs to be 
included appears scarce, based on that available, they mirror 
those for the economic evaluation of the same technology. Spe-
cifically, if the economic evaluation is limited to direct costs, so 
must the budget impact analysis, eg, Hungary and Ireland.
Reimbursement decisions: review 
committee composition, procedures,  
and key factors
In most of the centralized reimbursement systems, the assess-
ment and evaluation reports are sent to and scrutinized by 
a review committee (sometimes referred to as an appraisal 
committee). While the composition of this committee varies 
across systems, it is usually multidisciplinary, with members 
representing payers, administrators, health care providers, and 
academia (eg, health economists, Table 5). Approximately 
one-third have also appointed patient representatives to their 
respective committees (eg, Sweden, Switzerland, and the 
UK), although not always as voting members (Germany),18,19 
and one-fifth include manufacturers (Belgium, Switzerland, 
the UK, and Wales). In most systems, the authority of the 
review committee is advisory (ie, makes recommendations). 
Aside from lists of factors/criteria considered (Table 6), 
publicly available procedural information on committee 
deliberations is often limited to conditions under which 
presentations/testimonials from external experts (including 
patients) are sought or accepted and whether an incremental 
cost-effectiveness ratio threshold is employed. Among the 
exceptions is France. There, review committees (the Com-
mission d’Evaluation des Medicaments (CEM), followed by 
the Transparency Commission) adhere to a two stage process. 
First, the CEM assigns a “medical benefit” or “SMR” level/ClinicoEconomics and Outcomes Research 2011:3 submit your manuscript | www.dovepress.com
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Table 4 Comparison of economic evidence requirements
Country Centralized reimbursement  
review/decision-making  
body (role)
Economic analysis Budget impact analysis Other economic  
information Required Economic analysis  
types accepted
Perspective/ 
costs included
Comparator Sensitivity  
analysis
Systematic review  
of economic 
analysis studies
Required Costs  
included
Austria •   Association of Austrian  
Social Security institutions  
(decisions)55
•   Pharmaceutical Evaluation  
Board (recommendations)56
Yes for: 
• “  innovative products providing 
substantial therapeutic benefit
• “  where no comparable medical 
 preparation exists”21
•   Any type, but rationale  
for selection must be  
provided21
•   Should comply  
with internationally  
recognized  
pharmacoeconomic  
guidelines21
• Payer21 
•   Costs not  
specified
•   Most commonly used  
alternative21
Yes – type  
not specified21
Yes no information  
found
n/A • 3 year market sales forecast 
•   Price in other European Union  
countries
•   Reimbursement status in other  
European Union countries55
Belgium •   Minister of Social Affairs  
(decisions)
•   Commission on  
reimbursement of medicines/ 
drug reimbursement  
committee  
(recommendations)9,60
Yes for: 
•   Pharmaceuticals with added  
therapeutic value relative to  
existing alternatives (Class i)11,17
not required for orphan  
pharmaceuticals62
• Cost effectiveness 
• Cost utility 
•   Cost benefit not  
accepted11
•   Should comply  
with Belgium  
pharmacoeconomic  
guidelines17
•   Payer (includes  
patient  
copayments and  
government)11,17
•   Direct costs  
only11,17
•   Most commonly used  
alternative OR
•   Alternative most likely  
to be replaced
•   if add-on: current  
treatment without add-on17
•     Off-label treatments not  
acceptable11 
Rationale must be provided
Probabilistic17 Yes17 Yes11 •   Direct costs  
only11,17
• Price 
•   Reimbursement status in other  
European Union countries11,17
Czech  
Republic
•   State institute for Drug  
Control (decisions)65
Yes66 • Cost effectiveness138 • Payer66 
• Direct costs138
no information found Method not  
specified
no information  
found
Yes138 no information  
found
no information found
Denmark •   Danish Medicines Agency  
(decisions)68,69,121
•   Reimbursement Committee  
(recommendations)68,121
no, but often included  
to justify high price68,71,160
• Cost effectiveness 
•   Cost utility68
if included, methods  
should comply with  
Danish guidelines for  
the Socio-economic  
Analysis of Medicines68
•   Societal  
(if included)
•   Direct, indirect,  
and intangible;  
to be reported  
separately71
•   Most commonly used  
alternative38
Method not  
specified, but  
key parameters  
associated with  
uncertainty  
should be  
explored38
no information  
found
Yes38 no information  
found
•   Reimbursement status in other  
European Union countries
•   Estimated consumption  
(number of patients and  
utilization)38
Estonia •   Ministry of Social Affairs  
(decisions)72
•   Pharmaceuticals Committee  
(recommendations)72
Yes84,139 • Cost effectiveness 
• Cost utility 
•   Cost minimization 
rationale for selection  
must be provided139
• Payer139 
•   May present  
separate analysis  
from societal  
perspective84
•   Direct costs within  
and outside of the  
health care system  
(should be reported  
separately)139
•   Most commonly used  
alternative OR
•   Standard care139 
Rationale must be provided
Method not  
specified
no information  
found
no information  
found
no information  
found
no information found
Finland •   Pharmaceuticals Pricing  
Board (decisions)73,74,76
•   Pharmaceuticals Pricing  
Board Expert group  
(recommendations)75
Yes for: 
Pharmaceuticals considered  
for reimbursement in one of 
the special refund categories74,76
•   Any type, but  
rationale for selection  
must be provided76
•   Methods must comply  
with Ministry of Social  
Affairs and health  
guidelines76
• Societal76 
•   Direct and  
indirect costs – 
presented  
separately76
•   Alternative most likely  
to be replaced OR
•   Most commonly used  
alternative OR
• Most effective alternative OR 
•   Minimum management76 
Rationale must be provided
Method not  
specified
Yes76 Yes161 no information  
found
• Market sales forecast 
•   Reimbursement status in other  
European Union countries
•   Estimated consumption (number  
of patients and utilization)161
France •   Ministry for health and  
Social Security (decisions)20,78
•   French national Authority for  
health (recommendations)78
Yes for: 
•   Multiple technology appraisals  
of pharmaceuticals20
•   Any type, but  
rationale for selection  
must be provided22
•   Methods must comply 
with French economic  
guidelines20
•   Varies, but should 
take the widest 
possible perspective – 
rationale for  
selection must  
be provided 84
•   Direct costs; may 
include indirect 
costs, but must be 
presented separately22
Following 3 comparators 
required: 
•   Most commonly used 
alternative
•   Most recently reimbursed 
alternative
• Least expensive alternative16
Method not  
specified
Yes for  
pharmaceuticals22
Yes20 no information  
found
• Market sales forecast 
•   Reimbursement status in other  
European Union countries
•   Breakdown of costs  
for manufacturing and  
distribution22,162
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Table 4 Comparison of economic evidence requirements
Country Centralized reimbursement  
review/decision-making  
body (role)
Economic analysis Budget impact analysis Other economic  
information Required Economic analysis  
types accepted
Perspective/ 
costs included
Comparator Sensitivity  
analysis
Systematic review  
of economic 
analysis studies
Required Costs  
included
Austria •   Association of Austrian  
Social Security institutions  
(decisions)55
•   Pharmaceutical Evaluation  
Board (recommendations)56
Yes for: 
• “  innovative products providing 
substantial therapeutic benefit
• “  where no comparable medical 
 preparation exists”21
•   Any type, but rationale  
for selection must be  
provided21
•   Should comply  
with internationally  
recognized  
pharmacoeconomic  
guidelines21
• Payer21 
•   Costs not  
specified
•   Most commonly used  
alternative21
Yes – type  
not specified21
Yes no information  
found
n/A • 3 year market sales forecast 
•   Price in other European Union  
countries
•   Reimbursement status in other  
European Union countries55
Belgium •   Minister of Social Affairs  
(decisions)
•   Commission on  
reimbursement of medicines/ 
drug reimbursement  
committee  
(recommendations)9,60
Yes for: 
•   Pharmaceuticals with added  
therapeutic value relative to  
existing alternatives (Class i)11,17
not required for orphan  
pharmaceuticals62
• Cost effectiveness 
• Cost utility 
•   Cost benefit not  
accepted11
•   Should comply  
with Belgium  
pharmacoeconomic  
guidelines17
•   Payer (includes  
patient  
copayments and  
government)11,17
•   Direct costs  
only11,17
•   Most commonly used  
alternative OR
•   Alternative most likely  
to be replaced
•   if add-on: current  
treatment without add-on17
•     Off-label treatments not  
acceptable11 
Rationale must be provided
Probabilistic17 Yes17 Yes11 •   Direct costs  
only11,17
• Price 
•   Reimbursement status in other  
European Union countries11,17
Czech  
Republic
•   State institute for Drug  
Control (decisions)65
Yes66 • Cost effectiveness138 • Payer66 
• Direct costs138
no information found Method not  
specified
no information  
found
Yes138 no information  
found
no information found
Denmark •   Danish Medicines Agency  
(decisions)68,69,121
•   Reimbursement Committee  
(recommendations)68,121
no, but often included  
to justify high price68,71,160
• Cost effectiveness 
•   Cost utility68
if included, methods  
should comply with  
Danish guidelines for  
the Socio-economic  
Analysis of Medicines68
•   Societal  
(if included)
•   Direct, indirect,  
and intangible;  
to be reported  
separately71
•   Most commonly used  
alternative38
Method not  
specified, but  
key parameters  
associated with  
uncertainty  
should be  
explored38
no information  
found
Yes38 no information  
found
•   Reimbursement status in other  
European Union countries
•   Estimated consumption  
(number of patients and  
utilization)38
Estonia •   Ministry of Social Affairs  
(decisions)72
•   Pharmaceuticals Committee  
(recommendations)72
Yes84,139 • Cost effectiveness 
• Cost utility 
•   Cost minimization 
rationale for selection  
must be provided139
• Payer139 
•   May present  
separate analysis  
from societal  
perspective84
•   Direct costs within  
and outside of the  
health care system  
(should be reported  
separately)139
•   Most commonly used  
alternative OR
•   Standard care139 
Rationale must be provided
Method not  
specified
no information  
found
no information  
found
no information  
found
no information found
Finland •   Pharmaceuticals Pricing  
Board (decisions)73,74,76
•   Pharmaceuticals Pricing  
Board Expert group  
(recommendations)75
Yes for: 
Pharmaceuticals considered  
for reimbursement in one of 
the special refund categories74,76
•   Any type, but  
rationale for selection  
must be provided76
•   Methods must comply  
with Ministry of Social  
Affairs and health  
guidelines76
• Societal76 
•   Direct and  
indirect costs – 
presented  
separately76
•   Alternative most likely  
to be replaced OR
•   Most commonly used  
alternative OR
• Most effective alternative OR 
•   Minimum management76 
Rationale must be provided
Method not  
specified
Yes76 Yes161 no information  
found
• Market sales forecast 
•   Reimbursement status in other  
European Union countries
•   Estimated consumption (number  
of patients and utilization)161
France •   Ministry for health and  
Social Security (decisions)20,78
•   French national Authority for  
health (recommendations)78
Yes for: 
•   Multiple technology appraisals  
of pharmaceuticals20
•   Any type, but  
rationale for selection  
must be provided22
•   Methods must comply 
with French economic  
guidelines20
•   Varies, but should 
take the widest 
possible perspective – 
rationale for  
selection must  
be provided 84
•   Direct costs; may 
include indirect 
costs, but must be 
presented separately22
Following 3 comparators 
required: 
•   Most commonly used 
alternative
•   Most recently reimbursed 
alternative
• Least expensive alternative16
Method not  
specified
Yes for  
pharmaceuticals22
Yes20 no information  
found
• Market sales forecast 
•   Reimbursement status in other  
European Union countries
•   Breakdown of costs  
for manufacturing and  
distribution22,162
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Table 4 (Continued)
Country Centralized reimbursement  
review/decision-making  
body (role)
Economic analysis Budget impact analysis Other economic  
information Required Economic analysis  
types accepted
Perspective/ 
costs included
Comparator Sensitivity  
analysis
Systematic review  
of economic 
analysis studies
Required Costs  
included
germany •   Federal Joint Committee 
(decisions)19
•   institute for Quality and  
Efficiency in health Care  
(recommendations)19,24,144
Yes for: 
•   Technologies where  
alternative treatment exists8,18
Any one of: 
• Cost effectiveness 
• Cost utility 
•   Cost minimization/ 
cost comparison18
Efficiency frontier analysis12
• Payer 
• Patient83 
•   Direct and  
indirect costs8
•   Most commonly used  
alternative OR
•   Most effective alternative  
OR
• Minimum standard care8
One-way and  
multi-way  
(performed as  
probabilistic)24
Yes84 Yes, except  
when  
no alternative  
exists18
no information  
found
no information found
greece •   Transparency Committee  
in the Reimbursement and  
Medicinal Products  
(makes decisions)85,160
Yes for: 
•   Pharmaceuticals eligible for  
reference price system85
no information found no information found no information found no information  
found
no information  
found
Yes85 no information  
found
• Cost of daily treatment 
•   Reimbursement status in other  
European Union countries85
hungary •   Ministers of health and Finance 
(decisions)
•   national health insurance  
Fund Administration  
(recommendations)86,90,102
Yes84 Preference for: 
• Cost effectiveness 
• Cost utility163
• Payer 
•   Societal (also 
recommended) 
Report results from 
each perspective 
separately163
• Standard care163 Yes, but type  
not specified163
no information  
found
Yes84 •   if payer  
perspective,  
include direct 
costs only
•   if societal 
perspective,  
include 
indirect costs 
(productivity)163
no information found
ireland •   health Service Executive  
(decisions)91,92
Yes146 Preference for: 
• Cost utility10 
Any one of the following  
may be acceptable if  
rationale is provided: 
• Cost benefit 
• Cost effectiveness 
•   Cost minimization/ 
cost comparison147,165
•   Methods must comply with  
irish healthcare Technology  
Assessment guidelines146
• Payer147 
•   Direct costs  
only147
• Standard care125 Probabilistic and  
deterministic125
no information  
found
Yes •   Direct costs 
only91,147
no information found
italy •   italian Medicines Agency  
Technical Scientific  
Committee (decisions)94
•   italian Medicines Agency Pricing  
and Reimbursement Committee  
(recommendations)95
Yes for: 
•   Pharmaceuticals with a  
favorable “risk/benefit  
profile”97,148
Preference for: 
• Cost utility 
• Cost effectiveness148 
•   Methods must  
comply with italian  
pharmacoeconomic  
guidelines148
• Societal AnD 
• Payer148 
•   Direct and  
indirect costs148
•   Most commonly used  
alternative148
Methods not  
specified, but  
should involve  
multi-way  
analysis148
no information  
found
Yes148 no information  
found
•   Cost of treatment compared to  
those in same therapeutic class
• Market sales forecast 
•   Price in other European Union 
countries
•   Reimbursement status in other  
European Union countries
•   Estimated consumption (number  
of patients and utilization)
• industrial implications97
norway •   norwegian Medicines  
Agency (decisions)98
•   Department of Pharmaco 
economics (recommendations)98
Yes for: 
•   Pharmaceuticals with added  
therapeutic value relative to  
existing alternatives34
Preference for: 
•   Cost-value analysis150
Any one of the following  
may be acceptable if  
rationale is provided:
• Cost benefit 
• Cost effectiveness 
• Cost utility 
• Cost consequence 
•   Cost minimization/ 
cost comparison34 
•   Methods must comply 
with norwegian 
pharmacoeconomic 
guidelines34
• Societal AnD 
• Payer150
•   Most commonly used  
alternative OR 
• Least expensive alternative150
Probabilistic  
preferred150
no information  
found
Yes149 
Aggregate  
added  
expense to  
health service  
for first  
5 years149
no information 
found
• Market sales forecast 
•   Price in other European Union  
countries
•   Reimbursement status in other  
European Union countries
•   Estimated consumption (number  
of patients and utilization)149,150
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Table 4 (Continued)
Country Centralized reimbursement  
review/decision-making  
body (role)
Economic analysis Budget impact analysis Other economic  
information Required Economic analysis  
types accepted
Perspective/ 
costs included
Comparator Sensitivity  
analysis
Systematic review  
of economic 
analysis studies
Required Costs  
included
germany •   Federal Joint Committee 
(decisions)19
•   institute for Quality and  
Efficiency in health Care  
(recommendations)19,24,144
Yes for: 
•   Technologies where  
alternative treatment exists8,18
Any one of: 
• Cost effectiveness 
• Cost utility 
•   Cost minimization/ 
cost comparison18
Efficiency frontier analysis12
• Payer 
• Patient83 
•   Direct and  
indirect costs8
•   Most commonly used  
alternative OR
•   Most effective alternative  
OR
• Minimum standard care8
One-way and  
multi-way  
(performed as  
probabilistic)24
Yes84 Yes, except  
when  
no alternative  
exists18
no information  
found
no information found
greece •   Transparency Committee  
in the Reimbursement and  
Medicinal Products  
(makes decisions)85,160
Yes for: 
•   Pharmaceuticals eligible for  
reference price system85
no information found no information found no information found no information  
found
no information  
found
Yes85 no information  
found
• Cost of daily treatment 
•   Reimbursement status in other  
European Union countries85
hungary •   Ministers of health and Finance 
(decisions)
•   national health insurance  
Fund Administration  
(recommendations)86,90,102
Yes84 Preference for: 
• Cost effectiveness 
• Cost utility163
• Payer 
•   Societal (also 
recommended) 
Report results from 
each perspective 
separately163
• Standard care163 Yes, but type  
not specified163
no information  
found
Yes84 •   if payer  
perspective,  
include direct 
costs only
•   if societal 
perspective,  
include 
indirect costs 
(productivity)163
no information found
ireland •   health Service Executive  
(decisions)91,92
Yes146 Preference for: 
• Cost utility10 
Any one of the following  
may be acceptable if  
rationale is provided: 
• Cost benefit 
• Cost effectiveness 
•   Cost minimization/ 
cost comparison147,165
•   Methods must comply with  
irish healthcare Technology  
Assessment guidelines146
• Payer147 
•   Direct costs  
only147
• Standard care125 Probabilistic and  
deterministic125
no information  
found
Yes •   Direct costs 
only91,147
no information found
italy •   italian Medicines Agency  
Technical Scientific  
Committee (decisions)94
•   italian Medicines Agency Pricing  
and Reimbursement Committee  
(recommendations)95
Yes for: 
•   Pharmaceuticals with a  
favorable “risk/benefit  
profile”97,148
Preference for: 
• Cost utility 
• Cost effectiveness148 
•   Methods must  
comply with italian  
pharmacoeconomic  
guidelines148
• Societal AnD 
• Payer148 
•   Direct and  
indirect costs148
•   Most commonly used  
alternative148
Methods not  
specified, but  
should involve  
multi-way  
analysis148
no information  
found
Yes148 no information  
found
•   Cost of treatment compared to  
those in same therapeutic class
• Market sales forecast 
•   Price in other European Union 
countries
•   Reimbursement status in other  
European Union countries
•   Estimated consumption (number  
of patients and utilization)
• industrial implications97
norway •   norwegian Medicines  
Agency (decisions)98
•   Department of Pharmaco 
economics (recommendations)98
Yes for: 
•   Pharmaceuticals with added  
therapeutic value relative to  
existing alternatives34
Preference for: 
•   Cost-value analysis150
Any one of the following  
may be acceptable if  
rationale is provided:
• Cost benefit 
• Cost effectiveness 
• Cost utility 
• Cost consequence 
•   Cost minimization/ 
cost comparison34 
•   Methods must comply 
with norwegian 
pharmacoeconomic 
guidelines34
• Societal AnD 
• Payer150
•   Most commonly used  
alternative OR 
• Least expensive alternative150
Probabilistic  
preferred150
no information  
found
Yes149 
Aggregate  
added  
expense to  
health service  
for first  
5 years149
no information 
found
• Market sales forecast 
•   Price in other European Union  
countries
•   Reimbursement status in other  
European Union countries
•   Estimated consumption (number  
of patients and utilization)149,150
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Table 4 (Continued)
Country Centralized reimbursement  
review/decision-making  
body (role)
Economic analysis Budget impact analysis Other economic  
information Required Economic analysis  
types accepted
Perspective/ 
costs included
Comparator Sensitivity  
analysis
Systematic review  
of economic 
analysis studies
Required Costs  
included
Poland •   Ministry of health  
(decisions)99,166
Yes for: 
•   Pharmaceuticals with added  
therapeutic value relative  
to existing alternatives84
• Cost effectiveness 
• Cost utility84
• Societal AnD 
• Payer167
•   Alternative most likely  
to be replaced OR
•   Most commonly used  
alternative OR
•   Least expensive alternative  
OR
•   Standard care compliant  
with clinical practice  
guidelines151
Methods not  
specified
no information  
found
Yes84 no information  
found
no information found
Portugal • Ministry of health (decisions) 
•   inFARMED  
(recommendations)64,160
Yes44,160 Any one of : 
• Cost benefit 
• Cost effectiveness 
• Cost utility 
•   Cost minimization/ 
cost comparison;  
rationale for selection  
must be provided101
• Societal101 
• Direct costs 
•   indirect costs:  
only those  
related to lost  
productivity101
•   Most commonly used  
alternative
• Standard care101
Methods not  
specified
no information  
found
no101 n/A no information found
Scotland •   national health Service  
Scotland (decisions)30
•   Scottish Medicines Consortium  
(recommendations)
Yes168 Any one of : 
• Cost benefit 
• Cost effectiveness 
• Cost utility 
•   Cost minimization/ 
cost comparison;  
rationale for selection  
must be provided168
•   Methods must comply  
with SMC economic  
guidelines168
• Payer30 •   Alternative most likely  
to be replaced OR
•   Most commonly used  
alternative30
Probabilistic168 no information  
found
Yes30 no information  
found
•   national health Service  
resource implications30
Slovakia • Ministry of health (decisions) 
•   Reimbursement Committee  
for Medicinal Products  
(recommendations)105,107
Yes105,106 • Cost effectiveness 
•   Cost utility  
(if pharmaceutical has  
impact on quality of life)
•   Cost minimization/ 
cost comparison
•   Cost benefit not  
accepted169
Methods should comply  
with national economic  
guidelines170
• Payer169 
• Direct costs169
•   Alternative most likely  
to be replaced
•   if add-on: current  
treatment without add-on152
Probabilistic106,152 Yes152 Yes 
Estimated over  
first 5 years84
no information  
found
no information found
Spain •   Ministry of health Directorate  
general of Pharmacy and  
health Products; inter- 
Ministerial Pricing Commission  
(decisions)21,108,171
no21 Preference for: 
• Cost effectiveness 
• Cost utility10,21 
Any one of the  
following may be  
acceptable if rationale  
is provided: 
• Cost benefit 
• Cost effectiveness 
• Cost utility 
• Cost consequence 
•   Cost minimization/ 
cost comparison10
• Societal AnD 
•   Payer10 
Presented  
separately
•   Most commonly used  
alternative 
•   Standard care10
Rationale must be provided
Multi-way10 no information  
found
Yes, comparing  
“corresponding  
products”10
no information  
found
no information found
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Table 4 (Continued)
Country Centralized reimbursement  
review/decision-making  
body (role)
Economic analysis Budget impact analysis Other economic  
information Required Economic analysis  
types accepted
Perspective/ 
costs included
Comparator Sensitivity  
analysis
Systematic review  
of economic 
analysis studies
Required Costs  
included
Poland •   Ministry of health  
(decisions)99,166
Yes for: 
•   Pharmaceuticals with added  
therapeutic value relative  
to existing alternatives84
• Cost effectiveness 
• Cost utility84
• Societal AnD 
• Payer167
•   Alternative most likely  
to be replaced OR
•   Most commonly used  
alternative OR
•   Least expensive alternative  
OR
•   Standard care compliant  
with clinical practice  
guidelines151
Methods not  
specified
no information  
found
Yes84 no information  
found
no information found
Portugal • Ministry of health (decisions) 
•   inFARMED  
(recommendations)64,160
Yes44,160 Any one of : 
• Cost benefit 
• Cost effectiveness 
• Cost utility 
•   Cost minimization/ 
cost comparison;  
rationale for selection  
must be provided101
• Societal101 
• Direct costs 
•   indirect costs:  
only those  
related to lost  
productivity101
•   Most commonly used  
alternative
• Standard care101
Methods not  
specified
no information  
found
no101 n/A no information found
Scotland •   national health Service  
Scotland (decisions)30
•   Scottish Medicines Consortium  
(recommendations)
Yes168 Any one of : 
• Cost benefit 
• Cost effectiveness 
• Cost utility 
•   Cost minimization/ 
cost comparison;  
rationale for selection  
must be provided168
•   Methods must comply  
with SMC economic  
guidelines168
• Payer30 •   Alternative most likely  
to be replaced OR
•   Most commonly used  
alternative30
Probabilistic168 no information  
found
Yes30 no information  
found
•   national health Service  
resource implications30
Slovakia • Ministry of health (decisions) 
•   Reimbursement Committee  
for Medicinal Products  
(recommendations)105,107
Yes105,106 • Cost effectiveness 
•   Cost utility  
(if pharmaceutical has  
impact on quality of life)
•   Cost minimization/ 
cost comparison
•   Cost benefit not  
accepted169
Methods should comply  
with national economic  
guidelines170
• Payer169 
• Direct costs169
•   Alternative most likely  
to be replaced
•   if add-on: current  
treatment without add-on152
Probabilistic106,152 Yes152 Yes 
Estimated over  
first 5 years84
no information  
found
no information found
Spain •   Ministry of health Directorate  
general of Pharmacy and  
health Products; inter- 
Ministerial Pricing Commission  
(decisions)21,108,171
no21 Preference for: 
• Cost effectiveness 
• Cost utility10,21 
Any one of the  
following may be  
acceptable if rationale  
is provided: 
• Cost benefit 
• Cost effectiveness 
• Cost utility 
• Cost consequence 
•   Cost minimization/ 
cost comparison10
• Societal AnD 
•   Payer10 
Presented  
separately
•   Most commonly used  
alternative 
•   Standard care10
Rationale must be provided
Multi-way10 no information  
found
Yes, comparing  
“corresponding  
products”10
no information  
found
no information found
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Table 4 (Continued)
Country Centralized reimbursement  
review/decision-making  
body (role)
Economic analysis Budget impact analysis Other economic  
information Required Economic analysis  
types accepted
Perspective/ 
costs included
Comparator Sensitivity  
analysis
Systematic review  
of economic 
analysis studies
Required Costs  
included
Sweden •   Dental and Pharmaceutical  
Benefits Board (decisions)15,109
Yes, if requested21 Any one of: 
• Cost effectiveness 
• Cost utility 
•   Cost minimization/ 
cost comparison;  
rationale for selection  
must be provided15
•   Methods must comply  
with Swedish economic 
guidelines15
• Societal 
• Direct costs 
•   indirect costs:  
lost productivity  
and lost time  
for patients and  
carers14,15
•   Most commonly used  
alternative15
not specified no information  
found
•   Estimated average  
duration of use
•   Estimated consumption (number  
of patients and utilization)
• Estimated cost of use per day15
Switzerland •   Swiss Federal Office of Public  
health (decisions)
•   Federal Drug Commission 
(recommendations)113,114
no, but should be included 
if available115,172
no information found no information found no information found no information  
found
no information  
found
Yes115,172 no information  
found
•   Price in other European Union  
countries
•   Reimbursement status in other  
European Union countries
•   Estimated cost of use per 
day115,172
The netherlands •   Ministry of health, Welfare  
and Sport (decisions)
•   Medicinal Products  
Reimbursement Committee  
of the Dutch healthcare  
insurance Board  
(recommendations)116
Yes for pharmaceuticals  
with added therapeutic value  
(Annex 1B), except for orphan  
pharmaceuticals with small  
budget impact or absence  
of active alternative154
• Cost effectiveness 
• Cost utility 
•   Methods must  
comply with Dutch  
healthcare insurance  
Board economic  
guidelines36,84,173
• Societal 
• Direct costs154 
•   indirect costs  
may be included  
but must be  
reported  
separately154
•   Most commonly used  
alternative OR
•   Most relevant reimbursed  
alternative84,173
One-way,  
multi-way, and  
probabilistic35
no information  
found
Yes154 no information  
found
• Anticipated substitution effects 
• Price 
•   Estimated consumption (number  
of patients and utilization)154
United  
Kingdom
•   national institute for health  
and Clinical Excellence  
(decisions)
•   Technology Appraisals  
Committee (recommendations)7
Yes7 • Cost effectiveness 
• Cost utility 
•   Methods must comply  
with national institute  
for health and Clinical  
Excellence economic  
guidelines13,157
• Payer13,157 
•   Direct and  
indirect costs to  
national health  
Service and  
Personal Social  
Services
•   Most commonly used  
alternative OR
• Best practice alternative13,157
Probabilistic157 Yes13,157 Yes13,157 no information  
found
•   national health Service  
resource implications13,157
Wales •   Ministry for health and Social  
Services (decisions)
•   All Wales Medicines Strategy  
group (recommendations)28
Yes174 Any one of: 
• Cost effectiveness 
• Cost utility 
•   Cost minimization/ 
cost comparison;  
rationale for selection  
must be provided28,174
•   Methods must comply  
with economic  
guidelines28,174
• Societal28 •   Most commonly used  
alternative28
Probabilistic28 Yes28 Yes28,174 no information  
found
•   national health Service  
resource implications28,174
score to the candidate technology (a new pharmaceutical). 
The score is based on a five-point scale, with “I” representing 
“major medical benefit” and “V” representing “insufficient 
to justify reimbursement.”16,20–23 Upon approval of the score 
by the Minister, the CEM then compares the technology 
with already reimbursed alternatives in order to formulate an 
opinion on the “improvement in medical benefit” or “ASMR” 
level. Six possible levels exist, ranging from I (major inno-
vation) to VI (negative opinion regarding inclusion on the 
benefit list). Therefore, “  innovativeness” is viewed as the size 
of the incremental clinical benefit achieved by the candidate 
technology. The opinion of the CEM is forwarded to the 
Transparency Commission, who makes a formal recommen-
dation on the ASMR classification. This classification is, in 
turn, used to negotiate price and reimbursement rate. In Ger-
many, the “innovativeness” of a technology is also based on 
whether it offers “added therapeutic value.” Moreover, it plays 
an important role in determining the content of subsequent 
committee   deliberations, because “cost-benefit” analyses are 
only taken into account when a technology has been deemed ClinicoEconomics and Outcomes Research 2011:3 submit your manuscript | www.dovepress.com
Dovepress 
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Table 4 (Continued)
Country Centralized reimbursement  
review/decision-making  
body (role)
Economic analysis Budget impact analysis Other economic  
information Required Economic analysis  
types accepted
Perspective/ 
costs included
Comparator Sensitivity  
analysis
Systematic review  
of economic 
analysis studies
Required Costs  
included
Sweden •   Dental and Pharmaceutical  
Benefits Board (decisions)15,109
Yes, if requested21 Any one of: 
• Cost effectiveness 
• Cost utility 
•   Cost minimization/ 
cost comparison;  
rationale for selection  
must be provided15
•   Methods must comply  
with Swedish economic 
guidelines15
• Societal 
• Direct costs 
•   indirect costs:  
lost productivity  
and lost time  
for patients and  
carers14,15
•   Most commonly used  
alternative15
not specified no information  
found
•   Estimated average  
duration of use
•   Estimated consumption (number  
of patients and utilization)
• Estimated cost of use per day15
Switzerland •   Swiss Federal Office of Public  
health (decisions)
•   Federal Drug Commission 
(recommendations)113,114
no, but should be included 
if available115,172
no information found no information found no information found no information  
found
no information  
found
Yes115,172 no information  
found
•   Price in other European Union  
countries
•   Reimbursement status in other  
European Union countries
•   Estimated cost of use per 
day115,172
The netherlands •   Ministry of health, Welfare  
and Sport (decisions)
•   Medicinal Products  
Reimbursement Committee  
of the Dutch healthcare  
insurance Board  
(recommendations)116
Yes for pharmaceuticals  
with added therapeutic value  
(Annex 1B), except for orphan  
pharmaceuticals with small  
budget impact or absence  
of active alternative154
• Cost effectiveness 
• Cost utility 
•   Methods must  
comply with Dutch  
healthcare insurance  
Board economic  
guidelines36,84,173
• Societal 
• Direct costs154 
•   indirect costs  
may be included  
but must be  
reported  
separately154
•   Most commonly used  
alternative OR
•   Most relevant reimbursed  
alternative84,173
One-way,  
multi-way, and  
probabilistic35
no information  
found
Yes154 no information  
found
• Anticipated substitution effects 
• Price 
•   Estimated consumption (number  
of patients and utilization)154
United  
Kingdom
•   national institute for health  
and Clinical Excellence  
(decisions)
•   Technology Appraisals  
Committee (recommendations)7
Yes7 • Cost effectiveness 
• Cost utility 
•   Methods must comply  
with national institute  
for health and Clinical  
Excellence economic  
guidelines13,157
• Payer13,157 
•   Direct and  
indirect costs to  
national health  
Service and  
Personal Social  
Services
•   Most commonly used  
alternative OR
• Best practice alternative13,157
Probabilistic157 Yes13,157 Yes13,157 no information  
found
•   national health Service  
resource implications13,157
Wales •   Ministry for health and Social  
Services (decisions)
•   All Wales Medicines Strategy  
group (recommendations)28
Yes174 Any one of: 
• Cost effectiveness 
• Cost utility 
•   Cost minimization/ 
cost comparison;  
rationale for selection  
must be provided28,174
•   Methods must comply  
with economic  
guidelines28,174
• Societal28 •   Most commonly used  
alternative28
Probabilistic28 Yes28 Yes28,174 no information  
found
•   national health Service  
resource implications28,174
innovative.18–24 The review committee of the Italian Medicines 
Agency, ie, the Technical Scientific Committee, explicitly 
weighs both the availability of existing treatments and the 
extent of clinical benefit in its assessment of a new pharma-
ceutical’s innovativeness. The two attributes are scored sepa-
rately and then combined to determine whether it represents 
an “important,” “moderate,” or “modest”   innovation.25 This 
rating, along with the category of clinical value to which the 
pharmaceutical has been assigned, is sent to a second review 
committee, ie, the Pricing and Reimbursement Committee, 
which negotiates price and reimbursement status with the 
manufacturer.26,27
Regardless of the reimbursement system, one of the main 
goals of the review committee is to determine the “thera-
peutic value” of a candidate technology. Broadly, its assess-
ment combines consideration of clinical benefit with that of 
clinical need, taking into account key factors related to each 
  dimension. For clinical need, they comprise, at a   minimum, 
burden of illness (prevalence of severity) of the target 
  condition and availability of alternatives. For clinical benefit, ClinicoEconomics and Outcomes Research 2011:3 submit your manuscript | www.dovepress.com
Dovepress 
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t
i
v
e
n
e
s
s
,
 
a
p
p
l
i
c
a
b
i
l
i
t
y
,
 
a
n
d
 
c
o
n
v
e
n
i
e
n
c
e
 
 
b
a
s
e
d
 
o
n
 
e
v
i
d
e
n
c
e
 
s
u
b
m
i
t
t
e
d
 
b
y
 
m
a
n
u
f
a
c
t
u
r
e
r
;
 
p
r
i
c
i
n
g
 
 
c
o
m
m
i
s
s
i
o
n
 
s
i
m
u
l
t
a
n
e
o
u
s
l
y
 
e
x
a
m
i
n
e
s
 
p
r
i
c
i
n
g
 
d
o
s
s
i
e
r
,
 
 
d
e
t
e
r
m
i
n
e
s
 
m
a
x
i
m
u
m
 
p
r
i
c
e
,
 
a
n
d
 
n
o
t
i
fi
e
s
 
m
a
n
u
f
a
c
t
u
r
e
r
4
.
 
 
D
r
u
g
 
R
e
i
m
b
u
r
s
e
m
e
n
t
 
C
o
m
m
i
t
t
e
e
 
d
i
s
c
u
s
s
e
s
 
a
n
d
 
a
p
p
r
o
v
e
s
 
 
e
v
a
l
u
a
t
i
o
n
 
r
e
p
o
r
t
5
.
 
 
D
r
u
g
 
R
e
i
m
b
u
r
s
e
m
e
n
t
 
C
o
m
m
i
t
t
e
e
 
s
e
n
d
s
 
r
e
p
o
r
t
 
t
o
 
 
m
a
n
u
f
a
c
t
u
r
e
r
n
o
6
2
1
5
0
 
d
a
y
s
 
(
i
n
c
l
u
d
e
s
 
 
p
r
i
c
i
n
g
 
a
n
d
 
 
r
e
i
m
b
u
r
s
e
m
e
n
t
)
2
1
•
 
 
D
e
c
i
s
i
o
n
 
m
a
y
 
b
e
 
a
p
p
e
a
l
e
d
 
o
n
 
p
r
o
c
e
d
u
r
a
l
 
g
r
o
u
n
d
s
 
o
n
l
y
•
 
 
h
e
a
r
d
 
b
y
 
a
d
m
i
n
i
s
t
r
a
t
i
v
e
 
c
o
u
r
tClinicoEconomics and Outcomes Research 2011:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
145
Reimbursement of European health technologies
•
 
 
1
 
f
r
o
m
 
n
a
t
i
o
n
a
l
 
 
i
n
s
t
i
t
u
t
e
 
f
o
r
 
h
e
a
l
t
h
 
 
a
n
d
 
D
i
s
a
b
i
l
i
t
y
 
 
i
n
s
u
r
a
n
c
e
6
2
 
6
.
 
 
S
t
a
f
f
 
p
r
e
p
a
r
e
 
d
r
a
f
t
 
r
e
c
o
m
m
e
n
d
a
t
i
o
n
s
,
 
t
a
k
i
n
g
 
i
n
t
o
 
a
c
c
o
u
n
t
 
 
e
v
a
l
u
a
t
i
o
n
 
r
e
p
o
r
t
,
 
p
r
i
c
e
 
f
r
o
m
 
m
a
n
u
f
a
c
t
u
r
e
r
,
 
a
n
d
 
r
e
s
p
o
n
s
e
s
 
 
r
e
c
e
i
v
e
d
 
f
r
o
m
 
m
a
n
u
f
a
c
t
u
r
e
r
 
7
.
 
 
D
r
u
g
 
R
e
i
m
b
u
r
s
e
m
e
n
t
 
C
o
m
m
i
t
t
e
e
 
d
i
s
c
u
s
s
e
s
 
a
n
d
 
a
p
p
r
o
v
e
s
 
 
(
b
y
 
2
/
3
 
m
a
j
o
r
i
t
y
 
v
o
t
e
)
 
d
r
a
f
t
 
r
e
c
o
m
m
e
n
d
a
t
i
o
n
s
 
8
.
 
 
D
r
u
g
 
R
e
i
m
b
u
r
s
e
m
e
n
t
 
C
o
m
m
i
t
t
e
e
 
s
e
n
d
s
 
d
r
a
f
t
 
 
r
e
c
o
m
m
e
n
d
a
t
i
o
n
s
 
t
o
 
m
a
n
u
f
a
c
t
u
r
e
r
,
 
w
h
o
 
m
u
s
t
 
r
e
p
l
y
 
w
i
t
h
i
n
 
 
1
0
 
d
a
y
s
;
 
m
a
n
u
f
a
c
t
u
r
e
r
 
m
a
y
 
r
e
q
u
e
s
t
 
a
 
h
e
a
r
i
n
g
 
9
.
 
 
D
r
u
g
 
R
e
i
m
b
u
r
s
e
m
e
n
t
 
C
o
m
m
i
t
t
e
e
 
p
r
e
p
a
r
e
s
 
fi
n
a
l
 
 
r
e
c
o
m
m
e
n
d
a
t
i
o
n
s
,
 
t
a
k
i
n
g
 
i
n
t
o
 
a
c
c
o
u
n
t
 
r
e
s
p
o
n
s
e
s
 
r
e
c
e
i
v
e
d
 
 
f
r
o
m
 
m
a
n
u
f
a
c
t
u
r
e
r
1
0
.
 
 
M
i
n
i
s
t
e
r
 
r
e
c
e
i
v
e
s
 
r
e
c
o
m
m
e
n
d
a
t
i
o
n
s
,
 
s
e
e
k
s
 
a
d
v
i
c
e
 
f
r
o
m
 
 
M
i
n
i
s
t
e
r
 
o
f
 
B
u
d
g
e
t
 
a
n
d
 
fi
n
a
n
c
i
a
l
 
a
d
m
i
n
i
s
t
r
a
t
i
o
n
,
 
a
n
d
 
m
a
k
e
s
 
 
fi
n
a
l
 
d
e
c
i
s
i
o
n
9
,
1
7
,
2
1
,
6
2
,
1
7
5
C
z
e
c
h
 
 
R
e
p
u
b
l
i
c
•
 
 
S
t
a
t
e
 
i
n
s
t
i
t
u
t
e
 
f
o
r
 
D
r
u
g
 
 
C
o
n
t
r
o
l
 
(
d
e
c
i
s
i
o
n
s
)
6
5
,
1
7
0
n
o
 
i
n
f
o
r
m
a
t
i
o
n
 
f
o
u
n
d
1
.
 
 
M
a
n
u
f
a
c
t
u
r
e
r
 
s
u
b
m
i
t
s
 
a
p
p
l
i
c
a
t
i
o
n
 
f
o
r
 
r
e
i
m
b
u
r
s
e
m
e
n
t
 
t
o
 
S
t
a
t
e
 
 
i
n
s
t
i
t
u
t
e
 
f
o
r
 
D
r
u
g
 
C
o
n
t
r
o
l
2
.
 
 
i
n
t
e
r
n
a
l
 
s
t
a
f
f
 
(
D
e
p
a
r
t
m
e
n
t
 
f
o
r
 
P
r
i
c
e
 
a
n
d
 
R
e
i
m
b
u
r
s
e
m
e
n
t
 
 
R
e
g
u
l
a
t
i
o
n
)
 
c
o
n
s
u
l
t
 
w
i
t
h
 
m
e
d
i
c
a
l
 
e
x
p
e
r
t
s
,
 
h
e
a
l
t
h
 
e
c
o
n
o
m
i
s
t
s
,
 
 
a
n
d
 
p
a
t
i
e
n
t
 
g
r
o
u
p
s
,
 
a
n
d
 
p
r
e
p
a
r
e
 
e
v
a
l
u
a
t
i
o
n
 
r
e
p
o
r
t
;
 
a
s
s
e
s
s
 
 
s
a
f
e
t
y
,
 
e
f
fi
c
a
c
y
,
 
a
n
d
 
c
l
i
n
i
c
a
l
 
u
s
e
 
fi
r
s
t
,
 
a
n
d
 
t
h
e
n
 
fi
n
a
n
c
i
a
l
 
a
s
p
e
c
t
s
3
.
 
 
S
t
a
t
e
 
i
n
s
t
i
t
u
t
e
 
f
o
r
 
D
r
u
g
 
C
o
n
t
r
o
l
 
m
a
k
e
s
 
d
e
c
i
s
i
o
n
 
o
n
 
p
r
i
c
e
 
a
n
d
 
 
l
e
v
e
l
 
o
f
 
r
e
i
m
b
u
r
s
e
m
e
n
t
,
 
b
a
s
e
d
 
o
n
 
e
v
a
l
u
a
t
i
o
n
 
r
e
p
o
r
t
1
7
6
–
1
8
0
n
o
1
3
8
7
5
 
d
a
y
s
 
(
i
n
c
l
u
d
e
s
 
 
p
r
i
c
i
n
g
 
a
n
d
 
 
r
e
i
m
b
u
r
s
e
m
e
n
t
 
 
d
e
c
i
s
i
o
n
)
•
 
 
D
e
c
i
s
i
o
n
 
m
a
y
 
b
e
 
a
p
p
e
a
l
e
d
 
t
o
 
M
i
n
i
s
t
r
y
 
o
f
 
h
e
a
l
t
h
D
e
n
m
a
r
k
•
 
 
D
a
n
i
s
h
 
M
e
d
i
c
i
n
e
s
 
 
A
g
e
n
c
y
 
(
d
e
c
i
s
i
o
n
s
)
6
8
,
6
9
,
1
2
1
•
 
 
R
e
i
m
b
u
r
s
e
m
e
n
t
 
 
C
o
m
m
i
t
t
e
e
 
 
(
r
e
c
o
m
m
e
n
d
a
t
i
o
n
s
)
6
8
,
1
2
1
M
a
x
i
m
u
m
 
o
f
 
 
7
 
m
e
m
b
e
r
s
:
 
M
u
s
t
 
i
n
c
l
u
d
e
:
 
•
 
2
 
g
e
n
e
r
a
l
 
p
r
a
c
t
i
t
i
o
n
e
r
s
 
•
 
 
1
 
r
e
p
r
e
s
e
n
t
a
t
i
v
e
 
o
f
 
 
t
h
e
 
r
e
g
i
o
n
s
6
9
1
.
 
 
M
a
n
u
f
a
c
t
u
r
e
r
 
s
u
b
m
i
t
s
 
a
p
p
l
i
c
a
t
i
o
n
 
f
o
r
 
r
e
i
m
b
u
r
s
e
m
e
n
t
 
t
o
 
 
D
a
n
i
s
h
 
M
e
d
i
c
i
n
e
s
 
A
g
e
n
c
y
2
.
 
 
i
n
t
e
r
n
a
l
 
s
t
a
f
f
,
 
s
u
p
p
o
r
t
e
d
 
b
y
 
e
x
t
e
r
n
a
l
 
e
x
p
e
r
t
s
 
(
i
f
 
n
e
c
e
s
s
a
r
y
)
 
 
p
r
e
p
a
r
e
 
e
v
a
l
u
a
t
i
o
n
 
r
e
p
o
r
t
 
b
a
s
e
d
 
o
n
 
e
v
i
d
e
n
c
e
 
s
u
b
m
i
t
t
e
d
 
b
y
 
 
m
a
n
u
f
a
c
t
u
r
e
r
;
 
c
l
i
n
i
c
a
l
 
e
f
f
e
c
t
 
a
n
d
 
s
a
f
e
t
y
 
p
r
o
fi
l
e
 
c
o
m
p
a
r
e
d
 
t
o
 
 
a
l
r
e
a
d
y
 
r
e
i
m
b
u
r
s
e
d
 
p
h
a
r
m
a
c
e
u
t
i
c
a
l
 
a
n
d
 
n
o
n
-
p
h
a
r
m
a
c
e
u
t
i
c
a
l
 
 
p
r
o
d
u
c
t
s
 
f
o
r
 
s
a
m
e
 
i
n
d
i
c
a
t
i
o
n
3
.
 
 
D
a
n
i
s
h
 
M
e
d
i
c
i
n
e
s
 
A
g
e
n
c
y
 
s
i
m
u
l
t
a
n
e
o
u
s
l
y
 
p
r
e
p
a
r
e
s
 
p
r
i
c
e
 
 
s
u
r
v
e
y
4
.
 
 
h
e
a
l
t
h
 
e
c
o
n
o
m
i
c
s
 
e
x
p
e
r
t
(
s
)
 
e
v
a
l
u
a
t
e
(
s
)
 
e
c
o
n
o
m
i
c
 
a
n
a
l
y
s
i
s
,
 
 
i
f
 
s
u
b
m
i
t
t
e
d
5
.
 
 
R
e
i
m
b
u
r
s
e
m
e
n
t
 
C
o
m
m
i
t
t
e
e
 
r
e
v
i
e
w
s
 
e
v
a
l
u
a
t
i
o
n
 
r
e
p
o
r
t
,
 
 
p
r
i
c
e
 
s
u
r
v
e
y
,
 
a
n
d
 
r
e
v
i
e
w
 
o
f
 
e
c
o
n
o
m
i
c
 
a
n
a
l
y
s
i
s
 
a
n
d
 
m
a
k
e
s
 
 
r
e
i
m
b
u
r
s
e
m
e
n
t
 
r
e
c
o
m
m
e
n
d
a
t
i
o
n
 
t
o
 
D
a
n
i
s
h
 
M
e
d
i
c
i
n
e
s
 
A
g
e
n
c
y
6
.
 
 
i
f
 
n
e
g
a
t
i
v
e
,
 
D
a
n
i
s
h
 
M
e
d
i
c
i
n
e
s
 
A
g
e
n
c
y
 
s
e
n
d
s
 
d
r
a
f
t
 
 
r
e
c
o
m
m
e
n
d
a
t
i
o
n
s
 
t
o
 
m
a
n
u
f
a
c
t
u
r
e
r
7
.
 
 
D
a
n
i
s
h
 
M
e
d
i
c
i
n
e
s
 
A
g
e
n
c
y
 
B
o
a
r
d
 
m
a
k
e
s
 
fi
n
a
l
 
d
e
c
i
s
i
o
n
 
2
1
,
6
8
,
6
9
n
o
6
8
9
0
 
d
a
y
s
 
a
f
t
e
r
 
 
r
e
c
e
i
p
t
 
o
f
 
“
a
d
e
q
u
a
t
e
 
 
a
p
p
l
i
c
a
t
i
o
n
”
3
8
•
 
 
D
e
c
i
s
i
o
n
 
m
a
y
 
b
e
 
a
p
p
e
a
l
e
d
 
t
o
 
M
i
n
i
s
t
r
y
 
o
f
 
h
e
a
l
t
h
 
a
n
d
 
P
r
e
v
e
n
t
i
o
n
3
8
,
6
8
(
C
o
n
t
i
n
u
e
d
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T
a
b
l
e
 
5
 
(
C
o
n
t
i
n
u
e
d
)
C
o
u
n
t
r
y
C
e
n
t
r
a
l
i
z
e
d
 
 
r
e
i
m
b
u
r
s
e
m
e
n
t
 
 
r
e
v
i
e
w
/
d
e
c
i
s
i
o
n
-
 
m
a
k
i
n
g
 
b
o
d
y
 
(
r
o
l
e
)
C
o
m
m
i
t
t
e
e
 
 
c
o
m
p
o
s
i
t
i
o
n
S
t
e
p
s
 
i
n
 
r
e
v
i
e
w
/
d
e
c
i
s
i
o
n
-
m
a
k
i
n
g
 
p
r
o
c
e
s
s
U
s
e
 
o
f
 
c
o
s
t
-
 
e
f
f
e
c
t
i
v
e
n
e
s
s
 
 
t
h
r
e
s
h
o
l
d
T
i
m
e
l
i
n
e
s
 
f
o
r
 
 
r
e
v
i
e
w
/
 
d
e
c
i
s
i
o
n
A
p
p
e
a
l
s
 
 
m
e
c
h
a
n
i
s
m
s
E
s
t
o
n
i
a
•
 
 
M
i
n
i
s
t
r
y
 
o
f
 
S
o
c
i
a
l
 
A
f
f
a
i
r
s
 
 
(
d
e
c
i
s
i
o
n
s
)
7
2
•
 
 
P
h
a
r
m
a
c
e
u
t
i
c
a
l
s
 
 
C
o
m
m
i
t
t
e
e
 
 
(
r
e
c
o
m
m
e
n
d
a
t
i
o
n
s
)
7
2
n
o
 
i
n
f
o
r
m
a
t
i
o
n
 
f
o
u
n
d
n
o
 
i
n
f
o
r
m
a
t
i
o
n
 
f
o
u
n
d
n
o
 
 
i
n
f
o
r
m
a
t
i
o
n
 
 
f
o
u
n
d
n
o
 
i
n
f
o
r
m
a
t
i
o
n
 
 
f
o
u
n
d
n
o
 
i
n
f
o
r
m
a
t
i
o
n
 
f
o
u
n
d
F
i
n
l
a
n
d
•
 
 
P
h
a
r
m
a
c
e
u
t
i
c
a
l
s
 
P
r
i
c
i
n
g
 
 
B
o
a
r
d
 
(
d
e
c
i
s
i
o
n
s
)
7
3
,
7
4
,
7
6
•
 
 
P
h
a
r
m
a
c
e
u
t
i
c
a
l
s
 
P
r
i
c
i
n
g
 
 
B
o
a
r
d
 
E
x
p
e
r
t
 
g
r
o
u
p
 
 
(
r
e
c
o
m
m
e
n
d
a
t
i
o
n
s
)
7
5
7
 
m
e
m
b
e
r
s
 
o
f
 
 
P
h
a
r
m
a
c
e
u
t
i
c
a
l
s
 
P
r
i
c
i
n
g
 
 
B
o
a
r
d
:
 
•
 
 
2
 
f
r
o
m
 
M
i
n
i
s
t
r
y
 
 
o
f
 
S
o
c
i
a
l
 
A
f
f
a
i
r
s
 
a
n
d
 
 
h
e
a
l
t
h
•
 
 
2
 
f
r
o
m
 
S
o
c
i
a
l
 
 
i
n
s
u
r
a
n
c
e
 
i
n
s
t
i
t
u
t
i
o
n
 
 
(
K
e
l
a
)
•
 
 
1
 
f
r
o
m
 
M
i
n
i
s
t
r
y
 
 
o
f
 
F
i
n
a
n
c
e
•
 
 
1
 
f
r
o
m
 
n
a
t
i
o
n
a
l
 
 
A
g
e
n
c
y
 
f
o
r
 
M
e
d
i
c
i
n
e
s
•
 
 
1
 
f
r
o
m
 
n
a
t
i
o
n
a
l
 
 
R
e
s
e
a
r
c
h
 
a
n
d
 
 
D
e
v
e
l
o
p
m
e
n
t
 
C
e
n
t
r
e
 
 
f
o
r
 
W
e
l
f
a
r
e
 
a
n
d
 
 
h
e
a
l
t
h
7
 
m
e
m
b
e
r
s
 
o
f
 
E
x
p
e
r
t
 
 
g
r
o
u
p
:
 
•
 
 
i
n
c
l
u
d
e
s
 
i
n
d
i
v
i
d
u
a
l
s
 
 
w
i
t
h
 
m
e
d
i
c
a
l
,
 
 
p
h
a
r
m
a
c
o
l
o
g
i
c
a
l
,
 
h
e
a
l
t
h
 
 
e
c
o
n
o
m
i
c
s
,
 
a
n
d
 
s
o
c
i
a
l
 
 
i
n
s
u
r
a
n
c
e
 
e
x
p
e
r
t
i
s
e
7
5
,
1
8
1
1
.
 
 
M
a
n
u
f
a
c
t
u
r
e
r
 
s
u
b
m
i
t
s
 
a
p
p
l
i
c
a
t
i
o
n
 
f
o
r
 
r
e
i
m
b
u
r
s
e
m
e
n
t
 
t
o
 
 
P
h
a
r
m
a
c
e
u
t
i
c
a
l
s
 
P
r
i
c
i
n
g
 
B
o
a
r
d
 
s
e
c
r
e
t
a
r
i
a
t
2
.
 
 
i
n
t
e
r
n
a
l
 
s
t
a
f
f
,
 
w
i
t
h
 
s
u
p
p
o
r
t
 
f
r
o
m
 
E
x
p
e
r
t
 
g
r
o
u
p
,
 
p
r
e
p
a
r
e
 
 
e
v
a
l
u
a
t
i
o
n
 
r
e
p
o
r
t
 
b
a
s
e
d
 
o
n
 
e
v
i
d
e
n
c
e
 
s
u
b
m
i
t
t
e
d
 
 
b
y
 
m
a
n
u
f
a
c
t
u
r
e
r
3
.
 
 
E
x
p
e
r
t
 
g
r
o
u
p
 
r
e
v
i
e
w
s
 
r
e
p
o
r
t
 
a
n
d
 
f
o
r
m
u
l
a
t
e
s
 
o
p
i
n
i
o
n
s
4
.
 
 
P
h
a
r
m
a
c
e
u
t
i
c
a
l
s
 
P
r
i
c
i
n
g
 
B
o
a
r
d
 
S
e
c
r
e
t
a
r
i
a
t
 
p
r
e
s
e
n
t
s
 
s
u
m
m
a
r
y
 
 
o
f
 
r
e
p
o
r
t
 
a
n
d
 
o
p
i
n
i
o
n
s
,
 
a
l
o
n
g
 
w
i
t
h
 
w
r
i
t
t
e
n
 
s
t
a
t
e
m
e
n
t
 
 
r
e
g
a
r
d
i
n
g
 
t
h
e
 
p
o
t
e
n
t
i
a
l
 
i
m
p
a
c
t
 
o
f
 
t
h
e
 
p
h
a
r
m
a
c
e
u
t
i
c
a
l
 
o
n
 
i
t
s
 
 
b
u
d
g
e
t
 
p
r
o
v
i
d
e
d
 
b
y
 
K
e
l
a
,
 
t
o
 
P
h
a
r
m
a
c
e
u
t
i
c
a
l
s
 
P
r
i
c
i
n
g
 
B
o
a
r
d
5
.
 
 
P
h
a
r
m
a
c
e
u
t
i
c
a
l
s
 
P
r
i
c
i
n
g
 
B
o
a
r
d
 
f
o
r
m
u
l
a
t
e
s
 
r
e
c
o
m
m
e
n
d
a
t
i
o
n
s
6
.
 
 
i
f
 
n
e
g
a
t
i
v
e
,
 
P
h
a
r
m
a
c
e
u
t
i
c
a
l
s
 
P
r
i
c
i
n
g
 
B
o
a
r
d
 
s
e
n
d
s
 
 
r
e
c
o
m
m
e
n
d
a
t
i
o
n
s
 
t
o
 
m
a
n
u
f
a
c
t
u
r
e
r
,
 
w
h
o
 
m
a
y
 
c
h
o
o
s
e
 
t
o
 
 
l
o
w
e
r
 
p
r
i
c
e
 
o
r
 
p
r
o
v
i
d
e
 
a
d
d
i
t
i
o
n
a
l
 
e
v
i
d
e
n
c
e
7
.
 
 
P
h
a
r
m
a
c
e
u
t
i
c
a
l
s
 
P
r
i
c
i
n
g
 
B
o
a
r
d
 
m
a
k
e
s
 
fi
n
a
l
 
d
e
c
i
s
i
o
n
7
4
,
1
2
2
,
1
8
1
,
1
8
2
n
o
1
8
1
1
8
0
 
d
a
y
s
 
(
i
n
c
l
u
d
e
s
 
 
p
r
i
c
i
n
g
 
a
n
d
 
 
r
e
i
m
b
u
r
s
e
m
e
n
t
 
 
d
e
c
i
s
i
o
n
)
1
8
1
•
 
 
D
e
c
i
s
i
o
n
 
m
a
y
 
b
e
 
a
p
p
e
a
l
e
d
 
t
o
 
S
u
p
r
e
m
e
 
C
o
u
r
t
1
8
1
F
r
a
n
c
e
•
 
 
M
i
n
i
s
t
r
y
 
f
o
r
 
h
e
a
l
t
h
 
 
a
n
d
 
S
o
c
i
a
l
 
S
e
c
u
r
i
t
y
 
 
(
d
e
c
i
s
i
o
n
s
)
2
0
,
7
8
•
 
 
F
r
e
n
c
h
 
n
a
t
i
o
n
a
l
 
 
A
u
t
h
o
r
i
t
y
 
f
o
r
 
h
e
a
l
t
h
 
 
(
r
e
c
o
m
m
e
n
d
a
t
i
o
n
s
)
7
8
T
r
a
n
s
p
a
r
e
n
c
y
 
C
o
m
m
i
t
t
e
e
 
w
i
t
h
i
n
 
F
r
e
n
c
h
 
n
a
t
i
o
n
a
l
 
A
u
t
h
o
r
i
t
y
 
f
o
r
 
h
e
a
l
t
h
:
 
 
2
0
 
v
o
t
i
n
g
 
m
e
m
b
e
r
s
 
(
i
n
c
l
u
d
e
s
 
c
h
a
i
r
)
:
 
•
 
 
4
 
f
r
o
m
 
“
p
u
b
l
i
c
 
 
i
n
s
t
i
t
u
t
i
o
n
s
”
S
i
n
g
l
e
 
t
e
c
h
n
o
l
o
g
y
 
a
p
p
r
a
i
s
a
l
s
 
1
.
 
 
M
a
n
u
f
a
c
t
u
r
e
r
 
s
u
b
m
i
t
s
 
a
p
p
l
i
c
a
t
i
o
n
 
f
o
r
 
r
e
i
m
b
u
r
s
e
m
e
n
t
 
t
o
 
 
F
r
e
n
c
h
 
n
a
t
i
o
n
a
l
 
A
u
t
h
o
r
i
t
y
 
f
o
r
 
h
e
a
l
t
h
 
s
e
c
r
e
t
a
r
i
a
t
2
.
 
 
i
n
t
e
r
n
a
l
 
s
t
a
f
f
 
p
r
e
p
a
r
e
 
e
v
a
l
u
a
t
i
o
n
 
r
e
p
o
r
t
 
b
a
s
e
d
 
o
n
 
e
v
i
d
e
n
c
e
 
 
s
u
b
m
i
t
t
e
d
 
b
y
 
m
a
n
u
f
a
c
t
u
r
e
r
 
(
f
o
c
u
s
e
s
 
o
n
 
c
l
i
n
i
c
a
l
 
e
f
f
e
c
t
i
v
e
n
e
s
s
,
 
 
t
a
r
g
e
t
 
p
o
p
u
l
a
t
i
o
n
,
 
c
o
n
d
i
t
i
o
n
s
 
o
f
 
u
s
e
,
 
a
n
d
 
a
l
r
e
a
d
y
 
r
e
i
m
b
u
r
s
e
d
 
 
t
e
c
h
n
o
l
o
g
i
e
s
)
n
o
2
0
•
 
 
9
0
 
d
a
y
s
 
f
o
r
 
 
i
n
p
a
t
i
e
n
t
 
 
p
h
a
r
m
a
c
e
u
t
i
c
a
l
s
 
 
(
i
n
c
l
u
d
e
s
 
 
p
r
i
c
i
n
g
 
a
n
d
 
 
r
e
i
m
b
u
r
s
e
m
e
n
t
)
•
 
 
M
a
y
 
a
p
p
e
a
l
 
r
e
c
o
m
m
e
n
d
a
t
i
o
n
 
t
o
 
F
r
e
n
c
h
 
n
a
t
i
o
n
a
l
 
A
u
t
h
o
r
i
t
y
 
f
o
r
 
h
e
a
l
t
h
,
 
r
e
q
u
e
s
t
i
n
g
 
a
 
h
e
a
r
i
n
g
 
o
r
 
 
 
p
r
o
v
i
d
i
n
g
 
w
r
i
t
t
e
n
 
c
o
m
m
e
n
t
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•
 
 
3
 
f
r
o
m
 
m
a
i
n
 
h
e
a
l
t
h
 
 
i
n
s
u
r
a
n
c
e
 
f
u
n
d
•
 
 
1
 
f
r
o
m
 
p
h
a
r
m
a
c
e
u
t
i
c
a
l
 
 
i
n
d
u
s
t
r
y
•
 
 
1
2
 
w
i
t
h
 
m
e
d
i
c
a
l
 
a
n
d
 
 
p
h
a
r
m
a
c
o
l
o
g
i
c
a
l
 
 
e
x
p
e
r
t
i
s
e
7
8
,
1
8
4
7
 
 
S
p
e
c
i
a
l
i
s
t
 
 
s
u
b
c
o
m
m
i
t
t
e
e
s
 
o
f
 
 
c
l
i
n
i
c
a
l
 
e
x
p
e
r
t
s
3
.
 
 
E
x
t
e
r
n
a
l
 
c
l
i
n
i
c
a
l
 
a
n
d
 
m
e
t
h
o
d
o
l
o
g
i
c
a
l
 
e
x
p
e
r
t
s
 
r
e
v
i
e
w
 
 
e
v
a
l
u
a
t
i
o
n
 
r
e
p
o
r
t
4
.
 
 
C
o
m
m
i
s
s
i
o
n
 
d
’
E
v
a
l
u
a
t
i
o
n
 
d
e
s
 
M
e
d
i
c
a
m
e
n
t
s
 
r
e
v
i
e
w
s
 
 
e
v
a
l
u
a
t
i
o
n
 
r
e
p
o
r
t
 
a
n
d
 
e
x
p
e
r
t
 
o
p
i
n
i
o
n
s
 
t
o
 
a
p
p
r
a
i
s
e
 
t
h
e
 
 
“
m
e
d
i
c
a
l
 
b
e
n
e
fi
t
”
 
o
f
 
t
h
e
 
p
h
a
r
m
a
c
e
u
t
i
c
a
l
 
(
o
n
 
a
 
5
 
p
o
i
n
t
 
s
c
a
l
e
;
 
 
i
 
–
 
m
a
j
o
r
 
t
o
 
V
 
–
 
i
n
s
u
f
fi
c
i
e
n
t
 
t
o
 
j
u
s
t
i
f
y
 
r
e
i
m
b
u
r
s
e
m
e
n
t
)
5
.
 
 
M
i
n
i
s
t
e
r
 
m
a
k
e
s
 
fi
n
a
l
 
d
e
c
i
s
i
o
n
 
o
n
 
t
h
e
 
m
e
d
i
c
a
l
 
 
b
e
n
e
fi
t
 
l
e
v
e
l
/
s
c
o
r
e
6
.
 
 
C
o
m
m
i
s
s
i
o
n
 
d
’
E
v
a
l
u
a
t
i
o
n
 
d
e
s
 
M
e
d
i
c
a
m
e
n
t
s
 
t
h
e
n
 
p
e
r
f
o
r
m
s
 
 
c
o
m
p
a
r
a
t
i
v
e
 
a
s
s
e
s
s
m
e
n
t
 
o
f
 
p
h
a
r
m
a
c
e
u
t
i
c
a
l
 
w
i
t
h
 
a
l
r
e
a
d
y
 
 
r
e
i
m
b
u
r
s
e
d
 
a
l
t
e
r
n
a
t
i
v
e
s
 
t
o
 
a
p
p
r
a
i
s
e
 
t
h
e
 
“
i
m
p
r
o
v
e
m
e
n
t
 
i
n
 
 
m
e
d
i
c
a
l
 
b
e
n
e
fi
t
”
 
(
o
n
 
a
 
6
 
p
o
i
n
t
 
s
c
a
l
e
;
 
1
 
–
 
m
a
j
o
r
 
i
n
n
o
v
a
t
i
o
n
 
 
t
o
 
V
i
 
–
 
n
e
g
a
t
i
v
e
 
o
p
i
n
i
o
n
 
r
e
g
a
r
d
i
n
g
 
i
n
c
l
u
s
i
o
n
 
o
n
 
b
e
n
e
fi
t
 
l
i
s
t
)
7
.
 
 
T
r
a
n
s
p
a
r
e
n
c
y
 
C
o
m
m
i
s
s
i
o
n
 
c
o
n
s
i
d
e
r
s
 
a
d
v
i
c
e
 
r
e
c
e
i
v
e
d
 
f
r
o
m
 
 
C
o
m
m
i
s
s
i
o
n
 
d
’
E
v
a
l
u
a
t
i
o
n
 
d
e
s
 
M
e
d
i
c
a
m
e
n
t
s
 
a
n
d
 
a
s
s
i
g
n
s
 
 
a
n
 
“
i
m
p
r
o
v
e
m
e
n
t
 
i
n
 
m
e
d
i
c
a
l
 
b
e
n
e
fi
t
”
 
c
l
a
s
s
i
fi
c
a
t
i
o
n
 
t
o
 
t
h
e
 
 
p
h
a
r
m
a
c
e
u
t
i
c
a
l
8
.
 
 
O
n
c
e
 
p
o
s
i
t
i
v
e
 
r
e
i
m
b
u
r
s
e
m
e
n
t
 
r
e
c
o
m
m
e
n
d
a
t
i
o
n
 
i
s
 
r
e
c
e
i
v
e
d
,
 
 
t
h
e
 
C
o
m
i
t
e
 
E
c
o
n
o
m
i
q
u
e
 
d
e
s
 
p
r
o
d
u
i
t
s
 
d
e
 
S
a
n
t
e
 
=
 
n
e
g
o
t
i
a
t
e
s
 
 
p
r
i
c
e
 
w
i
t
h
 
m
a
n
u
f
a
c
t
u
r
e
r
 
a
n
d
 
t
h
e
 
U
n
i
o
n
 
n
a
t
i
o
n
a
l
e
 
d
e
s
 
C
a
i
s
s
e
s
 
 
d
’
A
s
s
u
r
a
n
c
e
 
M
a
l
a
d
i
e
 
fi
x
e
s
 
t
h
e
 
r
e
i
m
b
u
r
s
e
m
e
n
t
 
r
a
t
e
9
.
 
 
M
i
n
i
s
t
e
r
 
f
o
r
 
h
e
a
l
t
h
 
a
n
d
 
S
o
c
i
a
l
 
S
e
c
u
r
i
t
y
 
m
a
k
e
s
 
fi
n
a
l
 
d
e
c
i
s
i
o
n
 
 
o
n
 
r
e
i
m
b
u
r
s
e
m
e
n
t
 
l
e
v
e
l
 
a
n
d
 
p
r
i
c
e
1
6
,
2
0
–
2
3
M
u
l
t
i
p
l
e
 
t
e
c
h
n
o
l
o
g
y
 
a
p
p
r
a
i
s
a
l
s
1
.
 
 
F
r
e
n
c
h
 
n
a
t
i
o
n
a
l
 
A
u
t
h
o
r
i
t
y
 
f
o
r
 
h
e
a
l
t
h
 
a
p
p
r
o
v
e
s
 
t
e
c
h
n
o
l
o
g
y
 
 
t
o
p
i
c
 
f
o
r
 
m
u
l
t
i
p
l
e
 
t
e
c
h
n
o
l
o
g
y
 
a
p
p
r
a
i
s
a
l
s
2
.
 
 
F
r
e
n
c
h
 
n
a
t
i
o
n
a
l
 
A
u
t
h
o
r
i
t
y
 
f
o
r
 
h
e
a
l
t
h
 
c
o
n
d
u
c
t
s
 
c
o
n
s
u
l
t
a
t
i
o
n
s
 
 
w
i
t
h
 
r
e
l
e
v
a
n
t
 
s
t
a
k
e
h
o
l
d
e
r
s
 
a
n
d
 
t
h
e
 
i
n
t
e
r
d
i
s
c
i
p
l
i
n
a
r
y
 
E
c
o
n
o
m
i
c
 
 
E
v
a
l
u
a
t
i
o
n
 
a
n
d
 
P
u
b
l
i
c
 
h
e
a
l
t
h
 
C
o
m
m
i
t
t
e
e
 
t
o
 
d
e
fi
n
e
 
s
c
o
p
e
 
a
n
d
 
 
p
r
o
t
o
c
o
l
 
f
o
r
 
m
u
l
t
i
p
l
e
 
t
e
c
h
n
o
l
o
g
y
 
a
p
p
r
a
i
s
a
l
s
3
.
 
 
i
n
t
e
r
n
a
l
 
s
t
a
f
f
 
a
n
d
/
o
r
 
i
n
d
e
p
e
n
d
e
n
t
 
a
c
a
d
e
m
i
c
 
g
r
o
u
p
 
p
r
e
p
a
r
e
s
 
 
a
s
s
e
s
s
m
e
n
t
 
r
e
p
o
r
t
 
(
i
n
c
l
u
d
e
s
 
c
l
i
n
i
c
a
l
 
r
e
v
i
e
w
 
a
n
d
 
e
c
o
n
o
m
i
c
 
 
a
n
a
l
y
s
i
s
)
4
.
 
 
i
n
t
e
r
d
i
s
c
i
p
l
i
n
a
r
y
 
E
c
o
n
o
m
i
c
 
E
v
a
l
u
a
t
i
o
n
 
a
n
d
 
P
u
b
l
i
c
 
h
e
a
l
t
h
 
 
C
o
m
m
i
t
t
e
e
 
a
n
d
 
e
x
t
e
r
n
a
l
 
e
x
p
e
r
t
s
 
r
e
v
i
e
w
 
a
s
s
e
s
s
m
e
n
t
 
r
e
p
o
r
t
5
.
 
 
S
t
a
k
e
h
o
l
d
e
r
s
 
r
e
c
e
i
v
e
 
a
s
s
e
s
s
m
e
n
t
 
r
e
p
o
r
t
 
f
o
r
 
c
o
m
m
e
n
t
6
.
 
 
S
t
a
k
e
h
o
l
d
e
r
s
 
a
l
s
o
 
c
o
n
s
u
l
t
e
d
 
t
h
r
o
u
g
h
 
w
o
r
k
i
n
g
 
g
r
o
u
p
 
 
m
e
e
t
i
n
g
s
7
.
 
 
A
p
p
r
o
p
r
i
a
t
e
 
h
e
a
l
t
h
 
t
e
c
h
n
o
l
o
g
y
 
a
s
s
e
s
s
m
e
n
t
 
s
p
e
c
i
a
l
i
s
t
 
 
s
u
b
c
o
m
m
i
t
t
e
e
 
a
p
p
r
a
i
s
e
s
 
r
e
p
o
r
t
 
a
n
d
 
c
o
m
m
e
n
t
s
 
a
n
d
 
 
f
o
r
m
u
l
a
t
e
s
 
r
e
c
o
m
m
e
n
d
a
t
i
o
n
s
8
.
 
 
F
r
e
n
c
h
 
n
a
t
i
o
n
a
l
 
A
u
t
h
o
r
i
t
y
 
f
o
r
 
h
e
a
l
t
h
 
B
o
a
r
d
 
r
e
v
i
e
w
s
 
a
n
d
 
 
a
p
p
r
o
v
e
s
 
r
e
c
o
m
m
e
n
d
a
t
i
o
n
s
2
1
,
1
8
5
•
 
 
1
8
0
 
d
a
y
s
 
f
o
r
 
 
 
o
u
t
p
a
t
i
e
n
t
 
 
p
h
a
r
m
a
c
e
u
t
i
c
a
l
s
 
 
(
i
n
c
l
u
d
e
s
 
 
p
r
i
c
i
n
g
 
a
n
d
 
 
r
e
i
m
b
u
r
s
e
m
e
n
t
)
2
0
•
 
 
O
n
c
e
 
d
e
c
i
s
i
o
n
 
h
a
s
 
b
e
e
n
 
m
a
d
e
,
 
m
a
y
 
a
p
p
e
a
l
 
t
o
 
a
d
m
i
n
i
s
t
r
a
t
i
v
e
 
c
o
u
r
t
2
0
(
C
o
n
t
i
n
u
e
d
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T
a
b
l
e
 
5
 
(
C
o
n
t
i
n
u
e
d
)
C
o
u
n
t
r
y
C
e
n
t
r
a
l
i
z
e
d
 
 
r
e
i
m
b
u
r
s
e
m
e
n
t
 
 
r
e
v
i
e
w
/
d
e
c
i
s
i
o
n
-
 
m
a
k
i
n
g
 
b
o
d
y
 
(
r
o
l
e
)
C
o
m
m
i
t
t
e
e
 
 
c
o
m
p
o
s
i
t
i
o
n
S
t
e
p
s
 
i
n
 
r
e
v
i
e
w
/
d
e
c
i
s
i
o
n
-
m
a
k
i
n
g
 
p
r
o
c
e
s
s
U
s
e
 
o
f
 
c
o
s
t
-
 
e
f
f
e
c
t
i
v
e
n
e
s
s
 
 
t
h
r
e
s
h
o
l
d
T
i
m
e
l
i
n
e
s
 
f
o
r
 
 
r
e
v
i
e
w
/
 
d
e
c
i
s
i
o
n
A
p
p
e
a
l
s
 
 
m
e
c
h
a
n
i
s
m
s
g
e
r
m
a
n
y
•
 
 
F
e
d
e
r
a
l
 
J
o
i
n
t
 
 
C
o
m
m
i
t
t
e
e
 
(
d
e
c
i
s
i
o
n
s
)
1
9
•
 
 
i
n
s
t
i
t
u
t
e
 
f
o
r
 
Q
u
a
l
i
t
y
 
 
a
n
d
 
E
f
fi
c
i
e
n
c
y
 
i
n
 
 
h
e
a
l
t
h
 
C
a
r
e
 
 
(
r
e
c
o
m
m
e
n
d
a
t
i
o
n
s
)
1
9
1
3
 
m
e
m
b
e
r
s
 
i
n
c
l
u
d
i
n
g
 
 
r
e
p
r
e
s
e
n
t
a
t
i
v
e
s
 
f
r
o
m
:
 
•
 
 
A
s
s
o
c
i
a
t
i
o
n
s
 
o
f
 
 
p
h
y
s
i
c
i
a
n
s
,
 
d
e
n
t
i
s
t
s
,
 
 
a
n
d
 
p
h
y
s
i
o
t
h
e
r
a
p
i
s
t
s
•
 
h
o
s
p
i
t
a
l
 
a
s
s
o
c
i
a
t
i
o
n
s
 
•
 
S
i
c
k
n
e
s
s
 
f
u
n
d
s
 
•
	
	
P
a
t
i
e
n
t
 
o
r
g
a
n
i
z
a
t
i
o
n
s
 
 
(
n
o
n
v
o
t
i
n
g
)
1
8
,
1
9
1
.
 
 
F
e
d
e
r
a
l
 
J
o
i
n
t
 
C
o
m
m
i
t
t
e
e
 
m
a
k
e
s
 
d
e
c
i
s
i
o
n
 
t
o
 
a
s
s
e
s
s
 
t
e
c
h
n
o
l
o
g
y
 
 
a
n
d
 
n
o
t
i
fi
e
s
 
i
n
s
t
i
t
u
t
e
 
f
o
r
 
Q
u
a
l
i
t
y
 
a
n
d
 
E
f
fi
c
i
e
n
c
y
 
i
n
 
h
e
a
l
t
h
 
C
a
r
e
2
.
 
 
i
n
s
t
i
t
u
t
e
 
f
o
r
 
Q
u
a
l
i
t
y
 
a
n
d
 
E
f
fi
c
i
e
n
c
y
 
i
n
 
h
e
a
l
t
h
 
C
a
r
e
 
a
p
p
o
i
n
t
s
 
 
i
n
t
e
r
n
a
l
 
s
t
a
f
f
 
t
o
 
m
a
n
a
g
e
 
a
n
d
/
o
r
 
c
o
n
d
u
c
t
 
a
s
s
e
s
s
m
e
n
t
3
.
 
 
i
n
s
t
i
t
u
t
e
 
f
o
r
 
Q
u
a
l
i
t
y
 
a
n
d
 
E
f
fi
c
i
e
n
c
y
 
i
n
 
h
e
a
l
t
h
 
C
a
r
e
 
c
a
r
r
i
e
s
 
o
u
t
 
 
c
o
n
s
u
l
t
a
t
i
o
n
s
 
w
i
t
h
 
e
x
t
e
r
n
a
l
 
c
l
i
n
i
c
a
l
 
e
x
p
e
r
t
s
 
a
n
d
 
p
a
t
i
e
n
t
/
c
a
r
e
r
 
 
o
r
g
a
n
i
z
a
t
i
o
n
s
 
t
o
 
d
e
fi
n
e
 
a
s
s
e
s
s
m
e
n
t
 
s
c
o
p
e
 
a
n
d
 
p
r
o
t
o
c
o
l
4
.
 
 
i
n
s
t
i
t
u
t
e
 
f
o
r
 
Q
u
a
l
i
t
y
 
a
n
d
 
E
f
fi
c
i
e
n
c
y
 
i
n
 
h
e
a
l
t
h
 
C
a
r
e
 
p
o
s
t
s
 
d
r
a
f
t
 
 
s
c
o
p
e
 
a
n
d
 
p
r
o
t
o
c
o
l
 
o
n
 
w
e
b
s
i
t
e
 
f
o
r
 
p
u
b
l
i
c
 
c
o
m
m
e
n
t
5
.
 
 
i
n
t
e
r
n
a
l
 
s
t
a
f
f
,
 
s
u
p
p
o
r
t
e
d
 
b
y
 
e
x
t
e
r
n
a
l
 
e
x
p
e
r
t
s
,
 
p
r
e
p
a
r
e
 
 
a
s
s
e
s
s
m
e
n
t
,
 
fi
r
s
t
 
c
o
n
s
i
d
e
r
i
n
g
 
c
l
i
n
i
c
a
l
 
b
e
n
e
fi
t
 
o
r
 
i
n
n
o
v
a
t
i
v
e
n
e
s
s
 
 
(
i
e
,
 
i
s
 
t
h
e
 
fi
r
s
t
 
a
c
t
i
v
e
 
i
n
g
r
e
d
i
e
n
t
 
o
r
 
o
f
f
e
r
s
 
t
h
e
r
a
p
e
u
t
i
c
 
 
i
m
p
r
o
v
e
m
e
n
t
)
;
 
i
f
 
d
e
e
m
e
d
 
n
o
n
i
n
n
o
v
a
t
i
v
e
,
 
t
e
c
h
n
o
l
o
g
y
 
i
s
 
 
a
s
s
i
g
n
e
d
 
t
o
 
1
 
o
f
 
3
 
g
r
o
u
p
s
 
(
1
:
 
i
d
e
n
t
i
c
a
l
 
a
c
t
i
v
e
 
i
n
g
r
e
d
i
e
n
t
;
 
 
2
:
 
t
h
e
r
a
p
e
u
t
i
c
a
l
l
y
 
c
o
m
p
a
r
a
b
l
e
 
a
n
d
 
o
n
e
 
a
c
t
i
v
e
 
i
n
g
r
e
d
i
e
n
t
;
 
 
3
:
 
t
h
e
r
a
p
e
u
t
i
c
a
l
l
y
 
c
o
m
p
a
r
a
b
l
e
 
a
n
d
 
t
w
o
 
a
c
t
i
v
e
 
i
n
g
r
e
d
i
e
n
t
s
)
;
 
 
t
e
c
h
n
o
l
o
g
i
e
s
 
w
i
t
h
 
s
i
m
i
l
a
r
 
e
f
fi
c
a
c
y
/
e
f
f
e
c
t
i
v
e
n
e
s
s
 
m
u
s
t
 
 
d
e
m
o
n
s
t
r
a
t
e
 
c
o
m
p
a
r
a
b
l
e
 
e
f
fi
c
i
e
n
c
y
 
t
h
r
o
u
g
h
 
fi
n
d
i
n
g
s
 
f
r
o
m
 
 
e
f
fi
c
i
e
n
c
y
 
f
r
o
n
t
i
e
r
 
a
n
a
l
y
s
i
s
1
1
9
;
 
i
f
 
d
e
e
m
e
d
 
i
n
n
o
v
a
t
i
v
e
 
 
(
i
e
,
 
o
f
f
e
r
s
 
a
d
d
e
d
 
t
h
e
r
a
p
e
u
t
i
c
 
v
a
l
u
e
 
o
v
e
r
 
a
l
r
e
a
d
y
 
r
e
i
m
b
u
r
s
e
d
 
 
a
l
t
e
r
n
a
t
i
v
e
s
)
,
 
“
c
o
s
t
-
b
e
n
e
fi
t
”
 
a
n
a
l
y
s
i
s
 
i
s
 
p
e
r
f
o
r
m
e
d
 
 
t
o
 
s
e
t
 
m
a
x
i
m
u
m
 
r
e
i
m
b
u
r
s
a
b
l
e
 
a
m
o
u
n
t
;
 
i
f
 
t
e
c
h
n
o
l
o
g
y
 
t
r
e
a
t
s
 
 
l
i
f
e
-
t
h
r
e
a
t
e
n
i
n
g
 
c
o
n
d
i
t
i
o
n
 
f
o
r
 
w
h
i
c
h
 
t
h
e
r
e
 
a
r
e
 
n
o
 
a
l
t
e
r
n
a
t
i
v
e
s
,
 
 
c
o
s
t
 
m
u
s
t
 
n
o
t
 
b
e
 
c
o
n
s
i
d
e
r
e
d
1
8
,
1
9
6
.
 
 
i
n
s
t
i
t
u
t
e
 
f
o
r
 
Q
u
a
l
i
t
y
 
a
n
d
 
E
f
fi
c
i
e
n
c
y
 
i
n
 
h
e
a
l
t
h
 
C
a
r
e
 
s
t
e
e
r
i
n
g
 
 
c
o
m
m
i
t
t
e
e
 
r
e
v
i
e
w
s
 
d
r
a
f
t
 
r
e
p
o
r
t
 
a
n
d
 
r
e
c
o
m
m
e
n
d
a
t
i
o
n
s
 
f
o
r
 
 
q
u
a
l
i
t
y
 
a
s
s
u
r
a
n
c
e
7
.
 
 
i
n
s
t
i
t
u
t
e
 
f
o
r
 
Q
u
a
l
i
t
y
 
a
n
d
 
E
f
fi
c
i
e
n
c
y
 
i
n
 
h
e
a
l
t
h
 
C
a
r
e
 
p
o
s
t
s
 
d
r
a
f
t
 
 
r
e
p
o
r
t
 
a
n
d
 
r
e
c
o
m
m
e
n
d
a
t
i
o
n
s
 
o
n
 
w
e
b
s
i
t
e
 
f
o
r
 
p
u
b
l
i
c
 
c
o
m
m
e
n
t
8
.
 
 
S
t
a
f
f
 
p
r
e
p
a
r
e
 
fi
n
a
l
 
r
e
p
o
r
t
,
 
i
n
c
o
r
p
o
r
a
t
i
n
g
 
c
o
m
m
e
n
t
s
 
r
e
c
e
i
v
e
d
 
 
a
n
d
 
r
e
c
o
m
m
e
n
d
a
t
i
o
n
s
,
 
a
n
d
 
s
u
b
m
i
t
 
i
t
 
t
o
 
t
h
e
 
i
n
s
t
i
t
u
t
e
 
f
o
r
 
 
Q
u
a
l
i
t
y
 
a
n
d
 
E
f
fi
c
i
e
n
c
y
 
i
n
 
h
e
a
l
t
h
 
C
a
r
e
 
s
t
e
e
r
i
n
g
 
c
o
m
m
i
t
t
e
e
 
f
o
r
 
 
fi
n
a
l
 
q
u
a
l
i
t
y
 
a
s
s
u
r
a
n
c
e
 
r
e
v
i
e
w
 
a
n
d
 
t
h
e
n
 
t
o
 
t
h
e
 
B
o
a
r
d
 
f
o
r
 
 
fi
n
a
l
 
a
p
p
r
o
v
a
l
9
.
 
 
B
o
a
r
d
 
s
e
n
d
s
 
r
e
c
o
m
m
e
n
d
a
t
i
o
n
s
 
t
o
 
F
e
d
e
r
a
l
 
J
o
i
n
t
 
C
o
m
m
i
t
t
e
e
,
 
 
w
h
o
 
m
a
k
e
s
 
fi
n
a
l
 
d
e
c
i
s
i
o
n
1
9
,
2
4
,
1
2
4
,
1
4
4
n
o
1
8
n
o
 
i
n
f
o
r
m
a
t
i
o
n
 
 
f
o
u
n
d
•
 
 
M
a
y
 
n
o
t
 
a
p
p
e
a
l
 
r
e
c
o
m
m
e
n
d
a
t
i
o
n
s
•
 
 
D
e
c
i
s
i
o
n
 
m
a
y
 
b
e
 
a
p
p
e
a
l
e
d
 
t
o
 
a
d
m
i
n
i
s
t
r
a
t
i
v
e
 
c
o
u
r
t
1
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g
r
e
e
c
e
•
 
 
T
r
a
n
s
p
a
r
e
n
c
y
 
 
C
o
m
m
i
t
t
e
e
 
i
n
 
t
h
e
 
 
R
e
i
m
b
u
r
s
e
m
e
n
t
 
 
a
n
d
 
M
e
d
i
c
i
n
a
l
 
P
r
o
d
u
c
t
s
 
 
(
m
a
k
e
s
 
d
e
c
i
s
i
o
n
s
)
8
5
,
8
6
7
 
m
e
m
b
e
r
s
 
i
n
c
l
u
d
i
n
g
 
 
r
e
p
r
e
s
e
n
t
a
t
i
v
e
s
 
f
r
o
m
:
 
•
 
M
i
n
i
s
t
r
y
 
o
f
 
h
e
a
l
t
h
 
•
 
M
i
n
i
s
t
r
y
 
o
f
 
F
i
n
a
n
c
e
 
•
 
 
M
i
n
i
s
t
r
y
 
o
f
 
 
E
m
p
l
o
y
m
e
n
t
 
a
n
d
 
 
S
o
c
i
a
l
 
P
r
o
t
e
c
t
i
o
n
•
 
M
e
r
c
h
a
n
t
 
M
a
r
i
n
e
8
5
1
.
 
 
M
a
n
u
f
a
c
t
u
r
e
r
 
s
u
b
m
i
t
s
 
a
p
p
l
i
c
a
t
i
o
n
 
f
o
r
 
r
e
i
m
b
u
r
s
e
m
e
n
t
 
t
o
 
 
T
r
a
n
s
p
a
r
e
n
c
y
 
C
o
m
m
i
t
t
e
e
 
i
n
 
t
h
e
 
R
e
i
m
b
u
r
s
e
m
e
n
t
 
a
n
d
 
 
M
e
d
i
c
i
n
a
l
 
P
r
o
d
u
c
t
s
2
.
 
 
T
r
a
n
s
p
a
r
e
n
c
y
 
C
o
m
m
i
t
t
e
e
 
i
n
 
t
h
e
 
R
e
i
m
b
u
r
s
e
m
e
n
t
 
 
a
n
d
 
M
e
d
i
c
i
n
a
l
 
P
r
o
d
u
c
t
s
 
r
e
c
o
m
m
e
n
d
s
 
c
l
a
s
s
i
fi
c
a
t
i
o
n
 
o
f
 
 
p
h
a
r
m
a
c
e
u
t
i
c
a
l
 
i
n
t
o
 
p
r
e
-
e
x
i
s
t
i
n
g
 
t
h
e
r
a
p
e
u
t
i
c
 
c
a
t
e
g
o
r
y
 
b
a
s
e
d
 
 
o
n
 
“
t
h
e
r
a
p
e
u
t
i
c
 
a
n
d
 
p
h
a
r
m
a
c
o
e
c
o
n
o
m
i
c
 
e
f
f
e
c
t
i
v
e
n
e
s
s
”
3
.
 
 
T
r
a
n
s
p
a
r
e
n
c
y
 
C
o
m
m
i
t
t
e
e
 
i
n
 
t
h
e
 
R
e
i
m
b
u
r
s
e
m
e
n
t
 
a
n
d
 
 
M
e
d
i
c
i
n
a
l
 
P
r
o
d
u
c
t
s
 
s
e
n
d
s
 
c
l
a
s
s
i
fi
c
a
t
i
o
n
 
r
e
c
o
m
m
e
n
d
a
t
i
o
n
 
t
o
 
 
M
i
n
i
s
t
r
y
 
o
f
 
h
e
a
l
t
h
 
a
n
d
 
S
o
c
i
a
l
 
S
e
c
u
r
i
t
y
 
f
o
r
 
a
p
p
r
o
v
a
l
4
.
 
 
P
r
i
c
e
 
s
e
t
 
t
a
k
i
n
g
 
i
n
t
o
 
a
c
c
o
u
n
t
 
p
r
o
d
u
c
t
s
 
a
l
r
e
a
d
y
 
i
n
c
l
u
d
e
d
 
 
i
n
 
a
s
s
i
g
n
e
d
 
c
a
t
e
g
o
r
y
 
o
r
 
a
v
e
r
a
g
e
 
o
f
 
t
h
e
 
3
 
l
o
w
e
s
t
 
 
E
u
r
o
p
e
a
n
 
p
r
i
c
e
s
1
8
6
n
o
 
 
i
n
f
o
r
m
a
t
i
o
n
 
 
f
o
u
n
d
9
0
 
d
a
y
s
 
(
i
n
c
l
u
d
e
s
 
 
p
r
i
c
i
n
g
 
a
n
d
 
 
r
e
i
m
b
u
r
s
e
m
e
n
t
 
 
d
e
c
i
s
i
o
n
)
1
8
6
n
o
 
i
n
f
o
r
m
a
t
i
o
n
 
f
o
u
n
d
h
u
n
g
a
r
y
•
 
 
M
i
n
i
s
t
e
r
s
 
o
f
 
h
e
a
l
t
h
 
 
a
n
d
 
F
i
n
a
n
c
e
•
 
 
n
a
t
i
o
n
a
l
 
h
e
a
l
t
h
 
 
i
n
s
u
r
a
n
c
e
 
F
u
n
d
 
 
A
d
m
i
n
i
s
t
r
a
t
i
o
n
 
 
T
e
c
h
n
o
l
o
g
y
 
 
A
p
p
r
a
i
s
a
l
 
C
o
m
m
i
t
t
e
e
 
(
r
e
c
o
m
m
e
n
d
a
t
i
o
n
s
)
8
8
,
8
9
T
e
c
h
n
o
l
o
g
y
 
A
p
p
r
a
i
s
a
l
 
 
C
o
m
m
i
t
t
e
e
:
 
i
n
c
l
u
d
e
s
 
 
m
e
m
b
e
r
s
 
d
e
l
e
g
a
t
e
d
 
b
y
 
 
s
t
a
k
e
h
o
l
d
e
r
 
g
r
o
u
p
s
1
0
2
1
.
 
 
M
a
n
u
f
a
c
t
u
r
e
r
 
s
u
b
m
i
t
s
 
a
p
p
l
i
c
a
t
i
o
n
 
f
o
r
 
r
e
i
m
b
u
r
s
e
m
e
n
t
 
t
o
 
 
T
r
a
n
s
p
a
r
e
n
c
y
 
S
e
c
r
e
t
a
r
i
a
t
 
o
f
 
n
a
t
i
o
n
a
l
 
h
e
a
l
t
h
 
i
n
s
u
r
a
n
c
e
 
F
u
n
d
 
 
A
d
m
i
n
i
s
t
r
a
t
i
o
n
 
(
p
h
a
r
m
a
c
e
u
t
i
c
a
l
 
d
i
v
i
s
i
o
n
)
2
.
 
 
T
r
a
n
s
p
a
r
e
n
c
y
 
S
e
c
r
e
t
a
r
i
a
t
 
r
e
g
i
s
t
e
r
s
 
a
n
d
 
c
h
e
c
k
s
 
a
p
p
l
i
c
a
t
i
o
n
 
 
f
o
r
 
c
o
m
p
l
e
t
e
n
e
s
s
 
a
n
d
 
t
h
e
n
 
d
e
t
e
r
m
i
n
e
s
 
w
h
e
t
h
e
r
 
a
p
p
l
i
c
a
t
i
o
n
 
 
s
h
o
u
l
d
 
u
n
d
e
r
g
o
 
s
i
m
p
l
i
fi
e
d
 
p
r
o
c
e
d
u
r
e
 
o
r
 
n
o
r
m
a
l
 
p
r
o
c
e
d
u
r
e
;
 
 
n
o
r
m
a
l
 
p
r
o
c
e
d
u
r
e
 
a
p
p
l
i
e
s
 
t
o
 
n
e
w
 
a
g
e
n
t
s
,
 
i
n
d
i
c
a
t
i
o
n
s
,
 
r
o
u
t
e
s
 
 
o
f
 
a
d
m
i
n
i
s
t
r
a
t
i
o
n
,
 
a
n
d
 
c
o
m
b
i
n
a
t
i
o
n
s
3
.
 
 
n
a
t
i
o
n
a
l
 
h
e
a
l
t
h
 
i
n
s
u
r
a
n
c
e
 
F
u
n
d
 
A
d
m
i
n
i
s
t
r
a
t
i
o
n
 
D
e
p
a
r
t
m
e
n
t
 
 
o
f
 
P
h
a
r
m
a
c
e
u
t
i
c
a
l
s
 
p
r
e
p
a
r
e
s
 
a
 
p
r
e
l
i
m
i
n
a
r
y
 
e
v
a
l
u
a
t
i
o
n
4
.
 
 
i
f
 
a
p
p
l
i
c
a
t
i
o
n
 
i
s
 
a
s
s
i
g
n
e
d
 
t
o
 
n
o
r
m
a
l
 
p
r
o
c
e
d
u
r
e
,
 
T
r
a
n
s
p
a
r
e
n
c
y
 
 
S
e
c
r
e
t
a
r
i
a
t
 
t
r
a
n
s
f
e
r
s
 
i
t
 
t
o
 
T
e
c
h
n
o
l
o
g
y
 
A
s
s
e
s
s
m
e
n
t
 
O
f
fi
c
e
 
o
f
 
 
t
h
e
 
n
a
t
i
o
n
a
l
 
i
n
s
t
i
t
u
t
e
 
f
o
r
 
S
t
r
a
t
e
g
i
c
 
h
e
a
l
t
h
 
R
e
s
e
a
r
c
h
5
.
 
 
A
s
s
e
s
s
m
e
n
t
 
O
f
fi
c
e
 
p
r
e
p
a
r
e
s
 
a
s
s
e
s
s
m
e
n
t
 
r
e
p
o
r
t
 
c
o
m
p
r
i
s
i
n
g
 
a
 
 
s
y
s
t
e
m
a
t
i
c
 
r
e
v
i
e
w
 
o
f
 
c
l
i
n
i
c
a
l
 
e
v
i
d
e
n
c
e
 
a
n
d
 
e
c
o
n
o
m
i
c
 
a
n
a
l
y
s
i
s
6
.
 
 
T
e
c
h
n
o
l
o
g
y
 
A
p
p
r
a
i
s
a
l
 
C
o
m
m
i
t
t
e
e
 
d
e
l
i
b
e
r
a
t
e
s
 
o
v
e
r
 
r
e
p
o
r
t
,
 
 
p
r
e
l
i
m
i
n
a
r
y
 
e
v
a
l
u
a
t
i
o
n
 
o
f
 
p
h
a
r
m
a
c
e
u
t
i
c
a
l
 
d
e
p
a
r
t
m
e
n
t
,
 
 
a
n
d
 
a
d
v
i
c
e
 
f
r
o
m
 
p
r
o
f
e
s
s
i
o
n
a
l
 
c
o
l
l
e
g
e
s
,
 
a
n
d
 
f
o
r
m
u
l
a
t
e
s
 
a
 
 
r
e
c
o
m
m
e
n
d
a
t
i
o
n
7
.
 
 
D
i
r
e
c
t
o
r
 
o
f
 
p
h
a
r
m
a
c
e
u
t
i
c
a
l
 
d
i
v
i
s
i
o
n
 
a
p
p
r
o
v
e
s
 
 
r
e
c
o
m
m
e
n
d
a
t
i
o
n
 
a
n
d
 
f
o
r
w
a
r
d
s
 
i
t
 
t
o
 
t
h
e
 
M
i
n
i
s
t
e
r
s
 
o
f
 
h
e
a
l
t
h
 
 
a
n
d
 
F
i
n
a
n
c
e
9
0
,
1
0
2
,
1
8
7
n
o
 
 
i
n
f
o
r
m
a
t
i
o
n
 
 
f
o
u
n
d
n
o
 
i
n
f
o
r
m
a
t
i
o
n
 
 
f
o
u
n
d
D
e
c
i
s
i
o
n
 
m
a
y
 
b
e
 
a
p
p
e
a
l
e
d
 
t
o
 
A
p
p
e
a
l
s
 
C
o
m
m
i
t
t
e
e
 
i
n
c
l
u
d
e
s
 
r
e
p
r
e
s
e
n
t
a
t
i
v
e
s
 
f
r
o
m
:
 
•
 
 
M
i
n
i
s
t
r
y
 
o
f
 
h
e
a
l
t
h
•
 
 
M
i
n
i
s
t
r
y
 
o
f
 
F
i
n
a
n
c
e
•
 
 
M
i
n
i
s
t
r
y
 
o
f
 
E
c
o
n
o
m
y
•
 
 
n
a
t
i
o
n
a
l
 
i
n
s
t
i
t
u
t
e
 
o
f
 
P
h
a
r
m
a
c
y
•
 
 
P
r
i
m
e
 
M
i
n
i
s
t
e
r
’
s
 
o
f
fi
c
e
9
0
i
r
e
l
a
n
d
•
 
 
P
r
o
d
u
c
t
s
 
C
o
m
m
i
t
t
e
e
 
 
o
f
 
C
o
r
p
o
r
a
t
e
 
 
P
h
a
r
m
a
c
e
u
t
i
c
a
l
s
 
U
n
i
t
 
 
o
f
 
h
e
a
l
t
h
 
S
e
r
v
i
c
e
 
 
E
x
e
c
u
t
i
v
e
 
(
d
e
c
i
s
i
o
n
s
)
9
1
,
9
2
n
o
 
i
n
f
o
r
m
a
t
i
o
n
 
f
o
u
n
d
 
1
.
 
 
P
r
o
d
u
c
t
s
 
C
o
m
m
i
t
t
e
e
 
o
f
 
h
e
a
l
t
h
 
S
e
r
v
i
c
e
 
E
x
e
c
u
t
i
v
e
 
s
e
l
e
c
t
s
 
 
t
e
c
h
n
o
l
o
g
y
 
f
o
r
 
a
s
s
e
s
s
m
e
n
t
 
O
R
 
m
a
n
u
f
a
c
t
u
r
e
r
 
s
u
b
m
i
t
s
 
 
a
p
p
l
i
c
a
t
i
o
n
 
f
o
r
 
r
e
i
m
b
u
r
s
e
m
e
n
t
 
t
o
 
h
e
a
l
t
h
 
S
e
r
v
i
c
e
 
E
x
e
c
u
t
i
v
e
2
a
.
 
 
i
f
 
P
r
o
d
u
c
t
s
 
C
o
m
m
i
t
t
e
e
 
s
e
l
e
c
t
s
 
t
e
c
h
n
o
l
o
g
y
,
 
h
e
a
l
t
h
 
S
e
r
v
i
c
e
 
 
E
x
e
c
u
t
i
v
e
 
n
o
t
i
fi
e
s
 
m
a
n
u
f
a
c
t
u
r
e
r
 
o
f
 
r
e
f
e
r
r
a
l
 
t
o
 
n
a
t
i
o
n
a
l
 
 
C
e
n
t
r
e
 
f
o
r
 
P
h
a
r
m
a
c
o
e
c
o
n
o
m
i
c
s
n
o
 
fi
x
e
d
 
 
t
h
r
e
s
h
o
l
d
,
 
 
b
u
t
 
€
4
5
,
0
0
0
/
 
Q
A
L
Y
 
 
u
s
e
d
 
a
s
 
a
 
 
g
u
i
d
e
9
1
,
1
2
5
,
1
6
5
9
0
 
d
a
y
s
 
(
f
o
r
 
 
r
e
i
m
b
u
r
s
e
m
e
n
t
 
 
d
e
c
i
s
i
o
n
)
9
3
D
e
c
i
s
i
o
n
 
m
a
y
 
b
e
 
a
p
p
e
a
l
e
d
 
t
o
 
d
e
s
i
g
n
a
t
e
d
 
e
x
p
e
r
t
 
c
o
m
m
i
t
t
e
e
9
1
(
C
o
n
t
i
n
u
e
d
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T
a
b
l
e
 
5
 
(
C
o
n
t
i
n
u
e
d
)
C
o
u
n
t
r
y
C
e
n
t
r
a
l
i
z
e
d
 
 
r
e
i
m
b
u
r
s
e
m
e
n
t
 
 
r
e
v
i
e
w
/
d
e
c
i
s
i
o
n
-
 
m
a
k
i
n
g
 
b
o
d
y
 
(
r
o
l
e
)
C
o
m
m
i
t
t
e
e
 
 
c
o
m
p
o
s
i
t
i
o
n
S
t
e
p
s
 
i
n
 
r
e
v
i
e
w
/
d
e
c
i
s
i
o
n
-
m
a
k
i
n
g
 
p
r
o
c
e
s
s
U
s
e
 
o
f
 
c
o
s
t
-
 
e
f
f
e
c
t
i
v
e
n
e
s
s
 
 
t
h
r
e
s
h
o
l
d
T
i
m
e
l
i
n
e
s
 
f
o
r
 
 
r
e
v
i
e
w
/
 
d
e
c
i
s
i
o
n
A
p
p
e
a
l
s
 
 
m
e
c
h
a
n
i
s
m
s
2
b
.
 
 
i
f
 
m
a
n
u
f
a
c
t
u
r
e
r
 
s
u
b
m
i
t
s
 
a
p
p
l
i
c
a
t
i
o
n
,
 
s
t
a
f
f
 
p
r
e
p
a
r
e
 
p
r
e
l
i
m
i
n
a
r
y
 
 
e
v
a
l
u
a
t
i
o
n
 
r
e
p
o
r
t
 
b
a
s
e
d
 
o
n
 
e
v
i
d
e
n
c
e
 
f
r
o
m
 
m
a
n
u
f
a
c
t
u
r
e
r
3
a
.
 
 
S
t
a
f
f
 
w
i
t
h
i
n
 
n
a
t
i
o
n
a
l
 
C
e
n
t
r
e
 
f
o
r
 
P
h
a
r
m
a
c
o
e
c
o
n
o
m
i
c
s
 
 
a
p
p
o
i
n
t
e
d
 
t
o
 
c
o
m
p
r
i
s
e
 
r
e
v
i
e
w
 
g
r
o
u
p
3
b
.
 
 
P
r
o
d
u
c
t
s
 
C
o
m
m
i
t
t
e
e
 
r
e
v
i
e
w
s
 
e
v
a
l
u
a
t
i
o
n
 
r
e
p
o
r
t
 
a
n
d
 
 
d
e
c
i
d
e
s
 
w
h
e
t
h
e
r
 
t
o
 
r
e
f
e
r
 
t
e
c
h
n
o
l
o
g
y
 
t
o
 
n
a
t
i
o
n
a
l
 
C
e
n
t
r
e
 
 
f
o
r
 
P
h
a
r
m
a
c
o
e
c
o
n
o
m
i
c
s
 
f
o
r
 
f
o
r
m
a
l
 
p
h
a
r
m
a
c
o
e
c
o
n
o
m
i
c
 
 
e
v
a
l
u
a
t
i
o
n
 
o
r
 
r
e
c
o
m
m
e
n
d
 
r
e
i
m
b
u
r
s
e
m
e
n
t
4
a
.
 
 
R
e
v
i
e
w
 
g
r
o
u
p
 
m
e
e
t
s
 
w
i
t
h
 
m
a
n
u
f
a
c
t
u
r
e
r
 
t
o
 
d
e
t
e
r
m
i
n
e
 
s
c
o
p
e
 
 
a
n
d
 
r
e
q
u
i
r
e
m
e
n
t
s
 
f
o
r
 
e
v
a
l
u
a
t
i
o
n
4
b
.
 
 
i
f
 
r
e
f
e
r
r
e
d
,
 
n
a
t
i
o
n
a
l
 
C
e
n
t
r
e
 
f
o
r
 
P
h
a
r
m
a
c
o
e
c
o
n
o
m
i
c
s
 
 
c
o
n
d
u
c
t
s
 
p
h
a
r
m
a
c
o
e
c
o
n
o
m
i
c
 
e
v
a
l
u
a
t
i
o
n
5
a
.
 
 
M
a
n
u
f
a
c
t
u
r
e
r
 
p
r
e
p
a
r
e
s
 
p
h
a
r
m
a
c
o
e
c
o
n
o
m
i
c
 
s
u
b
m
i
s
s
i
o
n
,
 
 
w
h
i
c
h
 
i
n
c
l
u
d
e
s
 
c
o
s
t
-
e
f
f
e
c
t
i
v
e
n
e
s
s
 
a
n
d
 
b
u
d
g
e
t
 
i
m
p
a
c
t
 
a
n
a
l
y
s
e
s
5
b
.
 
 
n
a
t
i
o
n
a
l
 
C
e
n
t
r
e
 
f
o
r
 
P
h
a
r
m
a
c
o
e
c
o
n
o
m
i
c
s
 
s
e
n
d
s
 
 
p
h
a
r
m
a
c
o
e
c
o
n
o
m
i
c
 
e
v
a
l
u
a
t
i
o
n
 
t
o
 
m
a
n
u
f
a
c
t
u
r
e
r
 
f
o
r
 
 
c
o
m
m
e
n
t
6
a
.
 
 
R
e
v
i
e
w
 
g
r
o
u
p
 
p
r
e
p
a
r
e
s
 
e
v
a
l
u
a
t
i
o
n
 
r
e
p
o
r
t
 
b
a
s
e
d
 
o
n
 
 
m
a
n
u
f
a
c
t
u
r
e
r
’
s
 
s
u
b
m
i
s
s
i
o
n
6
b
.
 
 
n
a
t
i
o
n
a
l
 
C
e
n
t
r
e
 
f
o
r
 
P
h
a
r
m
a
c
o
e
c
o
n
o
m
i
c
s
 
p
r
e
p
a
r
e
s
 
fi
n
a
l
 
 
p
h
a
r
m
a
c
o
e
c
o
n
o
m
i
c
 
e
v
a
l
u
a
t
i
o
n
,
 
i
n
c
o
r
p
o
r
a
t
i
n
g
 
m
a
n
u
f
a
c
t
u
r
e
r
’
s
 
 
c
o
m
m
e
n
t
s
7
a
.
 
 
n
a
t
i
o
n
a
l
 
C
e
n
t
r
e
 
f
o
r
 
P
h
a
r
m
a
c
o
e
c
o
n
o
m
i
c
s
 
s
e
n
d
s
 
r
e
p
o
r
t
 
t
o
 
 
m
a
n
u
f
a
c
t
u
r
e
r
 
f
o
r
 
c
o
m
m
e
n
t
7
b
.
 
 
n
a
t
i
o
n
a
l
 
C
e
n
t
r
e
 
f
o
r
 
P
h
a
r
m
a
c
o
e
c
o
n
o
m
i
c
s
 
s
e
n
d
s
 
e
v
a
l
u
a
t
i
o
n
 
 
t
o
 
P
r
o
d
u
c
t
s
 
C
o
m
m
i
t
t
e
e
,
 
w
h
o
 
m
a
k
e
s
 
r
e
i
m
b
u
r
s
e
m
e
n
t
 
 
d
e
c
i
s
i
o
n
8
a
.
 
 
R
e
v
i
e
w
 
g
r
o
u
p
 
p
r
e
p
a
r
e
s
 
fi
n
a
l
 
e
v
a
l
u
a
t
i
o
n
 
r
e
p
o
r
t
,
 
i
n
c
o
r
p
o
r
a
t
i
n
g
 
 
m
a
n
u
f
a
c
t
u
r
e
r
’
s
 
c
o
m
m
e
n
t
s
9
a
.
 
 
n
a
t
i
o
n
a
l
 
C
e
n
t
r
e
 
f
o
r
 
P
h
a
r
m
a
c
o
e
c
o
n
o
m
i
c
s
 
s
e
n
d
s
 
r
e
p
o
r
t
 
 
t
o
 
P
r
o
d
u
c
t
s
 
C
o
m
m
i
t
t
e
e
,
 
w
h
o
 
m
a
k
e
s
 
r
e
i
m
b
u
r
s
e
m
e
n
t
 
 
d
e
c
i
s
i
o
n
9
1
,
9
3
,
1
2
5
,
1
4
7
i
t
a
l
y
•
 
 
i
t
a
l
i
a
n
 
M
e
d
i
c
i
n
e
s
 
A
g
e
n
c
y
 
T
e
c
h
n
i
c
a
l
 
S
c
i
e
n
t
i
fi
c
 
 
C
o
m
m
i
t
t
e
e
 
 
(
d
e
c
i
s
i
o
n
s
)
9
4
T
e
c
h
n
i
c
a
l
 
S
c
i
e
n
t
i
fi
c
 
 
C
o
m
m
i
t
t
e
e
:
 
i
n
c
l
u
d
e
s
 
 
1
7
 
m
e
m
b
e
r
s
:
 
•
 
h
e
a
l
t
h
 
c
a
r
e
 
p
r
o
v
i
d
e
r
s
 
•
 
P
h
a
r
m
a
c
i
s
t
s
1
.
 
 
M
a
n
u
f
a
c
t
u
r
e
r
 
s
u
b
m
i
t
s
 
a
p
p
l
i
c
a
t
i
o
n
 
f
o
r
 
r
e
i
m
b
u
r
s
e
m
e
n
t
 
t
o
 
 
i
t
a
l
i
a
n
 
M
e
d
i
c
i
n
e
s
 
A
g
e
n
c
y
2
.
 
 
T
e
c
h
n
i
c
a
l
 
S
c
i
e
n
t
i
fi
c
 
C
o
m
m
i
t
t
e
e
 
r
e
v
i
e
w
s
 
s
u
b
m
i
s
s
i
o
n
 
a
n
d
 
 
f
o
r
m
u
l
a
t
e
s
 
a
d
v
i
c
e
 
o
n
 
c
l
i
n
i
c
a
l
 
v
a
l
u
e
,
 
a
s
s
i
g
n
i
n
g
 
i
t
 
t
o
 
o
n
e
 
o
f
 
t
h
r
e
e
 
 
r
e
i
m
b
u
r
s
e
m
e
n
t
 
c
l
a
s
s
e
s
:
 
A
 
–
 
f
u
l
l
y
 
r
e
i
m
b
u
r
s
a
b
l
e
 
–
 
e
s
s
e
n
t
i
a
l
 
n
o
1
2
6
1
8
0
 
d
a
y
s
 
(
i
n
c
l
u
d
e
s
 
 
p
r
i
c
i
n
g
 
a
n
d
 
 
r
e
i
m
b
u
r
s
e
m
e
n
t
 
 
d
e
c
i
s
i
o
n
)
1
8
8
n
o
 
i
n
f
o
r
m
a
t
i
o
n
 
f
o
u
n
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•
 
 
i
t
a
l
i
a
n
 
M
e
d
i
c
i
n
e
s
 
 
 
A
g
e
n
c
y
 
P
r
i
c
i
n
g
 
 
a
n
d
 
R
e
i
m
b
u
r
s
e
m
e
n
t
 
 
C
o
m
m
i
t
t
e
e
 
 
(
r
e
c
o
m
m
e
n
d
a
t
i
o
n
s
)
9
5
•
 
 
P
h
a
r
m
a
c
o
l
o
g
i
s
t
s
 
P
r
i
c
i
n
g
 
a
n
d
 
 
R
e
i
m
b
u
r
s
e
m
e
n
t
 
 
C
o
m
m
i
t
t
e
e
:
 
i
n
c
l
u
d
e
s
 
 
1
2
 
m
e
m
b
e
r
s
:
•
 
A
c
a
d
e
m
i
c
s
 
•
 
h
e
a
l
t
h
 
c
a
r
e
 
p
r
o
v
i
d
e
r
s
•
 
 
A
d
m
i
n
i
s
t
r
a
t
o
r
s
 
 
r
e
s
p
o
n
s
i
b
l
e
 
f
o
r
 
 
m
a
n
a
g
i
n
g
 
 
p
h
a
r
m
a
c
e
u
t
i
c
a
l
 
 
s
e
r
v
i
c
e
s
9
5
 
 
 
p
r
o
d
u
c
t
s
 
a
n
d
 
t
h
o
s
e
 
i
n
t
e
n
d
e
d
 
f
o
r
 
c
h
r
o
n
i
c
 
d
i
s
e
a
s
e
s
;
 
 
h
 
–
 
F
u
l
l
y
 
r
e
i
m
b
u
r
s
a
b
l
e
 
i
n
 
h
o
s
p
i
t
a
l
s
;
 
a
n
d
 
C
 
–
 
n
o
n
-
r
e
i
m
b
u
r
s
a
b
l
e
.
 
 
P
h
a
r
m
a
c
e
u
t
i
c
a
l
s
 
i
n
 
c
l
a
s
s
e
s
 
A
 
a
n
d
 
h
 
a
r
e
 
f
u
r
t
h
e
r
 
a
s
s
i
g
n
e
d
 
t
o
 
 
o
n
e
 
o
f
 
t
h
r
e
e
 
c
l
a
s
s
e
s
:
 
i
 
–
 
t
r
e
a
t
m
e
n
t
s
 
f
o
r
 
s
e
r
i
o
u
s
 
d
i
s
e
a
s
e
s
;
 
 
i
i
 
–
 
t
r
e
a
t
m
e
n
t
s
 
t
o
 
r
e
d
u
c
e
 
o
r
 
e
l
i
m
i
n
a
t
e
 
r
i
s
k
 
o
f
 
s
e
r
i
o
u
s
 
d
i
s
e
a
s
e
s
;
 
 
a
n
d
 
i
i
i
 
–
 
t
r
e
a
t
m
e
n
t
s
 
f
o
r
 
n
o
n
-
s
e
r
i
o
u
s
 
d
i
s
e
a
s
e
s
3
.
 
 
T
e
c
h
n
i
c
a
l
 
S
c
i
e
n
t
i
fi
c
 
C
o
m
m
i
t
t
e
e
 
t
h
e
n
 
a
s
s
e
s
s
e
s
 
t
h
e
 
d
e
g
r
e
e
 
 
o
f
 
i
n
n
o
v
a
t
i
o
n
 
o
f
f
e
r
e
d
 
b
y
 
t
h
e
 
t
e
c
h
n
o
l
o
g
y
,
 
c
o
n
s
i
d
e
r
i
n
g
 
 
2
 
f
a
c
t
o
r
s
:
 
1
)
 
a
v
a
i
l
a
b
i
l
i
t
y
 
o
f
 
e
x
i
s
t
i
n
g
 
t
r
e
a
t
m
e
n
t
s
 
a
n
d
 
2
)
 
e
x
t
e
n
t
 
 
o
f
 
t
h
e
r
a
p
e
u
t
i
c
 
b
e
n
e
fi
t
;
 
s
c
o
r
e
s
 
o
n
 
e
a
c
h
 
f
a
c
t
o
r
 
a
r
e
 
c
o
m
b
i
n
e
d
 
 
t
o
 
d
e
t
e
r
m
i
n
e
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c
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c
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c
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c
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c
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d
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c
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c
a
l
:
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,
 
5
 
m
i
l
l
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o
n
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r
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a
r
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1
.
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c
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c
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c
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c
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c
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c
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c
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c
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c
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i
c
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n
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y
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c
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i
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r
u
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R
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n
t
4
.
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o
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d
i
c
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n
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y
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s
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a
l
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a
t
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n
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r
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f
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e
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l
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C
a
r
e
 
S
e
r
v
i
c
e
s
 
5
.
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n
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t
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n
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u
l
t
s
 
w
i
t
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t
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o
n
a
l
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o
u
n
c
i
l
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r
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l
t
h
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r
e
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r
i
o
r
i
t
i
e
s
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o
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e
t
e
r
m
i
n
e
 
w
h
e
t
h
e
r
 
p
h
a
r
m
a
c
e
u
t
i
c
a
l
 
w
o
u
l
d
 
b
e
 
 
v
i
e
w
e
d
 
a
s
”
 
m
o
n
e
y
 
w
e
l
l
 
s
p
e
n
t
”
n
o
3
4
1
8
0
 
d
a
y
s
 
(
i
n
c
l
u
d
e
s
 
 
p
r
i
c
i
n
g
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n
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r
e
i
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u
r
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e
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e
n
t
 
 
d
e
c
i
s
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n
)
3
4
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o
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n
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r
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d
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C
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d
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T
a
b
l
e
 
5
 
(
C
o
n
t
i
n
u
e
d
)
C
o
u
n
t
r
y
C
e
n
t
r
a
l
i
z
e
d
 
 
r
e
i
m
b
u
r
s
e
m
e
n
t
 
 
r
e
v
i
e
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e
c
i
s
i
o
n
-
 
m
a
k
i
n
g
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o
d
y
 
(
r
o
l
e
)
C
o
m
m
i
t
t
e
e
 
 
c
o
m
p
o
s
i
t
i
o
n
S
t
e
p
s
 
i
n
 
r
e
v
i
e
w
/
d
e
c
i
s
i
o
n
-
m
a
k
i
n
g
 
p
r
o
c
e
s
s
U
s
e
 
o
f
 
c
o
s
t
-
 
e
f
f
e
c
t
i
v
e
n
e
s
s
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r
e
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o
l
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i
m
e
l
i
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e
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r
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e
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i
e
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c
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s
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o
n
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p
p
e
a
l
s
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e
c
h
a
n
i
s
m
s
6
.
 
 
M
i
n
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s
t
r
y
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r
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u
l
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t
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s
 
r
e
c
o
m
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e
n
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n
;
 
i
f
 
p
o
s
i
t
i
v
e
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i
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s
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o
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r
l
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t
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r
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p
p
r
o
v
a
l
3
4
,
9
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,
1
8
9
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e
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l
t
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(
d
e
c
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9
9
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g
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r
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e
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l
t
h
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e
c
h
n
o
l
o
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y
 
A
s
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e
s
s
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t
 
 
C
o
n
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u
l
t
a
t
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e
 
 
C
o
u
n
c
i
l
 
a
n
d
 
D
r
u
g
 
 
M
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n
a
g
e
m
e
n
t
 
T
e
a
m
 
 
(
r
e
c
o
m
m
e
n
d
a
t
i
o
n
s
)
9
9
C
o
n
s
u
l
t
a
t
i
v
e
 
C
o
u
n
c
i
l
:
 
1
2
 
v
o
t
i
n
g
 
m
e
m
b
e
r
s
 
 
i
n
c
l
u
d
i
n
g
 
r
e
p
r
e
s
e
n
t
a
t
i
v
e
s
 
 
f
r
o
m
:
 
•
 
M
i
n
i
s
t
r
y
 
o
f
 
h
e
a
l
t
h
 
(
7
)
 
•
 
 
P
o
l
i
s
h
 
C
h
a
m
b
e
r
 
o
f
 
 
P
h
y
s
i
c
i
a
n
s
 
(
1
)
•
 
 
C
h
i
e
f
 
P
h
a
r
m
a
c
e
u
t
i
c
a
l
 
 
C
o
u
n
c
i
l
 
(
1
)
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u
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r
e
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o
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n
c
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l
 
o
f
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u
r
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s
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d
 
M
i
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w
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v
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s
•
 
 
n
a
t
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n
a
l
 
h
e
a
l
t
h
 
 
F
u
n
d
1
2
7
 
D
r
u
g
 
M
a
n
a
g
e
m
e
n
t
 
 
T
e
a
m
:
 
i
n
c
l
u
d
e
s
 
 
r
e
p
r
e
s
e
n
t
a
t
i
v
e
s
 
o
f
:
•
 
M
i
n
i
s
t
e
r
 
o
f
 
F
i
n
a
n
c
e
 
•
 
 
M
i
n
i
s
t
e
r
 
o
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c
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n
o
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y
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d
 
L
a
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o
u
r
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M
i
n
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o
c
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o
l
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y
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a
t
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n
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l
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l
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d
9
9
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b
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c
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l
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n
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p
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c
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c
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p
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c
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c
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p
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c
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c
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p
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c
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r
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n
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i
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R
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o
m
i
c
 
A
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.
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p
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p
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.
 
 
E
c
o
n
o
m
i
s
t
s
 
a
n
a
l
y
z
e
 
p
h
a
r
m
a
c
o
t
h
e
r
a
p
e
u
t
i
c
 
i
n
f
o
r
m
a
t
i
o
n
 
 
f
r
o
m
 
m
a
n
u
f
a
c
t
u
r
e
r
 
t
o
 
d
e
t
e
r
m
i
n
e
 
“
e
c
o
n
o
m
i
c
 
a
d
v
a
n
t
a
g
e
”
;
 
 
i
f
 
p
h
a
r
m
a
c
e
u
t
i
c
a
l
 
o
f
f
e
r
s
 
a
d
d
e
d
 
t
h
e
r
a
p
e
u
t
i
c
 
v
a
l
u
e
 
o
r
 
t
r
e
a
t
s
 
 
a
 
c
o
n
d
i
t
i
o
n
 
f
o
r
 
w
h
i
c
h
 
t
h
e
r
e
 
a
r
e
 
n
o
 
a
l
t
e
r
n
a
t
i
v
e
 
t
h
e
r
a
p
i
e
s
,
 
 
e
c
o
n
o
m
i
c
 
a
d
v
a
n
t
a
g
e
 
s
h
o
u
l
d
 
b
e
 
d
e
m
o
n
s
t
r
a
t
e
d
 
t
h
r
o
u
g
h
 
f
o
r
m
a
l
 
 
e
c
o
n
o
m
i
c
 
a
n
a
l
y
s
e
s
 
c
o
n
d
u
c
t
e
d
 
b
y
 
t
h
e
 
m
a
n
u
f
a
c
t
u
r
e
r
n
o
 
 
i
n
f
o
r
m
a
t
i
o
n
 
 
f
o
u
n
d
9
0
 
d
a
y
s
 
(
i
n
c
l
u
d
e
s
 
 
p
r
i
c
i
n
g
 
a
n
d
 
 
r
e
i
m
b
u
r
s
e
m
e
n
t
 
 
d
e
c
i
s
i
o
n
)
3
6
•
 
 
D
e
c
i
s
i
o
n
 
m
a
y
 
b
e
 
a
p
p
e
a
l
e
d
 
t
o
 
a
d
m
i
n
i
s
t
r
a
t
i
v
e
 
c
o
u
r
t
3
6ClinicoEconomics and Outcomes Research 2011:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
153
Reimbursement of European health technologies
4
.
 
 
U
s
i
n
g
 
fi
n
d
i
n
g
s
 
f
r
o
m
 
b
o
t
h
 
r
e
p
o
r
t
s
,
 
i
n
F
A
R
M
E
D
 
f
o
r
m
u
l
a
t
e
s
 
 
r
e
i
m
b
u
r
s
e
m
e
n
t
 
r
e
c
o
m
m
e
n
d
a
t
i
o
n
5
.
 
 
i
f
 
n
e
g
a
t
i
v
e
,
 
i
n
F
A
R
M
E
D
 
c
o
n
t
a
c
t
s
 
m
a
n
u
f
a
c
t
u
r
e
r
,
 
w
h
o
 
m
a
y
 
 
p
r
e
s
e
n
t
 
a
d
d
i
t
i
o
n
a
l
 
i
n
f
o
r
m
a
t
i
o
n
6
.
 
 
i
n
F
A
R
M
E
D
 
s
u
b
m
i
t
s
 
r
e
c
o
m
m
e
n
d
a
t
i
o
n
s
 
t
o
 
M
i
n
i
s
t
e
r
,
 
w
h
o
 
 
m
a
k
e
s
 
fi
n
a
l
 
d
e
c
i
s
i
o
n
3
6
,
1
0
1
,
1
9
1
S
c
o
t
l
a
n
d
•
 
 
n
a
t
i
o
n
a
l
 
h
e
a
l
t
h
 
S
e
r
v
i
c
e
 
 
S
c
o
t
l
a
n
d
 
(
d
e
c
i
s
i
o
n
s
)
3
0
•
 
 
S
c
o
t
t
i
s
h
 
M
e
d
i
c
i
n
e
s
 
 
C
o
n
s
o
r
t
i
u
m
 
 
(
r
e
c
o
m
m
e
n
d
a
t
i
o
n
s
)
n
o
 
i
n
f
o
r
m
a
t
i
o
n
 
 
f
o
u
n
d
1
.
 
 
M
a
n
u
f
a
c
t
u
r
e
r
 
s
u
b
m
i
t
s
 
a
p
p
l
i
c
a
t
i
o
n
 
f
o
r
 
r
e
i
m
b
u
r
s
e
m
e
n
t
 
t
o
 
 
S
c
o
t
t
i
s
h
 
M
e
d
i
c
i
n
e
s
 
C
o
n
s
o
r
t
i
u
m
2
.
 
 
i
n
t
e
r
n
a
l
 
s
t
a
f
f
 
(
“
a
s
s
e
s
s
m
e
n
t
 
t
e
a
m
”
)
,
 
s
u
p
p
o
r
t
e
d
 
b
y
 
c
l
i
n
i
c
a
l
 
 
a
n
d
 
e
c
o
n
o
m
i
c
 
e
x
p
e
r
t
s
,
 
p
r
e
p
a
r
e
 
e
v
a
l
u
a
t
i
o
n
 
r
e
p
o
r
t
 
b
a
s
e
d
 
o
n
 
 
e
v
i
d
e
n
c
e
 
s
u
b
m
i
t
t
e
d
 
b
y
 
m
a
n
u
f
a
c
t
u
r
e
r
3
.
 
 
n
e
w
 
D
r
u
g
s
 
C
o
m
m
i
t
t
e
e
 
r
e
v
i
e
w
s
 
r
e
p
o
r
t
 
a
n
d
 
p
r
e
p
a
r
e
s
 
d
r
a
f
t
 
 
r
e
c
o
m
m
e
n
d
a
t
i
o
n
s
 
f
o
r
 
t
h
e
 
S
c
o
t
t
i
s
h
 
M
e
d
i
c
i
n
e
s
 
C
o
n
s
o
r
t
i
u
m
4
.
 
 
n
e
w
 
D
r
u
g
s
 
C
o
m
m
i
t
t
e
e
 
a
l
s
o
 
s
e
n
d
s
 
d
r
a
f
t
 
r
e
c
o
m
m
e
n
d
a
t
i
o
n
s
 
 
t
o
 
m
a
n
u
f
a
c
t
u
r
e
r
 
f
o
r
 
c
o
m
m
e
n
t
5
.
 
 
M
a
n
u
f
a
c
t
u
r
e
r
 
s
e
n
d
s
 
c
o
m
m
e
n
t
s
 
t
o
 
S
c
o
t
t
i
s
h
 
M
e
d
i
c
i
n
e
s
 
 
C
o
n
s
o
r
t
i
u
m
,
 
w
h
i
c
h
 
a
l
s
o
 
c
o
n
s
i
d
e
r
s
 
s
u
b
m
i
s
s
i
o
n
s
 
r
e
c
e
i
v
e
d
 
 
f
r
o
m
 
p
a
t
i
e
n
t
 
i
n
t
e
r
e
s
t
 
g
r
o
u
p
s
6
.
 
 
S
c
o
t
t
i
s
h
 
M
e
d
i
c
i
n
e
s
 
C
o
n
s
o
r
t
i
u
m
 
f
o
r
m
u
l
a
t
e
s
 
fi
n
a
l
 
 
r
e
c
o
m
m
e
n
d
a
t
i
o
n
s
 
a
n
d
 
f
o
r
w
a
r
d
s
 
t
h
e
m
 
t
o
 
t
h
e
 
n
a
t
i
o
n
a
l
 
h
e
a
l
t
h
 
 
S
e
r
v
i
c
e
 
B
o
a
r
d
s
,
 
A
r
e
a
 
D
r
u
g
 
a
n
d
 
T
h
e
r
a
p
e
u
t
i
c
s
 
C
o
m
m
i
t
t
e
e
s
,
 
 
m
a
n
u
f
a
c
t
u
r
e
r
,
 
a
n
d
 
c
o
m
p
e
t
i
t
o
r
(
s
)
3
0
,
1
2
8
n
o
 
fi
x
e
d
 
 
t
h
r
e
s
h
o
l
d
,
 
 
b
u
t
 
r
a
n
g
e
 
 
o
f
 
£
2
0
,
0
0
0
–
 
£
3
0
,
0
0
0
/
Q
A
L
Y
 
 
u
s
e
d
 
a
s
 
a
 
 
g
u
i
d
e
3
0
n
o
 
i
n
f
o
r
m
a
t
i
o
n
 
 
f
o
u
n
d
•
 
 
D
e
c
i
s
i
o
n
s
 
m
a
y
 
b
e
 
a
p
p
e
a
l
e
d
 
o
n
 
p
r
o
c
e
s
s
-
r
e
l
a
t
e
d
 
a
n
d
 
s
c
i
e
n
t
i
fi
c
 
g
r
o
u
n
d
s
•
 
 
F
o
r
 
p
r
o
c
e
s
s
-
r
e
l
a
t
e
d
 
a
p
p
e
a
l
s
:
 
M
a
n
u
f
a
c
t
u
r
e
r
 
c
o
n
t
a
c
t
s
 
S
c
o
t
t
i
s
h
 
M
e
d
i
c
i
n
e
s
 
C
o
n
s
o
r
t
i
u
m
 
s
e
c
r
e
t
a
r
i
a
t
,
 
C
h
a
i
r
,
 
o
r
 
n
e
w
 
D
r
u
g
s
 
C
o
m
m
i
t
t
e
e
 
t
o
 
r
e
s
o
l
v
e
 
i
s
s
u
e
s
 
t
h
r
o
u
g
h
 
d
i
s
c
u
s
s
i
o
n
•
 
 
F
o
r
 
s
c
i
e
n
t
i
fi
c
 
d
i
s
p
u
t
e
s
:
 
M
a
y
 
r
e
s
u
b
m
i
t
 
o
r
 
c
o
n
v
e
n
e
 
i
n
d
e
p
e
n
d
e
n
t
 
p
a
n
e
l
 
a
p
p
o
i
n
t
e
d
 
b
y
 
S
c
o
t
t
i
s
h
 
M
e
d
i
c
i
n
e
s
 
C
o
n
s
o
r
t
i
u
m
S
l
o
v
a
k
i
a
•
 
 
M
i
n
i
s
t
r
y
 
o
f
 
h
e
a
l
t
h
 
 
(
d
e
c
i
s
i
o
n
s
)
•
 
 
R
e
i
m
b
u
r
s
e
m
e
n
t
 
 
C
o
m
m
i
t
t
e
e
 
f
o
r
 
 
M
e
d
i
c
i
n
a
l
 
P
r
o
d
u
c
t
s
 
 
(
r
e
c
o
m
m
e
n
d
a
t
i
o
n
s
)
1
0
5
,
1
0
7
R
e
i
m
b
u
r
s
e
m
e
n
t
 
 
C
o
m
m
i
t
t
e
e
:
 
i
n
c
l
u
d
e
s
 
1
1
 
m
e
m
b
e
r
s
 
 
r
e
p
r
e
s
e
n
t
i
n
g
:
 
•
 
M
i
n
i
s
t
r
y
 
o
f
 
h
e
a
l
t
h
 
(
3
)
 
•
 
 
S
l
o
v
a
k
i
a
n
 
m
e
d
i
c
a
l
 
 
c
h
a
m
b
e
r
 
(
3
)
•
 
 
h
e
a
l
t
h
 
i
n
s
u
r
a
n
c
e
 
 
f
u
n
d
s
 
(
5
)
1
0
1
1
.
 
 
M
a
n
u
f
a
c
t
u
r
e
r
 
s
u
b
m
i
t
s
 
a
p
p
l
i
c
a
t
i
o
n
 
f
o
r
 
r
e
i
m
b
u
r
s
e
m
e
n
t
,
 
 
i
n
c
l
u
d
i
n
g
 
p
r
o
p
o
s
e
d
 
m
a
x
i
m
u
m
 
r
e
t
a
i
l
 
p
r
i
c
e
,
 
t
o
 
M
i
n
i
s
t
r
y
 
 
o
f
 
h
e
a
l
t
h
2
.
 
 
S
t
a
f
f
 
e
v
a
l
u
a
t
e
 
p
h
a
r
m
a
c
e
u
t
i
c
a
l
 
u
s
i
n
g
 
e
v
i
d
e
n
c
e
 
f
r
o
m
 
 
m
a
n
u
f
a
c
t
u
r
e
r
 
t
o
 
d
e
t
e
r
m
i
n
e
 
w
h
e
r
e
 
i
t
s
 
i
C
E
R
 
l
i
e
s
 
i
n
 
 
t
h
e
 
a
c
c
e
p
t
e
d
 
i
C
E
R
 
t
h
r
e
s
h
o
l
d
 
r
a
n
g
e
3
.
 
 
O
n
e
 
o
f
 
2
2
 
s
p
e
c
i
a
l
i
s
t
 
w
o
r
k
i
n
g
 
g
r
o
u
p
s
 
t
h
e
n
 
e
v
a
l
u
a
t
e
s
 
t
h
e
 
 
p
h
a
r
m
a
c
e
u
t
i
c
a
l
 
a
c
c
o
r
d
i
n
g
 
t
o
 
i
t
s
 
a
n
a
t
o
m
i
c
 
a
n
d
 
t
h
e
r
a
p
e
u
t
i
c
 
 
c
l
a
s
s
i
fi
c
a
t
i
o
n
n
o
 
fi
x
e
d
 
 
t
h
r
e
s
h
o
l
d
,
 
 
b
u
t
 
r
a
n
g
e
 
 
o
f
 
€
2
0
,
0
0
0
–
 
€
2
6
,
5
0
0
/
 
Q
A
L
Y
 
u
s
e
d
 
 
a
s
 
a
 
g
u
i
d
e
1
0
5
n
o
 
i
n
f
o
r
m
a
t
i
o
n
 
 
f
o
u
n
d
•
 
 
D
e
c
i
s
i
o
n
 
m
a
y
 
b
e
 
a
p
p
e
a
l
e
d
 
t
o
 
M
i
n
i
s
t
r
y
(
C
o
n
t
i
n
u
e
d
)ClinicoEconomics and Outcomes Research 2011:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
154
Stafinski et al
T
a
b
l
e
 
5
 
(
C
o
n
t
i
n
u
e
d
)
C
o
u
n
t
r
y
C
e
n
t
r
a
l
i
z
e
d
 
 
r
e
i
m
b
u
r
s
e
m
e
n
t
 
 
r
e
v
i
e
w
/
d
e
c
i
s
i
o
n
-
 
m
a
k
i
n
g
 
b
o
d
y
 
(
r
o
l
e
)
C
o
m
m
i
t
t
e
e
 
 
c
o
m
p
o
s
i
t
i
o
n
S
t
e
p
s
 
i
n
 
r
e
v
i
e
w
/
d
e
c
i
s
i
o
n
-
m
a
k
i
n
g
 
p
r
o
c
e
s
s
U
s
e
 
o
f
 
c
o
s
t
-
 
e
f
f
e
c
t
i
v
e
n
e
s
s
 
 
t
h
r
e
s
h
o
l
d
T
i
m
e
l
i
n
e
s
 
f
o
r
 
 
r
e
v
i
e
w
/
 
d
e
c
i
s
i
o
n
A
p
p
e
a
l
s
 
 
m
e
c
h
a
n
i
s
m
s
4
.
 
 
A
 
s
e
p
a
r
a
t
e
 
w
o
r
k
i
n
g
 
g
r
o
u
p
 
e
v
a
l
u
a
t
e
s
 
p
h
a
r
m
a
c
o
e
c
o
n
o
m
i
c
 
d
a
t
a
5
.
 
 
E
v
a
l
u
a
t
i
o
n
s
 
f
r
o
m
 
b
o
t
h
 
w
o
r
k
i
n
g
 
g
r
o
u
p
s
 
a
r
e
 
f
o
r
w
a
r
d
e
d
 
t
o
 
t
h
e
 
 
R
e
i
m
b
u
r
s
e
m
e
n
t
 
C
o
m
m
i
t
t
e
e
6
.
 
 
T
h
e
 
R
e
i
m
b
u
r
s
e
m
e
n
t
 
C
o
m
m
i
t
t
e
e
 
r
e
v
i
e
w
s
 
t
h
e
 
r
e
p
o
r
t
s
 
a
n
d
 
 
f
o
r
m
u
l
a
t
e
s
 
a
 
r
e
i
m
b
u
r
s
e
m
e
n
t
 
d
e
c
i
s
i
o
n
1
0
2
,
1
0
6
,
1
0
7
,
1
3
1
,
1
6
9
S
p
a
i
n
•
 
 
M
i
n
i
s
t
r
y
 
o
f
 
h
e
a
l
t
h
 
 
D
i
r
e
c
t
o
r
a
t
e
 
g
e
n
e
r
a
l
 
 
o
f
 
P
h
a
r
m
a
c
y
 
 
a
n
d
 
h
e
a
l
t
h
 
P
r
o
d
u
c
t
s
;
 
 
i
n
t
e
r
-
M
i
n
i
s
t
e
r
i
a
l
 
 
P
r
i
c
i
n
g
 
C
o
m
m
i
s
s
i
o
n
 
 
(
d
e
c
i
s
i
o
n
s
)
2
1
,
1
0
8
i
n
t
e
r
-
M
i
n
i
s
t
e
r
i
a
l
 
P
r
i
c
i
n
g
 
 
C
o
m
m
i
s
s
i
o
n
:
 
i
n
c
l
u
d
e
s
 
 
r
e
p
r
e
s
e
n
t
a
t
i
v
e
s
 
f
r
o
m
:
 
•
 
M
i
n
i
s
t
r
y
 
o
f
 
h
e
a
l
t
h
 
•
 
M
i
n
i
s
t
r
y
 
o
f
 
E
c
o
n
o
m
y
 
•
 
M
i
n
i
s
t
r
y
 
o
f
 
i
n
d
u
s
t
r
y
1
3
2
1
.
 
 
M
i
n
i
s
t
r
y
 
o
f
 
h
e
a
l
t
h
 
i
n
i
t
i
a
t
e
s
 
r
e
i
m
b
u
r
s
e
m
e
n
t
 
d
e
c
i
s
i
o
n
-
m
a
k
i
n
g
 
 
p
r
o
c
e
s
s
 
u
p
o
n
 
r
e
c
e
i
p
t
 
o
f
 
n
o
t
i
c
e
 
o
f
 
m
a
r
k
e
t
 
a
p
p
r
o
v
a
l
 
f
o
r
 
n
e
w
 
 
p
h
a
r
m
a
c
e
u
t
i
c
a
l
2
.
 
 
M
i
n
i
s
t
r
y
 
o
f
 
h
e
a
l
t
h
 
i
n
v
i
t
e
s
 
m
a
n
u
f
a
c
t
u
r
e
r
 
t
o
 
p
r
o
v
i
d
e
 
a
l
l
 
 
r
e
l
e
v
a
n
t
 
i
n
f
o
r
m
a
t
i
o
n
 
t
o
 
i
n
t
e
r
-
M
i
n
i
s
t
e
r
i
a
l
 
P
r
i
c
i
n
g
 
C
o
m
m
i
s
s
i
o
n
3
.
 
 
i
n
t
e
r
n
a
l
 
s
t
a
f
f
 
o
f
 
M
i
n
i
s
t
r
y
 
o
f
 
h
e
a
l
t
h
 
p
r
e
p
a
r
e
 
e
v
a
l
u
a
t
i
o
n
 
r
e
p
o
r
t
4
.
 
 
i
n
t
e
r
-
M
i
n
i
s
t
e
r
i
a
l
 
P
r
i
c
i
n
g
 
C
o
m
m
i
s
s
i
o
n
 
r
e
v
i
e
w
s
 
r
e
p
o
r
t
 
a
n
d
 
 
m
a
k
e
s
 
r
e
i
m
b
u
r
s
e
m
e
n
t
 
a
n
d
 
p
r
i
c
i
n
g
 
d
e
c
i
s
i
o
n
1
0
8
,
1
3
2
n
o
1
3
2
1
8
0
 
d
a
y
s
 
(
i
n
c
l
u
d
e
s
 
 
p
r
i
c
i
n
g
 
a
n
d
 
 
r
e
i
m
b
u
r
s
e
m
e
n
t
 
 
d
e
c
i
s
i
o
n
)
1
3
2
n
o
 
i
n
f
o
r
m
a
t
i
o
n
 
f
o
u
n
d
S
w
e
d
e
n
•
 
 
D
e
n
t
a
l
 
a
n
d
 
 
P
h
a
r
m
a
c
e
u
t
i
c
a
l
 
B
e
n
e
fi
t
s
 
 
B
o
a
r
d
 
E
x
p
e
r
t
 
B
o
a
r
d
 
 
(
d
e
c
i
s
i
o
n
s
)
1
5
,
1
0
9
E
x
p
e
r
t
 
B
o
a
r
d
:
 
i
n
c
l
u
d
e
s
 
 
1
1
 
m
e
m
b
e
r
s
 
a
n
d
 
a
 
c
h
a
i
r
:
 
•
 
P
h
a
r
m
a
c
o
l
o
g
i
s
t
 
(
1
)
 
•
 
h
e
a
l
t
h
 
e
c
o
n
o
m
i
s
t
s
 
(
4
)
 
•
 
 
P
a
t
i
e
n
t
 
r
e
p
r
e
s
e
n
t
a
t
i
v
e
s
 
 
(
2
)
•
 
 
h
e
a
l
t
h
 
c
a
r
e
 
p
r
o
v
i
d
e
r
s
 
 
(
3
)
1
5
,
1
0
9
1
.
 
 
M
a
n
u
f
a
c
t
u
r
e
r
 
s
u
b
m
i
t
s
 
a
p
p
l
i
c
a
t
i
o
n
 
f
o
r
 
r
e
i
m
b
u
r
s
e
m
e
n
t
2
.
 
 
i
n
t
e
r
n
a
l
 
s
t
a
f
f
 
(
e
x
e
c
u
t
i
v
e
 
o
f
fi
c
e
r
,
 
h
e
a
l
t
h
 
e
c
o
n
o
m
i
s
t
,
 
a
n
d
 
 
l
e
g
a
l
 
e
x
p
e
r
t
)
 
r
e
v
i
e
w
 
s
u
b
m
i
s
s
i
o
n
 
t
o
 
d
e
t
e
r
m
i
n
e
 
i
f
 
a
p
p
l
i
c
a
t
i
o
n
 
 
c
o
n
t
a
i
n
s
 
s
u
f
fi
c
i
e
n
t
 
e
v
i
d
e
n
c
e
3
.
 
 
D
e
n
t
a
l
 
a
n
d
 
P
h
a
r
m
a
c
e
u
t
i
c
a
l
 
B
e
n
e
fi
t
s
 
B
o
a
r
d
 
s
e
n
d
s
 
c
o
p
y
 
o
f
 
a
p
p
l
i
c
a
t
i
o
n
 
 
t
o
 
P
h
a
r
m
a
c
e
u
t
i
c
a
l
 
B
e
n
e
fi
t
s
 
g
r
o
u
p
 
f
o
r
 
C
o
u
n
t
y
 
C
o
u
n
c
i
l
s
 
f
o
r
 
r
e
v
i
e
w
4
.
 
 
i
n
t
e
r
n
a
l
 
s
t
a
f
f
 
p
r
e
p
a
r
e
 
e
v
a
l
u
a
t
i
o
n
 
r
e
p
o
r
t
 
a
n
d
 
d
r
a
f
t
 
 
r
e
c
o
m
m
e
n
d
a
t
i
o
n
s
 
i
n
 
t
h
e
 
f
o
r
m
 
o
f
 
a
 
“
m
e
m
o
r
a
n
d
u
m
”
5
.
 
 
D
e
n
t
a
l
 
a
n
d
 
P
h
a
r
m
a
c
e
u
t
i
c
a
l
 
B
e
n
e
fi
t
s
 
B
o
a
r
d
 
s
e
n
d
s
 
c
o
p
y
 
 
o
f
 
m
e
m
o
r
a
n
d
u
m
 
t
o
 
m
a
n
u
f
a
c
t
u
r
e
r
 
f
o
r
 
r
e
v
i
e
w
6
.
 
 
M
a
n
u
f
a
c
t
u
r
e
r
 
m
a
y
 
r
e
q
u
e
s
t
 
a
 
m
e
e
t
i
n
g
 
w
i
t
h
 
t
h
e
 
B
o
a
r
d
,
 
d
u
r
i
n
g
 
 
w
h
i
c
h
 
i
t
 
c
a
n
 
p
r
e
s
e
n
t
 
c
a
s
e
,
 
d
i
s
p
u
t
e
 
a
r
g
u
m
e
n
t
s
 
w
h
i
c
h
 
f
o
r
m
 
t
h
e
 
 
b
a
s
i
s
 
o
f
 
r
e
c
o
m
m
e
n
d
a
t
i
o
n
s
,
 
a
n
d
 
r
e
f
u
t
e
 
f
a
c
t
u
a
l
 
e
r
r
o
r
s
7
.
 
 
M
e
e
t
i
n
g
 
o
f
 
E
x
p
e
r
t
 
B
o
a
r
d
 
h
e
l
d
 
–
 
m
e
m
o
r
a
n
d
u
m
,
 
 
m
a
n
u
f
a
c
t
u
r
e
r
’
s
 
c
o
m
m
e
n
t
s
,
 
a
n
d
 
a
n
y
 
f
e
e
d
b
a
c
k
 
r
e
c
e
i
v
e
d
 
f
r
o
m
 
 
t
h
e
 
P
h
a
r
m
a
c
e
u
t
i
c
a
l
 
B
e
n
e
fi
t
s
 
g
r
o
u
p
 
a
r
e
 
r
e
v
i
e
w
e
d
;
 
e
x
t
e
r
n
a
l
 
 
e
x
p
e
r
t
s
 
m
a
y
 
b
e
 
i
n
v
i
t
e
d
 
t
o
 
p
a
r
t
i
c
i
p
a
t
e
 
i
n
 
d
e
l
i
b
e
r
a
t
i
o
n
s
;
8
.
 
 
E
x
p
e
r
t
 
B
o
a
r
d
 
m
a
k
e
s
 
fi
n
a
l
 
r
e
i
m
b
u
r
s
e
m
e
n
t
 
d
e
c
i
s
i
o
n
3
3
,
1
9
2
n
o
 
fi
x
e
d
 
 
t
h
r
e
s
h
o
l
d
,
 
 
b
u
t
 
€
4
5
,
0
0
0
/
 
Q
A
L
Y
 
u
s
e
d
 
 
a
s
 
a
 
g
u
i
d
e
3
5
1
8
0
 
d
a
y
s
 
(
i
n
c
l
u
d
e
s
 
 
p
r
i
c
i
n
g
 
a
n
d
 
 
r
e
i
m
b
u
r
s
e
m
e
n
t
 
d
e
c
i
s
i
o
n
)
1
9
2
•
 
 
D
e
c
i
s
i
o
n
 
m
a
y
 
b
e
 
a
p
p
e
a
l
e
d
 
o
n
 
p
r
o
c
e
d
u
r
a
l
s
 
g
r
o
u
n
d
s
 
o
n
l
y
1
5
,
3
3
,
1
9
2
•
 
 
B
o
a
r
d
 
m
a
y
 
r
e
c
o
n
s
i
d
e
r
 
d
e
c
i
s
i
o
n
 
b
e
f
o
r
e
 
a
p
p
e
a
l
 
i
s
 
h
e
a
r
d
 
b
y
 
a
d
m
i
n
i
s
t
r
a
t
i
v
e
 
c
o
u
r
t
1
9
2
S
w
i
t
z
e
r
l
a
n
d
•
 
 
S
w
i
s
s
 
F
e
d
e
r
a
l
 
O
f
fi
c
e
 
 
o
f
 
P
u
b
l
i
c
 
h
e
a
l
t
h
 
 
(
d
e
c
i
s
i
o
n
s
)
•
 
 
F
e
d
e
r
a
l
 
D
r
u
g
 
 
C
o
m
m
i
s
s
i
o
n
 
 
(
r
e
c
o
m
m
e
n
d
a
t
i
o
n
s
)
1
1
3
,
1
1
4
F
e
d
e
r
a
l
 
D
r
u
g
 
 
C
o
m
m
i
s
s
i
o
n
:
 
i
n
c
l
u
d
e
s
 
 
2
5
 
v
o
t
i
n
g
 
m
e
m
b
e
r
s
 
 
r
e
p
r
e
s
e
n
t
i
n
g
:
 
•
 
A
c
a
d
e
m
i
c
s
 
(
4
)
 
•
 
P
h
y
s
i
c
i
a
n
s
 
(
3
)
 
•
 
P
h
a
r
m
a
c
i
s
t
s
 
(
3
)
1
.
 
 
M
a
n
u
f
a
c
t
u
r
e
r
 
s
u
b
m
i
t
s
 
a
p
p
l
i
c
a
t
i
o
n
 
f
o
r
 
r
e
i
m
b
u
r
s
e
m
e
n
t
2
.
 
 
F
e
d
e
r
a
l
 
D
r
u
g
 
C
o
m
m
i
s
s
i
o
n
 
r
e
v
i
e
w
s
 
a
p
p
l
i
c
a
t
i
o
n
 
a
n
d
 
m
a
k
e
s
 
 
a
 
c
l
a
s
s
i
fi
c
a
t
i
o
n
 
r
e
c
o
m
m
e
n
d
a
t
i
o
n
:
 
p
h
a
r
m
a
c
e
u
t
i
c
a
l
 
m
a
y
 
b
e
 
 
c
l
a
s
s
i
fi
e
d
 
i
n
t
o
 
o
n
e
 
o
f
 
fi
v
e
 
c
a
t
e
g
o
r
i
e
s
 
o
f
 
r
e
l
a
t
i
v
e
 
e
f
f
e
c
t
i
v
e
n
e
s
s
:
 
 
1
 
–
 
T
h
e
r
a
p
e
u
t
i
c
 
b
r
e
a
k
t
h
r
o
u
g
h
;
 
2
 
–
 
T
h
e
r
a
p
e
u
t
i
c
 
p
r
o
g
r
e
s
s
;
 
 
3
 
–
 
S
a
v
i
n
g
 
c
o
m
p
a
r
e
d
 
t
o
 
o
t
h
e
r
 
d
r
u
g
s
;
 
4
 
–
 
n
o
 
t
h
e
r
a
p
e
u
t
i
c
 
 
p
r
o
g
r
e
s
s
 
a
n
d
 
n
o
 
s
a
v
i
n
g
s
;
 
a
n
d
 
5
 
–
 
n
o
t
 
a
p
p
r
o
p
r
i
a
t
e
 
f
o
r
 
t
h
e
 
s
o
c
i
a
l
 
h
e
a
l
t
h
 
i
n
s
u
r
a
n
c
e
n
o
 
 
i
n
f
o
r
m
a
t
i
o
n
 
 
f
o
u
n
d
n
o
 
i
n
f
o
r
m
a
t
i
o
n
 
 
f
o
u
n
d
•
 
 
D
e
c
i
s
i
o
n
 
m
a
y
 
b
e
 
a
p
p
e
a
l
e
d
 
t
o
 
F
e
d
e
r
a
l
 
O
f
fi
c
e
 
o
f
 
P
u
b
l
i
c
 
h
e
a
l
t
h
1
1
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•
 
h
e
a
l
t
h
 
i
n
s
u
r
e
r
s
 
(
5
)
 
•
 
h
o
s
p
i
t
a
l
s
 
(
1
)
 
•
 
 
P
a
t
i
e
n
t
 
 
o
r
g
a
n
i
z
a
t
i
o
n
s
 
(
2
)
•
 
M
a
n
u
f
a
c
t
u
r
e
r
s
 
(
2
)
 
•
 
 
F
e
d
e
r
a
l
 
O
f
fi
c
e
 
o
f
 
 
S
o
c
i
a
l
 
i
n
s
u
r
a
n
c
e
 
(
1
)
•
 
C
a
n
t
o
n
s
 
(
1
)
 
•
 
S
w
i
s
s
m
e
d
i
c
 
(
1
)
 
•
 
 
A
r
m
y
 
p
h
a
r
m
a
c
y
 
 
(
1
)
1
1
3
,
1
1
4
3
.
 
 
F
e
d
e
r
a
l
 
O
f
fi
c
e
 
o
f
 
P
u
b
l
i
c
 
h
e
a
l
t
h
 
m
a
k
e
s
 
fi
n
a
l
 
d
e
c
i
s
i
o
n
,
 
b
a
s
e
d
 
 
o
n
 
F
e
d
e
r
a
l
 
D
r
u
g
 
C
o
m
m
i
s
s
i
o
n
’
s
 
r
e
c
o
m
m
e
n
d
a
t
i
o
n
,
 
a
s
s
e
s
s
m
e
n
t
 
 
b
y
 
S
w
i
s
s
 
A
g
e
n
c
y
 
f
o
r
 
T
h
e
r
a
p
e
u
t
i
c
 
P
r
o
d
u
c
t
s
 
f
o
r
 
m
a
r
k
e
t
 
 
a
u
t
h
o
r
i
z
a
t
i
o
n
 
a
n
d
 
i
n
t
e
r
n
a
l
 
a
n
d
 
e
x
t
e
r
n
a
l
 
p
r
i
c
e
 
r
e
f
e
r
e
n
c
i
n
g
4
.
 
 
i
f
 
F
e
d
e
r
a
l
 
O
f
fi
c
e
 
o
f
 
P
u
b
l
i
c
 
h
e
a
l
t
h
 
p
l
a
n
s
 
t
o
 
m
a
k
e
 
a
 
n
e
g
a
t
i
v
e
 
 
d
e
c
i
s
i
o
n
,
 
t
h
e
 
m
a
n
u
f
a
c
t
u
r
e
r
 
i
s
 
i
n
f
o
r
m
e
d
 
p
r
i
o
r
 
t
o
 
i
s
s
u
i
n
g
 
t
h
e
 
 
fi
n
a
l
 
d
e
c
i
s
i
o
n
;
 
m
a
n
u
f
a
c
t
u
r
e
r
 
m
a
y
 
a
p
p
l
y
 
f
o
r
 
r
e
-
e
v
a
l
u
a
t
i
o
n
 
 
o
n
 
t
h
e
 
b
a
s
i
s
 
o
f
 
p
r
i
c
e
 
a
d
j
u
s
t
m
e
n
t
s
 
o
r
 
a
v
a
i
l
a
b
i
l
i
t
y
 
 
o
f
 
a
d
d
i
t
i
o
n
a
l
 
d
a
t
a
1
1
4
T
h
e
 
 
n
e
t
h
e
r
l
a
n
d
s
•
 
 
M
i
n
i
s
t
r
y
 
o
f
 
h
e
a
l
t
h
,
 
 
W
e
l
f
a
r
e
 
a
n
d
 
S
p
o
r
t
 
 
(
d
e
c
i
s
i
o
n
s
)
•
 
 
D
u
t
c
h
 
h
e
a
l
t
h
c
a
r
e
 
 
i
n
s
u
r
a
n
c
e
 
B
o
a
r
d
 
 
C
o
m
m
i
t
t
e
e
 
(
C
h
F
)
 
 
(
r
e
c
o
m
m
e
n
d
a
t
i
o
n
s
)
2
6
C
o
m
m
i
t
t
e
e
 
o
f
 
t
h
e
 
 
D
u
t
c
h
 
h
e
a
l
t
h
c
a
r
e
 
 
i
n
s
u
r
a
n
c
e
 
B
o
a
r
d
:
 
 
i
n
c
l
u
d
e
s
:
 
•
 
 
A
 
m
a
x
i
m
u
m
 
o
f
 
 
2
4
 
m
e
m
b
e
r
s
 
w
i
t
h
 
 
e
x
p
e
r
t
i
s
e
 
i
n
 
v
a
r
i
o
u
s
 
 
m
e
d
i
c
a
l
 
d
i
s
c
i
p
l
i
n
e
s
,
 
 
h
e
a
l
t
h
 
s
c
i
e
n
c
e
s
 
a
n
d
 
 
e
c
o
n
o
m
i
c
s
•
 
 
2
–
3
 
n
o
n
v
o
t
i
n
g
 
m
e
m
b
e
r
s
 
f
r
o
m
 
t
h
e
 
 
M
i
n
i
s
t
r
y
2
1
,
1
1
7
 
i
n
c
l
u
d
e
s
:
•
 
 
3
 
D
u
t
c
h
 
h
e
a
l
t
h
c
a
r
e
 
 
i
n
s
u
r
a
n
c
e
 
B
o
a
r
d
 
b
o
a
r
d
 
 
o
f
 
d
i
r
e
c
t
o
r
s
•
 
 
6
 
m
e
m
b
e
r
s
 
w
i
t
h
 
 
h
e
a
l
t
h
 
a
n
d
 
s
o
c
i
a
l
 
 
s
e
c
u
r
i
t
y
 
i
n
s
u
r
a
n
c
e
 
 
e
x
p
e
r
t
i
s
e
2
1
F
o
r
 
o
u
t
p
a
t
i
e
n
t
 
p
h
a
r
m
a
c
e
u
t
i
c
a
l
s
:
 
 
1
.
 
 
M
a
n
u
f
a
c
t
u
r
e
r
 
s
u
b
m
i
t
s
 
a
p
p
l
i
c
a
t
i
o
n
 
f
o
r
 
r
e
i
m
b
u
r
s
e
m
e
n
t
 
 
t
o
 
M
i
n
i
s
t
e
r
 
o
f
 
h
e
a
l
t
h
 
2
.
 
 
i
n
t
e
r
n
a
l
 
s
t
a
f
f
 
p
r
e
p
a
r
e
 
e
v
a
l
u
a
t
i
o
n
,
 
w
h
i
c
h
 
i
n
c
l
u
d
e
s
 
 
4
 
d
r
a
f
t
 
r
e
p
o
r
t
s
 
(
s
u
m
m
a
r
y
,
 
p
h
a
r
m
a
c
o
t
h
e
r
a
p
e
u
t
i
c
,
 
p
h
a
r
m
a
c
o
e
c
o
n
o
m
i
c
,
 
a
n
d
 
b
u
d
g
e
t
 
i
m
p
a
c
t
 
a
s
s
e
s
s
m
e
n
t
s
 
 
b
a
s
e
d
 
o
n
 
e
v
i
d
e
n
c
e
 
f
r
o
m
 
m
a
n
u
f
a
c
t
u
r
e
r
,
 
a
s
 
w
e
l
l
 
a
s
 
 
i
n
d
e
p
e
n
d
e
n
t
l
y
 
c
o
n
d
u
c
t
e
d
 
l
i
t
e
r
a
t
u
r
e
 
r
e
v
i
e
w
)
;
 
i
f
 
d
e
e
m
e
d
 
 
n
e
c
e
s
s
a
r
y
,
 
s
t
a
f
f
 
m
a
y
 
c
o
n
s
u
l
t
 
w
i
t
h
 
m
a
n
u
f
a
c
t
u
r
e
r
,
 
e
x
t
e
r
n
a
l
 
 
e
x
p
e
r
t
s
,
 
a
n
d
 
s
t
a
k
e
h
o
l
d
e
r
s
 
3
.
 
 
C
h
F
 
r
e
v
i
e
w
s
 
r
e
p
o
r
t
 
a
n
d
 
c
o
n
s
u
l
t
s
 
w
i
t
h
 
m
a
n
u
f
a
c
t
u
r
e
r
 
a
n
d
 
 
o
t
h
e
r
 
s
t
a
k
e
h
o
l
d
e
r
s
 
4
.
 
 
S
t
a
f
f
 
r
e
v
i
s
e
 
r
e
p
o
r
t
,
 
i
n
c
o
r
p
o
r
a
t
i
n
g
 
r
e
s
u
l
t
s
 
o
f
 
C
h
F
 
d
e
l
i
b
e
r
a
t
i
o
n
s
 
 
a
n
d
 
c
o
m
m
e
n
t
s
 
f
r
o
m
 
m
a
n
u
f
a
c
t
u
r
e
r
 
a
n
d
 
o
t
h
e
r
 
s
t
a
k
e
h
o
l
d
e
r
s
 
5
.
 
 
D
u
t
c
h
 
h
e
a
l
t
h
c
a
r
e
 
i
n
s
u
r
a
n
c
e
 
B
o
a
r
d
 
s
e
n
d
s
 
r
e
v
i
s
e
d
 
r
e
p
o
r
t
 
t
o
 
 
m
a
n
u
f
a
c
t
u
r
e
r
 
a
n
d
 
s
t
a
k
e
h
o
l
d
e
r
s
 
f
o
r
 
c
o
m
m
e
n
t
 
6
.
 
 
C
h
F
 
m
e
e
t
s
 
t
o
 
d
i
s
c
u
s
s
 
r
e
v
i
s
e
d
 
r
e
p
o
r
t
 
a
n
d
 
c
o
m
m
e
n
t
s
 
r
e
c
e
i
v
e
d
 
 
a
n
d
 
p
r
e
p
a
r
e
 
fi
n
a
l
 
a
d
v
i
c
e
 
7
.
 
 
D
u
t
c
h
 
h
e
a
l
t
h
c
a
r
e
 
i
n
s
u
r
a
n
c
e
 
B
o
a
r
d
 
b
o
a
r
d
 
o
f
 
d
i
r
e
c
t
o
r
s
 
 
r
e
c
e
i
v
e
s
 
fi
n
a
l
 
r
e
p
o
r
t
,
 
w
h
i
c
h
 
i
s
 
a
l
s
o
 
s
e
n
t
 
t
o
 
m
a
n
u
f
a
c
t
u
r
e
r
 
a
n
d
 
 
s
t
a
k
e
h
o
l
d
e
r
s
 
a
p
p
o
i
n
t
e
d
 
b
y
 
D
u
t
c
h
 
h
e
a
l
t
h
c
a
r
e
 
i
n
s
u
r
a
n
c
e
 
B
o
a
r
d
 
 
f
o
r
 
c
o
m
m
e
n
t
 
8
.
 
 
D
u
t
c
h
 
h
e
a
l
t
h
c
a
r
e
 
i
n
s
u
r
a
n
c
e
 
B
o
a
r
d
 
b
o
a
r
d
 
o
f
 
d
i
r
e
c
t
o
r
s
 
 
m
e
e
t
 
t
o
 
d
i
s
c
u
s
s
 
fi
n
a
l
 
r
e
p
o
r
t
 
a
n
d
 
c
o
m
m
e
n
t
s
 
r
e
c
e
i
v
e
d
 
a
n
d
 
 
f
o
r
m
u
l
a
t
e
 
r
e
c
o
m
m
e
n
d
a
t
i
o
n
s
;
 
m
a
y
 
c
o
n
s
u
l
t
 
w
i
t
h
 
t
h
e
 
A
p
p
r
a
i
s
a
l
 
 
C
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p
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Table 6 Comparison of key factors considered during committee deliberations
Country Centralized  
reimbursement  
review/decision- 
making body  
(role)
Clinical need Clinical benefit/value* Cost-benefit  
ratio (cost- 
effectiveness;  
efficiency; “value  
for money”)†
Impact on health  
resources/ 
affordability  
(budget impact)
Innovativeness Other
Disease burden  
(severity and  
number of  
patients)
Availability  
of alternatives
Place of  
technology in  
care pathway/ 
strategy
Safety 
(risk–benefit  
ratio; harm– 
benefit ratio)
Efficacy/ 
effectiveness
Side  
effects
Acceptability 
(tolerance,  
convenience)
Austria •   Association of Austrian  
Social Security  
institutions (decisions)55
•   Pharmaceutical Evaluation  
Board (recommendations)56
Yes55 Yes58 not  
specified
not specified Yes55 not  
specified
not  
specified
Yes (“pharmaco- 
economic  
evidence”)58
Yes55 Yes50 •   Price in other European 
Union countries58
Belgium •   Ministry of health and Social  
Affairs (decisions)
•   Drug Reimbursement Committee 
(recommendations)9,60
Yes11,17 Yes21 not  
specified
Yes9 Yes (across  
patient  
subgroups)9
Yes9 Yes11,17 Yes11,17 Yes11,17 Yes35 •   Feasibility of  
implementation11,17
• Market price11,17 
• Social needs11,17,21
Czech  
Republic
•   State institute for Drug  
Control (decisions)65,176
Yes84 Yes84 not  
specified
Yes84 Yes84 not  
specified
Yes66 Yes84 Yes84 not  
specified
•   Clinical practice  
guidelines138
• Public interest35
Denmark •   Danish Medicines Agency  
(decisions)68,69,121
•     Reimbursement Committee  
(recommendations)68,121
not  
specified
not  
specified
not  
specified
Yes21,68 Yes (across  
patient  
subgroups)21,68
Yes21,68 not  
specified
Yes21,68 not  
specified
not  
specified
•   Reasonableness of price 
relative to therapeutic  
value21,68
Estonia •   Ministry of Social Affairs  
(decisions)72
•   Pharmaceuticals Committee 
(recommendations)72
Yes84 Yes84 not  
specified
not  
specified
Yes84 not  
specified
not  
specified
Yes84 Yes84 not  
specified
• “Cost efficiency”§140
Finland •   Pharmaceuticals Pricing  
Board (decisions)74,76,77
•   Pharmaceuticals Pricing  
Board Expert group  
(recommendations)75
Yes181 Yes181 not  
specified
not  
specified
Yes (across  
patient  
subgroups)181
not  
specified
not  
specified
Yes181 Yes181 not  
specified
•   Research and  
development35
•   Level of uncertainty in 
supporting evidence181
•   Price in other European 
Union countries181
•   Market forecast and share75
•   Daily cost of treatment  
per day75
France •   Ministry for health and Social  
Security (decisions)20,78
•   French national Authority for  
health (recommendations)78
Yes35 Yes35 Yes35 Yes80 Yes35 Yes80 Yes80 not  
specified
Yes80 Yes35 • Public health impact16,35 
•   Costs relative to  
current treatment199
germany •   Federal Joint  
Committee (decisions)24
•   institute for Quality and  
Efficiency in health Care  
(recommendations)19,24
Yes19 Yes19 not  
specified
Yes19 Yes19 not  
specified
not  
specified
Yes‡19 Yes113 Yes19
greece •   Transparency Committee in the  
Reimbursement and Medicinal  
Products (makes decisions)85
Yes186 Yes186 not  
specified
Yes186 Yes186 not  
specified
not  
specified
Yes (“pharmaco- 
economic 
effectiveness”)186
not  
specified
not  
specified
•   Daily cost of  
treatment186
•   Reimbursement status  
in other European  
Union countries186
hungary • Ministers of health and Finance
•   national health insurance  
Fund Administration  
(recommendations)88
Yes186 Yes84 not  
specified
not  
specified
Yes84 not  
specified
not  
specified
Yes186 Yes84 not  
specified
• Equity26
ireland •   health Service Executive 
(decisions)91,92,147
Yes125,165 Yes125,165 not  
specified
not  
specified
Yes125,165 not  
specified
not  
specified
Yes125,165 Yes125,165 Yes125,165 •   Level of uncertainty in  
supporting evidence125
•   Wider societal costs  
and benefits165
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Table 6 Comparison of key factors considered during committee deliberations
Country Centralized  
reimbursement  
review/decision- 
making body  
(role)
Clinical need Clinical benefit/value* Cost-benefit  
ratio (cost- 
effectiveness;  
efficiency; “value  
for money”)†
Impact on health  
resources/ 
affordability  
(budget impact)
Innovativeness Other
Disease burden  
(severity and  
number of  
patients)
Availability  
of alternatives
Place of  
technology in  
care pathway/ 
strategy
Safety 
(risk–benefit  
ratio; harm– 
benefit ratio)
Efficacy/ 
effectiveness
Side  
effects
Acceptability 
(tolerance,  
convenience)
Austria •   Association of Austrian  
Social Security  
institutions (decisions)55
•   Pharmaceutical Evaluation  
Board (recommendations)56
Yes55 Yes58 not  
specified
not specified Yes55 not  
specified
not  
specified
Yes (“pharmaco- 
economic  
evidence”)58
Yes55 Yes50 •   Price in other European 
Union countries58
Belgium •   Ministry of health and Social  
Affairs (decisions)
•   Drug Reimbursement Committee 
(recommendations)9,60
Yes11,17 Yes21 not  
specified
Yes9 Yes (across  
patient  
subgroups)9
Yes9 Yes11,17 Yes11,17 Yes11,17 Yes35 •   Feasibility of  
implementation11,17
• Market price11,17 
• Social needs11,17,21
Czech  
Republic
•   State institute for Drug  
Control (decisions)65,176
Yes84 Yes84 not  
specified
Yes84 Yes84 not  
specified
Yes66 Yes84 Yes84 not  
specified
•   Clinical practice  
guidelines138
• Public interest35
Denmark •   Danish Medicines Agency  
(decisions)68,69,121
•     Reimbursement Committee  
(recommendations)68,121
not  
specified
not  
specified
not  
specified
Yes21,68 Yes (across  
patient  
subgroups)21,68
Yes21,68 not  
specified
Yes21,68 not  
specified
not  
specified
•   Reasonableness of price 
relative to therapeutic  
value21,68
Estonia •   Ministry of Social Affairs  
(decisions)72
•   Pharmaceuticals Committee 
(recommendations)72
Yes84 Yes84 not  
specified
not  
specified
Yes84 not  
specified
not  
specified
Yes84 Yes84 not  
specified
• “Cost efficiency”§140
Finland •   Pharmaceuticals Pricing  
Board (decisions)74,76,77
•   Pharmaceuticals Pricing  
Board Expert group  
(recommendations)75
Yes181 Yes181 not  
specified
not  
specified
Yes (across  
patient  
subgroups)181
not  
specified
not  
specified
Yes181 Yes181 not  
specified
•   Research and  
development35
•   Level of uncertainty in 
supporting evidence181
•   Price in other European 
Union countries181
•   Market forecast and share75
•   Daily cost of treatment  
per day75
France •   Ministry for health and Social  
Security (decisions)20,78
•   French national Authority for  
health (recommendations)78
Yes35 Yes35 Yes35 Yes80 Yes35 Yes80 Yes80 not  
specified
Yes80 Yes35 • Public health impact16,35 
•   Costs relative to  
current treatment199
germany •   Federal Joint  
Committee (decisions)24
•   institute for Quality and  
Efficiency in health Care  
(recommendations)19,24
Yes19 Yes19 not  
specified
Yes19 Yes19 not  
specified
not  
specified
Yes‡19 Yes113 Yes19
greece •   Transparency Committee in the  
Reimbursement and Medicinal  
Products (makes decisions)85
Yes186 Yes186 not  
specified
Yes186 Yes186 not  
specified
not  
specified
Yes (“pharmaco- 
economic 
effectiveness”)186
not  
specified
not  
specified
•   Daily cost of  
treatment186
•   Reimbursement status  
in other European  
Union countries186
hungary • Ministers of health and Finance
•   national health insurance  
Fund Administration  
(recommendations)88
Yes186 Yes84 not  
specified
not  
specified
Yes84 not  
specified
not  
specified
Yes186 Yes84 not  
specified
• Equity26
ireland •   health Service Executive 
(decisions)91,92,147
Yes125,165 Yes125,165 not  
specified
not  
specified
Yes125,165 not  
specified
not  
specified
Yes125,165 Yes125,165 Yes125,165 •   Level of uncertainty in  
supporting evidence125
•   Wider societal costs  
and benefits165
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Table 6 (Continued)
Country Centralized  
reimbursement  
review/decision- 
making body  
(role)
Clinical need Clinical benefit/value* Cost-benefit  
ratio (cost- 
effectiveness;  
efficiency; “value  
for money”)†
Impact on health  
resources/ 
affordability  
(budget impact)
Innovativeness Other
Disease burden  
(severity and  
number of  
patients)
Availability  
of alternatives
Place of  
technology in  
care pathway/ 
strategy
Safety 
(risk–benefit  
ratio; harm– 
benefit ratio)
Efficacy/ 
effectiveness
Side  
effects
Acceptability 
(tolerance,  
convenience)
italy •   italian Medicines Agency Technical  
Scientific Committee (decisions)94
•   italian Medicines Agency Pricing 
and Reimbursement Committee 
(recommendations)95
Yes27 Yes27 not  
specified
Yes96 Yes (across  
patient  
subgroups)27
not  
specified
Yes27 Yes27 Yes27 Yes20 •   Daily cost of  
treatment27
• “  Special medical  
needs”96
•   Price in other European 
Union countries200
•   Market forecast and share96
norway •   norwegian Medicines Agency  
(decisions)98
•   Department of  
Pharmacoeconomics  
(recommendations)98
Yes34 not  
specified
not  
specified
Yes149 Yes (across  
patient  
subgroups)34
not  
specified
not  
specified
Yes34 Yes34 not  
specified
• Equity35 
• “Solidarity”34 
• “Rationality”34
Poland • Ministry of health (decisions)99 Yes84 not  
specified
not  
specified
Yes84 Yes84 not  
specified
not  
specified
Yes84 Yes84 not  
specified
Portugal • Ministry of health (decisions)
•   inFARMED  
(recommendations)36,44
Yes36 Yes36 not  
specified
Yes36 Yes36 not  
specified
not  
specified
Yes36  not  
specified
not  
specified
• Equity36 
• “Universality”36 
• “Accessibility”36
Scotland •   national health Service  
Scotland (decisions)30
•   Scottish Medicines Consortium  
(recommendations)
Yes104 Yes30 not  
specified
Yes104 Yes104 not  
specified
not  
specified
Yes104 Yes104 Yes30 •   Whether pharmaceutical  
reverses rather than  
stabilizes condition  
or bridges a gap to  
curative therapy104
•   Level of uncertainty in  
supporting evidence30
•   Wider societal costs  
and benefits30
Slovakia • Ministry of health (decisions)
•   Reimbursement Committee  
for Medicinal Products  
(recommendations)105,107,169
Yes106 Yes84 not  
specified
Yes106 Yes106 Yes106 Yes106 Yes84,105 Yes84,106 not  
specified
•   Price of other  
pharmaceuticals within  
reference category106
Spain •   Ministry of health Directorate  
general of Pharmacy and health  
Products; inter-Ministerial Pricing  
Commission (decisions)21,108
Yes132 Yes132 not  
specified
Yes10 Yes (across  
patient  
subgroups)132
not  
specified
not  
specified
not specified Yes132 Yes108 • “Social utility”132
•   Rationalization of  
public expenditures  
on pharmaceuticals132
•   Specific needs of certain 
groups of people132
•   Research and  
development132
•   Price in other European  
Union countries132
• Market forecast132
Sweden •   Dental and Pharmaceutical  
Benefits Board Expert Board  
(decisions)15,109,110
Yes21 Yes109 not  
specified
Yes21 Yes (across  
patient  
subgroups)15,21
not  
specified
not  
specified
Yes21 no21 not  
specified
• Equity35
•   “Reasonableness of  
cost from medical,  
humanitarian, and  
socio-economic  
perspective”33
• Solidarity21
Switzerland •   Swiss Federal Office of Public  
health (decisions)
•   Federal Drug Commission  
(recommendations)113,114
not  
specified
not  
specified
not  
specified
not specified Yes108 not  
specified
not  
specified
Yes (“value for  
money”)109
not specified Yes108 •   Research and  
development109
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Table 6 (Continued)
Country Centralized  
reimbursement  
review/decision- 
making body  
(role)
Clinical need Clinical benefit/value* Cost-benefit  
ratio (cost- 
effectiveness;  
efficiency; “value  
for money”)†
Impact on health  
resources/ 
affordability  
(budget impact)
Innovativeness Other
Disease burden  
(severity and  
number of  
patients)
Availability  
of alternatives
Place of  
technology in  
care pathway/ 
strategy
Safety 
(risk–benefit  
ratio; harm– 
benefit ratio)
Efficacy/ 
effectiveness
Side  
effects
Acceptability 
(tolerance,  
convenience)
italy •   italian Medicines Agency Technical  
Scientific Committee (decisions)94
•   italian Medicines Agency Pricing 
and Reimbursement Committee 
(recommendations)95
Yes27 Yes27 not  
specified
Yes96 Yes (across  
patient  
subgroups)27
not  
specified
Yes27 Yes27 Yes27 Yes20 •   Daily cost of  
treatment27
• “  Special medical  
needs”96
•   Price in other European 
Union countries200
•   Market forecast and share96
norway •   norwegian Medicines Agency  
(decisions)98
•   Department of  
Pharmacoeconomics  
(recommendations)98
Yes34 not  
specified
not  
specified
Yes149 Yes (across  
patient  
subgroups)34
not  
specified
not  
specified
Yes34 Yes34 not  
specified
• Equity35 
• “Solidarity”34 
• “Rationality”34
Poland • Ministry of health (decisions)99 Yes84 not  
specified
not  
specified
Yes84 Yes84 not  
specified
not  
specified
Yes84 Yes84 not  
specified
Portugal • Ministry of health (decisions)
•   inFARMED  
(recommendations)36,44
Yes36 Yes36 not  
specified
Yes36 Yes36 not  
specified
not  
specified
Yes36  not  
specified
not  
specified
• Equity36 
• “Universality”36 
• “Accessibility”36
Scotland •   national health Service  
Scotland (decisions)30
•   Scottish Medicines Consortium  
(recommendations)
Yes104 Yes30 not  
specified
Yes104 Yes104 not  
specified
not  
specified
Yes104 Yes104 Yes30 •   Whether pharmaceutical  
reverses rather than  
stabilizes condition  
or bridges a gap to  
curative therapy104
•   Level of uncertainty in  
supporting evidence30
•   Wider societal costs  
and benefits30
Slovakia • Ministry of health (decisions)
•   Reimbursement Committee  
for Medicinal Products  
(recommendations)105,107,169
Yes106 Yes84 not  
specified
Yes106 Yes106 Yes106 Yes106 Yes84,105 Yes84,106 not  
specified
•   Price of other  
pharmaceuticals within  
reference category106
Spain •   Ministry of health Directorate  
general of Pharmacy and health  
Products; inter-Ministerial Pricing  
Commission (decisions)21,108
Yes132 Yes132 not  
specified
Yes10 Yes (across  
patient  
subgroups)132
not  
specified
not  
specified
not specified Yes132 Yes108 • “Social utility”132
•   Rationalization of  
public expenditures  
on pharmaceuticals132
•   Specific needs of certain 
groups of people132
•   Research and  
development132
•   Price in other European  
Union countries132
• Market forecast132
Sweden •   Dental and Pharmaceutical  
Benefits Board Expert Board  
(decisions)15,109,110
Yes21 Yes109 not  
specified
Yes21 Yes (across  
patient  
subgroups)15,21
not  
specified
not  
specified
Yes21 no21 not  
specified
• Equity35
•   “Reasonableness of  
cost from medical,  
humanitarian, and  
socio-economic  
perspective”33
• Solidarity21
Switzerland •   Swiss Federal Office of Public  
health (decisions)
•   Federal Drug Commission  
(recommendations)113,114
not  
specified
not  
specified
not  
specified
not specified Yes108 not  
specified
not  
specified
Yes (“value for  
money”)109
not specified Yes108 •   Research and  
development109
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Table 6 (Continued)
Country Centralized  
reimbursement  
review/decision- 
making body  
(role)
Clinical need Clinical benefit/value* Cost-benefit  
ratio (cost- 
effectiveness;  
efficiency; “value  
for money”)†
Impact on health  
resources/ 
affordability  
(budget impact)
Innovativeness Other
Disease burden  
(severity and  
number of  
patients)
Availability  
of alternatives
Place of  
technology in  
care pathway/ 
strategy
Safety 
(risk–benefit  
ratio; harm– 
benefit ratio)
Efficacy/ 
effectiveness
Side  
effects
Acceptability 
(tolerance,  
convenience)
The netherlands •   Ministry of health,  
Welfare and Sport (decisions)
•   Dutch healthcare insurance  
Board Committee of the  
Dutch healthcare insurance  
Board (recommendations)31
Yes35 Yes21 not  
specified
Yes35 Yes35,117 Yes35 Yes35 Yes35,117 Yes¥21,201 Yes35 • Rarity
•   Feasibility of  
implementation117
• Accessibility
•   Level of uncertainty in  
supporting evidence115
•   individual versus  
collective  
responsibility201
• Public health impact35
United Kingdom •   national institute for health and 
Clinical Excellence (decisions)
•   Technology Appraisals  
Committee (recommendations)7
Yes202 Yes202 Yes202 Yes202 Yes (across  
patient 
subgroups)202
not 
specified
not  
specified
Yes202 not specified Yes35,197 •   Level of uncertainty in 
supporting evidence196
•   Whether technology 
represents life-extending, 
end of life treatment37
•   Wider societal costs and 
benefits196
• Public health impact35,197 
•   Alignment with broad 
government priorities202
•   iCERs of already funded 
programmes13,157
Wales •   Ministry for health and Social 
Services (decisions)
•   All Wales Medicines Strategy  
group (recommendations)120
Yes28 not  
specified
not  
specified
not  
specified
Yes (across  
patient 
subgroups)28
not 
specified
not  
specified
Yes28 Yes174 Yes28 •   Level of uncertainty in 
supporting evidence174
•   Wider societal costs and 
benefits28
•   Alignment with broad 
government priorities28
•   iCERs of funded 
programmes28
Notes: *in a well-defined population; †price proportionate to effect; §cost efficiency takes into account costs of treatment per patient, as well as costs of compensatory 
allowance due to lost income and costs of restoring patients’ capacity to work; ‡efficiency of resource use within a single therapeutic area relative to existing interventions; 
¥not a formal criterion.
they include at least safety (risk–benefit ratio) and efficacy/
effectiveness, on the basis of which an overall estimate of 
the ratio of the benefits to harms of a candidate technology 
is estimated (Table 6). While a further goal shared by most 
review committees is to formulate an opinion on whether 
the candidate technology represents “value for money” or 
an efficient use of resources, their approach to accomplish-
ing this differs. Approximately one-third are guided by, but 
not compelled to adhere to, a predefined incremental cost-
effectiveness threshold or threshold range.28,29 Typically, if the 
incremental cost-effectiveness for a candidate technology lies 
below the threshold, it is deemed cost-effective or good value 
for money. If it lies above the threshold, additional factors 
are taken into account when judging acceptability (eg, uncer-
tainties in estimates of outcomes, the severity of condition, 
and wider societal benefits).30,31 Across systems whose 
committees do not refer to an incremental cost-effectiveness 
threshold, approaches to operationalizing “value or money” 
appear vague, with information largely limited to statements 
such as “reasonableness of cost relative to therapeutic value” 
(Table 6).32 Similarly, although all but one of the systems 
(Sweden21) list “affordability” or “impact of the candidate 
technology on health system resources” among factors/cri-
teria considered by their respective review committees, no 
information describing processes for deciding whether or not 
a technology is affordable could be found.
Equity or ethical implications comprise decision-making 
factors/criteria (explicitly or implicitly) in one-third of ClinicoEconomics and Outcomes Research 2011:3 submit your manuscript | www.dovepress.com
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Table 6 (Continued)
Country Centralized  
reimbursement  
review/decision- 
making body  
(role)
Clinical need Clinical benefit/value* Cost-benefit  
ratio (cost- 
effectiveness;  
efficiency; “value  
for money”)†
Impact on health  
resources/ 
affordability  
(budget impact)
Innovativeness Other
Disease burden  
(severity and  
number of  
patients)
Availability  
of alternatives
Place of  
technology in  
care pathway/ 
strategy
Safety 
(risk–benefit  
ratio; harm– 
benefit ratio)
Efficacy/ 
effectiveness
Side  
effects
Acceptability 
(tolerance,  
convenience)
The netherlands •   Ministry of health,  
Welfare and Sport (decisions)
•   Dutch healthcare insurance  
Board Committee of the  
Dutch healthcare insurance  
Board (recommendations)31
Yes35 Yes21 not  
specified
Yes35 Yes35,117 Yes35 Yes35 Yes35,117 Yes¥21,201 Yes35 • Rarity
•   Feasibility of  
implementation117
• Accessibility
•   Level of uncertainty in  
supporting evidence115
•   individual versus  
collective  
responsibility201
• Public health impact35
United Kingdom •   national institute for health and 
Clinical Excellence (decisions)
•   Technology Appraisals  
Committee (recommendations)7
Yes202 Yes202 Yes202 Yes202 Yes (across  
patient 
subgroups)202
not 
specified
not  
specified
Yes202 not specified Yes35,197 •   Level of uncertainty in 
supporting evidence196
•   Whether technology 
represents life-extending, 
end of life treatment37
•   Wider societal costs and 
benefits196
• Public health impact35,197 
•   Alignment with broad 
government priorities202
•   iCERs of already funded 
programmes13,157
Wales •   Ministry for health and Social 
Services (decisions)
•   All Wales Medicines Strategy  
group (recommendations)120
Yes28 not  
specified
not  
specified
not  
specified
Yes (across  
patient 
subgroups)28
not 
specified
not  
specified
Yes28 Yes174 Yes28 •   Level of uncertainty in 
supporting evidence174
•   Wider societal costs and 
benefits28
•   Alignment with broad 
government priorities28
•   iCERs of funded 
programmes28
Notes: *in a well-defined population; †price proportionate to effect; §cost efficiency takes into account costs of treatment per patient, as well as costs of compensatory 
allowance due to lost income and costs of restoring patients’ capacity to work; ‡efficiency of resource use within a single therapeutic area relative to existing interventions; 
¥not a formal criterion.
systems. For example, Sweden’s Dental and Pharmaceutical 
Benefits Board stipulates two principles that decisions must 
reflect, ie, the “need and solidarity principle” (patients in 
the greatest need or “worse off” must be given priority) and 
the “human value principle” (sociodemographic character-
istics of patient populations cannot influence decisions).21,33 
Along with “solidarity,” the Norwegian Medicines Agency 
explicitly takes into account “equity,” as do review com-
mittees in Hungary and Poland.26,34–36 However, the way 
in which this is accomplished during deliberations is not 
clear. Committees using an incremental cost-effectiveness 
threshold to guide decisions implicitly incorporate equity 
by virtue of the assumptions underpinning the incremental 
cost-effectiveness calculation (ie, each quality-adjusted 
life-year [QALY] carries the same weight, regardless of the 
characteristics of the patients receiving it (eg, age, gender, 
social status, income). Consideration of additional, often 
competing ethical principles by these committees is opera-
tionalized through “exception” conditions under which the 
normal “efficiency” expectations do not need to be met (eg, 
“last chance” therapies, orphan technologies, life-extending, 
end-of-life treatments).37 Under such conditions, not all 
QALYs are deemed equal. Rather, a form of “solidarity” 
premium is applied, where, for example, QALYs gained in 
the later stages of disease are given greater weight. While 
there is little disagreement over the importance of instituting 
“exception” conditions as a means of ensuring that reimburse-
ment decisions embody the broader values of the population, ClinicoEconomics and Outcomes Research 2011:3 submit your manuscript | www.dovepress.com
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Table 7 Comparison of conditional reimbursement policy options for managing decision uncertainties
Country Centralized reimbursement  
review/decision-making body  
(role)
Policy options for addressing decision-making uncertainties
Reassessment Value-based pricing/ 
reimbursement
Reimbursement as part  
of a formal study
Risk-sharing schemes/ 
payment by results
Other
Austria •   Association of Austrian Social  
Security institutions (decisions)55
•   Pharmaceutical Evaluation Board  
(recommendations)56
• Yes 
•   Association of Austrian Social Security  
institutions may remove pharmaceutical  
from benefit list in the wake of new clinical  
or economic evidence
•   Manufacturer may suggest delisting  
pharmaceutical21
no56 no information found no information found no information found
Belgium • Minister of Social Affairs (decisions)
•   Drug Reimbursement Committee  
(recommendations)9
•   Yes – automatic reassessment  
of pharmaceuticals offering added  
therapeutic value 1.5 to 3 years after  
inclusion on benefit list
•   Minister of Social Affairs or manufacturer  
may suggest delisting a pharmaceutical41,49
no information found no information found Financially or clinically based: 
•   For pharmaceuticals offering added  
therapeutic value for which the Drug  
Reimbursement Committee  
formulated a negative reimbursement  
recommendation49
Financially based:
•   Price-volume agreements – “Provision  
Fund” established – Advances paid by 
manufacturers are used to cover 75%  
of overrun41
•   Creation of Special Solidarity Fund 
–   grants, on an individual basis,  
reimbursement of pharmaceuticals for  
rare diseases or rare indications 
unavailable in Belgium
–   Only granted if patient meets certain  
criteria and has exhausted all other  
treatment options
– Must be prescribed by relevant specialist 
–   Reimbursement decisions made by  
College of Medical Doctors Directors62
Czech  
Republic
•   State institute for Drug Control  
(decisions)65
•   Yes – for “highly innovative” pharmaceuticals 
without evidence of effectiveness and  
“efficiency”
•   granted provisional reimbursement  
for 1 year, after which pharmaceutical  
is reassessed65
Manufacturer may request a 
surcharge of up to 30% over 
the basic reimbursement 
level if evidence 
suggests pharmaceutical 
demonstrates “superior” 
therapeutic benefits66
no information found no information found no information found
Denmark •   Danish Medicines Agency  
(decisions)68,69,121
•   Reimbursement Committee  
(recommendations)68,121
•   Pharmaceuticals reassessed as part of  
therapeutic class reviews every 5 years
•   Pharmaceutical may be scheduled for  
a separate reassessment when initial  
reimbursement decision is made  
if Reimbursement Committee considers  
it necessary to collect additional  
information about the use of the  
pharmaceutical in clinical practice before  
making a definitive decision50
no information found no information found Clinically based: 
•   Example: “no cure no pay” scheme for  
valsartan for high blood pressure
•   individual level schemes 
–   Patient may apply for reimbursement  
on an individual basis, which requires  
evidence of treatment effect for  
continued reimbursement46
–   Typically for patients who have  
exhausted all other options
– Period of reimbursement varies68
no information found
Estonia •   Ministry of Social Affairs  
(decisions)72
•   Pharmaceuticals Committee  
(recommendations)72
no information found no information found no information found Financially based: 
•   For all new pharmaceuticals –  
price-volume agreements mandatory  
for 1 year following reimbursement  
decision41
no information found
Finland •   Pharmaceuticals Pricing Board  
(decisions)73,74,76
•   Pharmaceuticals Pricing Board  
Expert group (recommendations)75
•   Yes – for all pharmaceuticals
•   Automatic reassessment every 3 to 5 years  
after inclusion on benefit list182,203
no information found no information found no information found no information found
France •   Ministry for health and Social  
Security (decisions)20,78
•   French national Authority  
for health (recommendations)78
For pharmaceuticals 
•   Yes – for all pharmaceuticals
•   Automatic reassessment every 5 years after  
inclusion on benefit list20
For medical devices
•   Yes – for devices
•   Automatic reassessment within 5 years of  
inclusion on benefit list20,162
no information found •   May provide provisional coverage  
for a set period during which  
“real-world” effectiveness  
and/or economic implications must  
be assessed through a study: 
–   To be carried out: 
1)   By skilled teams in a limited number  
of selected centers
2) Under well-defined conditions of use 
3) Using a protocol approved by French 
For pharmaceuticals 
Financially based: 
•   Price-volume agreements 
–   Manufacturer must “pay back” the cost  
of sales exceeding those forecasted  
for the first 4 years 23,43
–   Pharmaceuticals exempt from such  
schemes for various periods depending  
on their “improvement in medical benefit”  
For pharmaceuticals for serious or rare  
diseases 
•   May be granted temporary access in  
a hospital setting for 1 year162 
For “innovative” medical devices
•   May establish “innovation point of contact”  
and an internal multidisciplinary network162
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Table 7 Comparison of conditional reimbursement policy options for managing decision uncertainties
Country Centralized reimbursement  
review/decision-making body  
(role)
Policy options for addressing decision-making uncertainties
Reassessment Value-based pricing/ 
reimbursement
Reimbursement as part  
of a formal study
Risk-sharing schemes/ 
payment by results
Other
Austria •   Association of Austrian Social  
Security institutions (decisions)55
•   Pharmaceutical Evaluation Board  
(recommendations)56
• Yes 
•   Association of Austrian Social Security  
institutions may remove pharmaceutical  
from benefit list in the wake of new clinical  
or economic evidence
•   Manufacturer may suggest delisting  
pharmaceutical21
no56 no information found no information found no information found
Belgium • Minister of Social Affairs (decisions)
•   Drug Reimbursement Committee  
(recommendations)9
•   Yes – automatic reassessment  
of pharmaceuticals offering added  
therapeutic value 1.5 to 3 years after  
inclusion on benefit list
•   Minister of Social Affairs or manufacturer  
may suggest delisting a pharmaceutical41,49
no information found no information found Financially or clinically based: 
•   For pharmaceuticals offering added  
therapeutic value for which the Drug  
Reimbursement Committee  
formulated a negative reimbursement  
recommendation49
Financially based:
•   Price-volume agreements – “Provision  
Fund” established – Advances paid by 
manufacturers are used to cover 75%  
of overrun41
•   Creation of Special Solidarity Fund 
–   grants, on an individual basis,  
reimbursement of pharmaceuticals for  
rare diseases or rare indications 
unavailable in Belgium
–   Only granted if patient meets certain  
criteria and has exhausted all other  
treatment options
– Must be prescribed by relevant specialist 
–   Reimbursement decisions made by  
College of Medical Doctors Directors62
Czech  
Republic
•   State institute for Drug Control  
(decisions)65
•   Yes – for “highly innovative” pharmaceuticals 
without evidence of effectiveness and  
“efficiency”
•   granted provisional reimbursement  
for 1 year, after which pharmaceutical  
is reassessed65
Manufacturer may request a 
surcharge of up to 30% over 
the basic reimbursement 
level if evidence 
suggests pharmaceutical 
demonstrates “superior” 
therapeutic benefits66
no information found no information found no information found
Denmark •   Danish Medicines Agency  
(decisions)68,69,121
•   Reimbursement Committee  
(recommendations)68,121
•   Pharmaceuticals reassessed as part of  
therapeutic class reviews every 5 years
•   Pharmaceutical may be scheduled for  
a separate reassessment when initial  
reimbursement decision is made  
if Reimbursement Committee considers  
it necessary to collect additional  
information about the use of the  
pharmaceutical in clinical practice before  
making a definitive decision50
no information found no information found Clinically based: 
•   Example: “no cure no pay” scheme for  
valsartan for high blood pressure
•   individual level schemes 
–   Patient may apply for reimbursement  
on an individual basis, which requires  
evidence of treatment effect for  
continued reimbursement46
–   Typically for patients who have  
exhausted all other options
– Period of reimbursement varies68
no information found
Estonia •   Ministry of Social Affairs  
(decisions)72
•   Pharmaceuticals Committee  
(recommendations)72
no information found no information found no information found Financially based: 
•   For all new pharmaceuticals –  
price-volume agreements mandatory  
for 1 year following reimbursement  
decision41
no information found
Finland •   Pharmaceuticals Pricing Board  
(decisions)73,74,76
•   Pharmaceuticals Pricing Board  
Expert group (recommendations)75
•   Yes – for all pharmaceuticals
•   Automatic reassessment every 3 to 5 years  
after inclusion on benefit list182,203
no information found no information found no information found no information found
France •   Ministry for health and Social  
Security (decisions)20,78
•   French national Authority  
for health (recommendations)78
For pharmaceuticals 
•   Yes – for all pharmaceuticals
•   Automatic reassessment every 5 years after  
inclusion on benefit list20
For medical devices
•   Yes – for devices
•   Automatic reassessment within 5 years of  
inclusion on benefit list20,162
no information found •   May provide provisional coverage  
for a set period during which  
“real-world” effectiveness  
and/or economic implications must  
be assessed through a study: 
–   To be carried out: 
1)   By skilled teams in a limited number  
of selected centers
2) Under well-defined conditions of use 
3) Using a protocol approved by French 
For pharmaceuticals 
Financially based: 
•   Price-volume agreements 
–   Manufacturer must “pay back” the cost  
of sales exceeding those forecasted  
for the first 4 years 23,43
–   Pharmaceuticals exempt from such  
schemes for various periods depending  
on their “improvement in medical benefit”  
For pharmaceuticals for serious or rare  
diseases 
•   May be granted temporary access in  
a hospital setting for 1 year162 
For “innovative” medical devices
•   May establish “innovation point of contact”  
and an internal multidisciplinary network162
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Table 7 (Continued)
Country Centralized reimbursement  
review/decision-making body  
(role)
Policy options for addressing decision-making uncertainties
Reassessment Value-based pricing/ 
reimbursement
Reimbursement as part  
of a formal study
Risk-sharing schemes/ 
payment by results
Other
         national Authority for health  
Transparency Committee
•   Applies to pharmaceuticals that: 
1) Target a large population; 
2)   May be prescribed outside their  
labeled indications; or
3)   May have a significant impact on health  
care organizations16,20
•   Also applies to medical devices –  
French national Authority for health  
specifies study protocoll20
(ie, improvement in medical benefit) level: 
“improvement in medical benefit” i – 36 months; 
“improvement in medical benefit” ii – 24 months; 
“improvement in medical benefit” iii – 24 months  
at 50%;   and “improvement in medical benefit”  
iV – 24 months at 25%
–   Also applies to “orphan drugs” (eg, eculizumab 
for paroxysmal nocturnal hemoglobinuria and 
galsulfase for mucopolysaccharidosis type Vi)41
germany •   Federal Joint Committee 
(decisions)19
•   institute for Quality and Efficiency  
in health Care (recommendations)19
For medical devices and procedures
•   May provide provisional coverage for  
a set period during which  
“real-world” effectiveness  
and/or economic implications must  
be assessed through a study204
For pharmaceuticals 
Financially based: 
•   Price-volume agreements 
–   “target agreements”: if prescription  
volume target is exceeded by 25%,  
manufacturers must “pay back” sickness  
funds (eg, insulin analogs, olanzapine,  
risperidone, clopidogrel, zolendronate,  
mycophenolic acid, everolimus, and  
cyclosporine)41
•   no reimbursement limit for potentially  
effective technologies used to manage  
life-threatening technologies for which  
there are no alternatives82
greece •   Transparency Committee in the  
Reimbursement and Medicinal  
Products (makes decisions)85
no information found no information found no information found no information found no information found
hungary •   Ministers of health and Finance
•   national health insurance  
Fund Administration  
(recommendations)88,89
no information found no information found no information found Financially based: 
•   Price-volume agreements 
–   12% of reimbursed sales must be paid  
to the Ministry by the manufacturer
–   if Ministry spending on pharmaceutical  
exceeds agreed-to budget, the  
manufacturer must refund the Ministry  
an additional amount based on a  
predefined formula41
no information found
ireland •   Products Committee of Corporate  
Pharmaceuticals Unit of health  
Service Executive (decisions)91,92
no information found no information found no information found no information found no information found
italy •   italian Medicines Agency Technical  
Scientific Committee (decisions)94
•   italian Medicines Agency Pricing  
and Reimbursement Committee  
(recommendations)95
no automatic/routine reassessment, with  
the exception of pharmaceuticals reimbursed  
under condition that additional studies would  
be conducted25
no information found For pharmaceuticals classified as  
“potentially innovative”
•   May require manufacturer to conduct  
additional studies within 3 years
•   Pharmaceuticals for patients enrolled  
in the studies must be covered by the  
manufacturer25
•   have established ongoing registries  
to monitor prescribing and assess  
“therapeutic value” in practice  
(real-world settings) in order to inform  
future management and reimbursed  
pricing decisions (eg, cetuximab,  
lenalidomide, ibritumomab, tiuxetan,  
palifermin, temporfin, and trastuzumab)41
Clinically based: 
•   Pharmaceutical initially reimbursed by  
national health Service at 50% or 100%  
for a fixed number of treatment cycles,  
after which it is only reimbursed for  
patients achieving predefined clinical  
response; manufacturer may be required  
to refund the cost of pharmaceutical  
in non-responding patients (eg, sunitinib,  
sorafenib, dasatinib, and nilotinib)
•   Registries used to track outcomes  
included in scheme47
•   Manufacturer initially provides  
pharmaceutical at no cost for a fixed  
period, after which national health  
Service pays for pharmaceutical in  
patients achieving predefined clinical  
response (eg, donepezil)41 
•   individual reimbursement 
–   Patients may be granted individual  
reimbursement of pharmaceuticals not  
on the benefit list if: 
1) no alternative exists 
2)   Requested pharmaceutical is available  
in other European Union states
3) Clinical trials are underway
4)   Pharmaceutical is already reimbursed  
for a different indication96,205
•   Establishment of “innovative medicines  
fund” 
–   Commits 20% of available resources 
to reimbursement of “innovative” 
pharmaceuticals, ranked from most to 
least innovative using the following criteria: 
1)   Treats serious conditions that are  
lifethreatening or cause hospitalization 
or permanent disability
(Continued)ClinicoEconomics and Outcomes Research 2011:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
167
Reimbursement of European health technologies
Table 7 (Continued)
Country Centralized reimbursement  
review/decision-making body  
(role)
Policy options for addressing decision-making uncertainties
Reassessment Value-based pricing/ 
reimbursement
Reimbursement as part  
of a formal study
Risk-sharing schemes/ 
payment by results
Other
         national Authority for health  
Transparency Committee
•   Applies to pharmaceuticals that: 
1) Target a large population; 
2)   May be prescribed outside their  
labeled indications; or
3)   May have a significant impact on health  
care organizations16,20
•   Also applies to medical devices –  
French national Authority for health  
specifies study protocoll20
(ie, improvement in medical benefit) level: 
“improvement in medical benefit” i – 36 months; 
“improvement in medical benefit” ii – 24 months; 
“improvement in medical benefit” iii – 24 months  
at 50%;   and “improvement in medical benefit”  
iV – 24 months at 25%
–   Also applies to “orphan drugs” (eg, eculizumab 
for paroxysmal nocturnal hemoglobinuria and 
galsulfase for mucopolysaccharidosis type Vi)41
germany •   Federal Joint Committee 
(decisions)19
•   institute for Quality and Efficiency  
in health Care (recommendations)19
For medical devices and procedures
•   May provide provisional coverage for  
a set period during which  
“real-world” effectiveness  
and/or economic implications must  
be assessed through a study204
For pharmaceuticals 
Financially based: 
•   Price-volume agreements 
–   “target agreements”: if prescription  
volume target is exceeded by 25%,  
manufacturers must “pay back” sickness  
funds (eg, insulin analogs, olanzapine,  
risperidone, clopidogrel, zolendronate,  
mycophenolic acid, everolimus, and  
cyclosporine)41
•   no reimbursement limit for potentially  
effective technologies used to manage  
life-threatening technologies for which  
there are no alternatives82
greece •   Transparency Committee in the  
Reimbursement and Medicinal  
Products (makes decisions)85
no information found no information found no information found no information found no information found
hungary •   Ministers of health and Finance
•   national health insurance  
Fund Administration  
(recommendations)88,89
no information found no information found no information found Financially based: 
•   Price-volume agreements 
–   12% of reimbursed sales must be paid  
to the Ministry by the manufacturer
–   if Ministry spending on pharmaceutical  
exceeds agreed-to budget, the  
manufacturer must refund the Ministry  
an additional amount based on a  
predefined formula41
no information found
ireland •   Products Committee of Corporate  
Pharmaceuticals Unit of health  
Service Executive (decisions)91,92
no information found no information found no information found no information found no information found
italy •   italian Medicines Agency Technical  
Scientific Committee (decisions)94
•   italian Medicines Agency Pricing  
and Reimbursement Committee  
(recommendations)95
no automatic/routine reassessment, with  
the exception of pharmaceuticals reimbursed  
under condition that additional studies would  
be conducted25
no information found For pharmaceuticals classified as  
“potentially innovative”
•   May require manufacturer to conduct  
additional studies within 3 years
•   Pharmaceuticals for patients enrolled  
in the studies must be covered by the  
manufacturer25
•   have established ongoing registries  
to monitor prescribing and assess  
“therapeutic value” in practice  
(real-world settings) in order to inform  
future management and reimbursed  
pricing decisions (eg, cetuximab,  
lenalidomide, ibritumomab, tiuxetan,  
palifermin, temporfin, and trastuzumab)41
Clinically based: 
•   Pharmaceutical initially reimbursed by  
national health Service at 50% or 100%  
for a fixed number of treatment cycles,  
after which it is only reimbursed for  
patients achieving predefined clinical  
response; manufacturer may be required  
to refund the cost of pharmaceutical  
in non-responding patients (eg, sunitinib,  
sorafenib, dasatinib, and nilotinib)
•   Registries used to track outcomes  
included in scheme47
•   Manufacturer initially provides  
pharmaceutical at no cost for a fixed  
period, after which national health  
Service pays for pharmaceutical in  
patients achieving predefined clinical  
response (eg, donepezil)41 
•   individual reimbursement 
–   Patients may be granted individual  
reimbursement of pharmaceuticals not  
on the benefit list if: 
1) no alternative exists 
2)   Requested pharmaceutical is available  
in other European Union states
3) Clinical trials are underway
4)   Pharmaceutical is already reimbursed  
for a different indication96,205
•   Establishment of “innovative medicines  
fund” 
–   Commits 20% of available resources 
to reimbursement of “innovative” 
pharmaceuticals, ranked from most to 
least innovative using the following criteria: 
1)   Treats serious conditions that are  
lifethreatening or cause hospitalization 
or permanent disability
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Table 7 (Continued)
Country Centralized reimbursement  
review/decision-making body  
(role)
Policy options for addressing decision-making uncertainties
Reassessment Value-based pricing/ 
reimbursement
Reimbursement as part  
of a formal study
Risk-sharing schemes/ 
payment by results
Other
Financially based:
•   Expenditure cap 
–   Cost per patient per year  
cannot exceed a certain amount  
(eg, bevacizumab)41
2)   Used for risk factors for serious  
conditions
3) Used for nonserious conditions25,188
–   if fund is overspent, manufacturers  
participate in refunding the system  
proportional to market share95
norway •   norwegian Medicines Agency 
(recommendations/decisions)34,98
•   Ministry of health and Care Services  
(recommendations/decisions) 
•   Department of Pharmacoeconomics  
(recommendations)98
•   Pharmaceuticals may be reassessed as part  
of ongoing therapeutic class reviews34
no information found no information found no information found •   individual reimbursement 
–   For patients who have exhausted all  
reimbursed alternatives and/or have  
serious or rare conditions 
–   May be requested by specialists only
–   Reimbursement decision made by 
norwegian Labour and Welfare 
Organization
–   Pharmaceutical does not need to have 
obtained market approval34
Poland •   Ministry of health (decisions)99
•   Drug Management Team  
(recommendations)99
no information found no information found no information found no information found no information found
Portugal •   Ministry of health (decisions)
•   inFARMED (recommendations)44,101
no information found no information found no information found Financially based: 
•   Price-volume agreements 
–   growth rate in pharmaceutical  
expenditures fixed per year; if  
exceeded, manufacturers must  
refund the system up to 69.6%  
of the coverage up to a predetermined  
amount, eg, €35 million (2006)44
no information found
Scotland •   national health Service Scotland  
(decisions)30
•   Scottish Medicines Consortium  
(recommendations)
•		 Yes – for all pharmaceuticals
•   Automatic reassessment, but review period  
varies with the pharmaceutical; depends  
upon when additional evidence is expected  
to be available128
no information found no information found no information found no information found
Slovakia •   Ministry of health (decisions)
•   Reimbursement Committee  
for Medicinal Products  
(recommendations)105,106
no information found no information found no information found no information found no information found
Spain •   Ministry of health Directorate  
general of Pharmacy and health  
Products; inter-Ministerial Pricing  
Commission (decisions)21,108
no information found no information found no information found no information found no information found
Sweden •   Dental and Pharmaceutical  
Benefits Board Expert Board  
(decisions)15,206–209
•		 Yes – for all pharmaceuticals
•   Automatic reassessment, but review period  
varies with the pharmaceutical; depends  
upon when additional evidence is expected  
to be available51,135
•   Pharmaceuticals may also be reassessed as  
part of ongoing therapeutic class reviews51,135
•   Reimbursement price 
may be adjusted to reflect 
actual costs and benefits 
once such information 
becomes available  
(eg, continuous 
intraduodenal infusion 
of levodopa/carbidopa 
for advanced Parkinson’s 
disease)209
•   May require submission of evidence  
from studies collecting “real-world” data  
on clinical, economic, and quality of life  
outcomes205,209
no information found no information found
Switzerland •   Swiss Federal Office of Public  
health (decisions)
•   Federal Drug Commission  
(recommendations)113,114
no information found •   “innovation premium” 
–   granted to innovative 
pharmaceuticals 
(ie, therapeutic 
breakthrough products)
no information found no information found no information found
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Table 7 (Continued)
Country Centralized reimbursement  
review/decision-making body  
(role)
Policy options for addressing decision-making uncertainties
Reassessment Value-based pricing/ 
reimbursement
Reimbursement as part  
of a formal study
Risk-sharing schemes/ 
payment by results
Other
Financially based:
•   Expenditure cap 
–   Cost per patient per year  
cannot exceed a certain amount  
(eg, bevacizumab)41
2)   Used for risk factors for serious  
conditions
3) Used for nonserious conditions25,188
–   if fund is overspent, manufacturers  
participate in refunding the system  
proportional to market share95
norway •   norwegian Medicines Agency 
(recommendations/decisions)34,98
•   Ministry of health and Care Services  
(recommendations/decisions) 
•   Department of Pharmacoeconomics  
(recommendations)98
•   Pharmaceuticals may be reassessed as part  
of ongoing therapeutic class reviews34
no information found no information found no information found •   individual reimbursement 
–   For patients who have exhausted all  
reimbursed alternatives and/or have  
serious or rare conditions 
–   May be requested by specialists only
–   Reimbursement decision made by 
norwegian Labour and Welfare 
Organization
–   Pharmaceutical does not need to have 
obtained market approval34
Poland •   Ministry of health (decisions)99
•   Drug Management Team  
(recommendations)99
no information found no information found no information found no information found no information found
Portugal •   Ministry of health (decisions)
•   inFARMED (recommendations)44,101
no information found no information found no information found Financially based: 
•   Price-volume agreements 
–   growth rate in pharmaceutical  
expenditures fixed per year; if  
exceeded, manufacturers must  
refund the system up to 69.6%  
of the coverage up to a predetermined  
amount, eg, €35 million (2006)44
no information found
Scotland •   national health Service Scotland  
(decisions)30
•   Scottish Medicines Consortium  
(recommendations)
•		 Yes – for all pharmaceuticals
•   Automatic reassessment, but review period  
varies with the pharmaceutical; depends  
upon when additional evidence is expected  
to be available128
no information found no information found no information found no information found
Slovakia •   Ministry of health (decisions)
•   Reimbursement Committee  
for Medicinal Products  
(recommendations)105,106
no information found no information found no information found no information found no information found
Spain •   Ministry of health Directorate  
general of Pharmacy and health  
Products; inter-Ministerial Pricing  
Commission (decisions)21,108
no information found no information found no information found no information found no information found
Sweden •   Dental and Pharmaceutical  
Benefits Board Expert Board  
(decisions)15,206–209
•		 Yes – for all pharmaceuticals
•   Automatic reassessment, but review period  
varies with the pharmaceutical; depends  
upon when additional evidence is expected  
to be available51,135
•   Pharmaceuticals may also be reassessed as  
part of ongoing therapeutic class reviews51,135
•   Reimbursement price 
may be adjusted to reflect 
actual costs and benefits 
once such information 
becomes available  
(eg, continuous 
intraduodenal infusion 
of levodopa/carbidopa 
for advanced Parkinson’s 
disease)209
•   May require submission of evidence  
from studies collecting “real-world” data  
on clinical, economic, and quality of life  
outcomes205,209
no information found no information found
Switzerland •   Swiss Federal Office of Public  
health (decisions)
•   Federal Drug Commission  
(recommendations)113,114
no information found •   “innovation premium” 
–   granted to innovative 
pharmaceuticals 
(ie, therapeutic 
breakthrough products)
no information found no information found no information found
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Table 7 (Continued)
Country Centralized reimbursement  
review/decision-making body  
(role)
Policy options for addressing decision-making uncertainties
Reassessment Value-based pricing/ 
reimbursement
Reimbursement as part  
of a formal study
Risk-sharing schemes/ 
payment by results
Other
–   Surcharge of #20% of 
external reference price is 
added for a maximum of 
15 years113,114,205
The  
netherlands
•   Ministry of health, Welfare  
and Sport (decisions)
•   Dutch healthcare insurance  
Board Committee of the Dutch  
healthcare insurance Board  
(recommendations)31
•		 Yes – for all pharmaceuticals
•   Automatic reassessment – time period not  
specified31,210,211
no information found new inpatient pharmaceuticals with  
projected costs .5% of hospital budget 
•   granted provisional reimbursement  
for 3 years, during which studies  
collecting “real-world” data on  
cost-effectiveness must be conducted119 
high-cost pharmaceuticals for rare  
conditions
•   granted provisional reimbursement  
for use in an academic hospital for  
4 years, during which manufacturer  
must sponsor studies collecting  
“real-world” data on cost  
effectiveness and budget impact119
no information found no information found
United  
Kingdom
•   national institute for health  
and Clinical Excellence (decisions)
•   Technology Appraisals Committee  
(recommendations)7
•		 Yes – for all technologies
•   Automatic reassessment, but review period  
varies with the pharmaceutical; depends  
upon when additional evidence is expected  
to be available13,29,157
•   Proposed “flexible pricing” 
scheme: 
–   Manufacturers can 
adjust the price of 
a pharmaceutical in 
response to emerging 
additional evidence 
on actual benefit or 
approval of a new 
indication which alters 
the value that the 
pharmaceutical offers to 
patients
–   national institute for 
health and Clinical 
Excellence assesses 
whether new price and 
evidence represents 
“value for money” and 
may veto a new price on 
an existing indication45,48
•   “innovation pass” 
–   Selected “innovative” technologies  
are made available for 3 years, during  
which studies to collect data needed  
to inform standard national institute  
for health and Clinical Excellence  
processes are conducted48
For pharmaceuticals 
“Patient access schemes”42 
Financially based: 
•   Manufacturer proposes discounts  
or rebates to reduce the cost of  
a pharmaceutical to the national health  
Service, thus improving its  
cost-effectiveness 
–   Manufacturer must obtain approval  
for such a scheme from the Department  
of health prior to national institute  
for health and Clinical Excellence  
review29,212–214
•   Expenditure cap 
–   Cost per patient per year cannot  
exceed a certain amount  
(eg, ustekinumab and erlotinib)45 
Clinically based:
•   Manufacturer covers the cost of initial  
fixed number of cycle(s) of treatment,  
after which national health Service pays  
for patients achieving predefined clinical  
response (eg, sunitinib)45
•   national health Service covers the  
cost of initial fixed number of cycles of  
treatment, after which manufacturer  
refunds the cost of treatment in patients  
failing to achieve predefined clinical  
response (eg, bortezomib)40
•   national health Service covers the cost 
 of the pharmaceutical for a fixed period,  
after which the price is reduced or  
refunds are issued to achieve predefined  
iCER (eg, interferon β, glatiramer  
acetate, and azathioprine)45
•   End-of-life medicines guidance 
–   Pharmaceuticals used to extend life by  
at least 3 months for patients with 
less than 24 months to live may be 
reimbursed, even if iCER exceeds 
threshold range37–48
•   Pharmaceuticals for rare conditions  
guidance 
–   May be reimbursed when iCER exceeds  
threshold range if:
–   Target conditions in which incidence  
,7000 patients/year in the UK
–   There is sufficient evidence 
demonstrating that pharmaceutical 
offers substantial average increase in life 
expectancy over alternatives205
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Table 7 (Continued)
Country Centralized reimbursement  
review/decision-making body  
(role)
Policy options for addressing decision-making uncertainties
Reassessment Value-based pricing/ 
reimbursement
Reimbursement as part  
of a formal study
Risk-sharing schemes/ 
payment by results
Other
–   Surcharge of #20% of 
external reference price is 
added for a maximum of 
15 years113,114,205
The  
netherlands
•   Ministry of health, Welfare  
and Sport (decisions)
•   Dutch healthcare insurance  
Board Committee of the Dutch  
healthcare insurance Board  
(recommendations)31
•		 Yes – for all pharmaceuticals
•   Automatic reassessment – time period not  
specified31,210,211
no information found new inpatient pharmaceuticals with  
projected costs .5% of hospital budget 
•   granted provisional reimbursement  
for 3 years, during which studies  
collecting “real-world” data on  
cost-effectiveness must be conducted119 
high-cost pharmaceuticals for rare  
conditions
•   granted provisional reimbursement  
for use in an academic hospital for  
4 years, during which manufacturer  
must sponsor studies collecting  
“real-world” data on cost  
effectiveness and budget impact119
no information found no information found
United  
Kingdom
•   national institute for health  
and Clinical Excellence (decisions)
•   Technology Appraisals Committee  
(recommendations)7
•		 Yes – for all technologies
•   Automatic reassessment, but review period  
varies with the pharmaceutical; depends  
upon when additional evidence is expected  
to be available13,29,157
•   Proposed “flexible pricing” 
scheme: 
–   Manufacturers can 
adjust the price of 
a pharmaceutical in 
response to emerging 
additional evidence 
on actual benefit or 
approval of a new 
indication which alters 
the value that the 
pharmaceutical offers to 
patients
–   national institute for 
health and Clinical 
Excellence assesses 
whether new price and 
evidence represents 
“value for money” and 
may veto a new price on 
an existing indication45,48
•   “innovation pass” 
–   Selected “innovative” technologies  
are made available for 3 years, during  
which studies to collect data needed  
to inform standard national institute  
for health and Clinical Excellence  
processes are conducted48
For pharmaceuticals 
“Patient access schemes”42 
Financially based: 
•   Manufacturer proposes discounts  
or rebates to reduce the cost of  
a pharmaceutical to the national health  
Service, thus improving its  
cost-effectiveness 
–   Manufacturer must obtain approval  
for such a scheme from the Department  
of health prior to national institute  
for health and Clinical Excellence  
review29,212–214
•   Expenditure cap 
–   Cost per patient per year cannot  
exceed a certain amount  
(eg, ustekinumab and erlotinib)45 
Clinically based:
•   Manufacturer covers the cost of initial  
fixed number of cycle(s) of treatment,  
after which national health Service pays  
for patients achieving predefined clinical  
response (eg, sunitinib)45
•   national health Service covers the  
cost of initial fixed number of cycles of  
treatment, after which manufacturer  
refunds the cost of treatment in patients  
failing to achieve predefined clinical  
response (eg, bortezomib)40
•   national health Service covers the cost 
 of the pharmaceutical for a fixed period,  
after which the price is reduced or  
refunds are issued to achieve predefined  
iCER (eg, interferon β, glatiramer  
acetate, and azathioprine)45
•   End-of-life medicines guidance 
–   Pharmaceuticals used to extend life by  
at least 3 months for patients with 
less than 24 months to live may be 
reimbursed, even if iCER exceeds 
threshold range37–48
•   Pharmaceuticals for rare conditions  
guidance 
–   May be reimbursed when iCER exceeds  
threshold range if:
–   Target conditions in which incidence  
,7000 patients/year in the UK
–   There is sufficient evidence 
demonstrating that pharmaceutical 
offers substantial average increase in life 
expectancy over alternatives205
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Table 7 (Continued)
Country Centralized reimbursement  
review/decision-making body  
(role)
Policy options for addressing decision-making uncertainties
Reassessment Value-based pricing/ 
reimbursement
Reimbursement as part  
of a formal study
Risk-sharing schemes/ 
payment by results
Other
Wales •   Ministry for health and Social  
Services (decisions)
•   All Wales Medicines Strategy group  
new Medicines group  
(recommendations)120
•		 Yes – for all pharmaceuticals
•   Automatic reassessment, but review  
period varies with the pharmaceutical;  
depends upon when additional evidence  
is expected to be available174
no information found no information found no information found no information found
considerable debate around definitions/qualifiers (eg, what 
constitutes “last chance”? or by what period of time must 
a technology lengthen survival in order to be regarded as 
“life-extending”?) remains. Finally, the following factors are 
simply listed as criteria/factors by a small proportion of com-
mittees: alignment with government priorities; feasibility; 
and/or risk of off-label use of the technology (Table 6).
In general, systems aim to complete single technology 
reviews within 180 days of submission/identification of 
candidate technology, the time period prescribed by the 
European Union Transparency Directive. Based on tracking 
data, the actual time required appears to depend primarily on 
whether the assessment report accompanies a reimbursement 
application (eg, Belgium) or is undertaken (internally or 
externally) by the system once a technology is identified for 
review (eg, the UK, Table 5). In the latter case, review times 
can be 90 days or less (eg, Denmark and France).20,38
The majority of systems have established mechanisms 
for appealing recommendations or decisions. Briefly, there 
are two main types of disputes, ie, those related to process 
and those amounting to disagreements over the interpreta-
tion of the evidence. In approximately one-third of systems, 
acceptable grounds for appeals are those of the first type only 
(“failed to act in accordance with processes”39). For the most 
part, appeals are heard by an expert panel appointed by the 
respective health care organization or “payer” (eg, Ministry 
of Health, Table 5). Alternatively, they must be filed in an 
administrative court (eg, Germany and Sweden).
Conditional reimbursement enabling 
access to new technologies
Increasingly, reimbursement systems are expressing inter-
est in and/or implementing reimbursement policy options 
that extend beyond the traditional “yes,” “no,” or “yes with 
restrictions” options. Such policy options take the form 
of provisional reimbursement arrangements, in which 
  funding for a technology is provided in the interim while 
evidence needed to make a definitive decision is collected.40 
  Collectively referred to as “Access with Evidence Develop-
ment” (AED) schemes, they have emerged in response to calls 
for mechanisms that balance access to new technologies with 
the need to ensure their safe, effective, and efficient introduc-
tion and use in the health care system. In recent years, these 
calls have heightened, as tension between payers and manu-
facturers, patients, and providers has intensified. Many new 
high-cost technologies are supported by limited, albeit prom-
ising, evidence. Therefore, reimbursement decisions are made 
under conditions of considerable uncertainty, with significant 
risks and consequences of “getting it wrong” (wasted scarce 
resources and poor health outcomes). AED schemes attempt 
to reduce such risks through “managed entry” of new tech-
nologies into everyday clinical practice. There are three main 
types, ie, coverage linked to an outcomes guarantee, cover-
age as part of a study, and automatic reassessment (Table 7). 
Often referred to as “risk-sharing” schemes, “patient access 
schemes,” and “payment by results,” the first type consists of 
contractual arrangements between payers and manufacturers, 
where payment is tied to the achievement of an outcome, be 
it financial or health-related.41,42 Such schemes have been 
employed in approximately one-third of the systems in 
this review (Table 7). They include financially-based price-
volume agreements, where manufacturers must “pay back” 
the cost of sales exceeding those forecasted (eg, Belgium, 
France, Germany, Hungary, Portugal),41,43,44 and expenditure 
caps, in which manufacturers cover the cost of “treatment” 
in patients for whom costs over a fixed time period exceed 
a prespecified amount (eg, Italy, the UK).41,45 Health-related 
risk sharing arrangements, also called “no cure no pay” 
schemes, have been implemented by a smaller proportion of 
systems (Belgium, Denmark, Italy, the UK).41,45–47 Under such 
schemes, continued reimbursement of a technology (usu-
ally a pharmaceutical for a rare disorder or cancer) requires 
evidence of a predefined treatment effect. The second type, 
“coverage as part of a study,” involves provision of interim 
funding by payers in order to conduct studies designed to 
collect specific information needed to fill key evidence gaps. ClinicoEconomics and Outcomes Research 2011:3 submit your manuscript | www.dovepress.com
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Table 7 (Continued)
Country Centralized reimbursement  
review/decision-making body  
(role)
Policy options for addressing decision-making uncertainties
Reassessment Value-based pricing/ 
reimbursement
Reimbursement as part  
of a formal study
Risk-sharing schemes/ 
payment by results
Other
Wales •   Ministry for health and Social  
Services (decisions)
•   All Wales Medicines Strategy group  
new Medicines group  
(recommendations)120
•		 Yes – for all pharmaceuticals
•   Automatic reassessment, but review  
period varies with the pharmaceutical;  
depends upon when additional evidence  
is expected to be available174
no information found no information found no information found no information found
Typically, such evidence gaps relate to the effectiveness and/
or cost implications of the technology in “real world” set-
tings. Funding may be partial (costs of the technology and/or 
health care associated with its use) or full (all health care and 
research costs). This type of scheme constitutes a policy option 
in approximately one quarter of the reimbursement systems, 
the majority of which have mandates that span pharmaceutical 
and nonpharmaceutical technologies (eg, France, Germany, 
the UK, Table 7). Eligible technologies vary across systems, 
but often include those defined as “innovative” (eg, granted 
an “innovation pass” in the UK) and those anticipated to 
significantly impact health care organization budgets (eg, the 
Netherlands).25,48 The third type of AED scheme, “automatic 
reassessment,” comprises a programmed review of a reim-
bursement decision following a fixed period on the “benefit 
list” or when additional evidence is available.49–51 It has become 
a part of the policy framework in half of the reimbursement 
systems included in this review, with most requiring reassess-
ments of all technologies within their decision-making scope 
(Table 7). Despite the appeal of AED schemes, evidence of 
their effectiveness is both limited and mixed. Recent reviews 
have highlighted the challenges involved in both their design 
and implementation.52,53 Such challenges primarily stem from 
the need to reach consensus among stakeholders on the terms 
of the scheme. Often, considerable time and resources have 
been required to resolve disagreements over elements such as 
the value proposition, outcomes to be measured and for what 
period, how the scheme should be funded, and to whom its 
oversight should be handed. Further, negotiations have, in some 
cases, resulted in complex arrangements that failed to generate 
the evidence needed to support a policy decision and/or created 
a significant administrative burden on payers and providers 
involved in its implementation. In an effort to address these 
issues, guidelines for conducting AED schemes, derived from 
international experiences to date, were recently published.53,54 
Moreover, some systems have proposed alternative approaches 
to dealing with decision uncertainties. For example, earlier 
this year, National Institute of Health and Clinical Excellence 
announced a new form of value-based reimbursement termed 
“flexible pricing.”45–48 Under this approach, manufacturers 
adjust the price of a technology (pharmaceutical) in response 
to additional evidence of actual benefit to patients as it emerges. 
The National Institute of Health and Clinical Excellence sub-
sequently assess this evidence, along with the proposed price, 
and determines whether the technology represents “value for 
money.” If a negative opinion is reached, the National Institute 
of Health and Clinical Excellence may veto the proposed price. 
Given the potential benefits of such an approach (eg, reduced 
administrative burden and system resource requirements) it has 
already sparked interest among the National Institute of Health 
and Clinical Excellence’s counterparts across Europe.
Role of manufacturers in steps 
comprising the reimbursement review 
process
Few reimbursement systems have established roles for 
manufacturers beyond referral of a technology for review 
and the opportunity to comment on draft reports and/or 
preliminary recommendations (Table 8). Where “multiple 
technology appraisal” processes exist and assessment reports 
are commissioned or undertaken by the reimbursement sys-
tem, manufacturers may participate in defining the scope 
or protocol of the assessment (France, Germany, the UK) 
or submit information to the group preparing such reports 
(Germany, Ireland, Spain, the UK). Among systems that 
prepare the evaluation report only, about half invite manu-
facturers to contribute information (Scotland, Italy, Sweden, 
the UK, Wales). Involvement of manufacturers otherwise 
appears limited to single examples, eg, able to participate in 
consultations during the assessment (France) or attend review 
committee meetings (Wales).
Conclusion
Centralized reimbursement systems have become an 
important policy tool in many European countries. Their 
introduction has, inarguably, brought greater consistency to ClinicoEconomics and Outcomes Research 2011:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
174
Stafinski et al
Table 8 Comparison of the role of manufacturers in centralized reimbursement processes
Country Centralized  
reimbursement  
review/decision- 
making body (role)
Refer technology  
topics for  
reimbursement 
consideration
Participate in  
defining scope  
and/or protocol  
of assessment
Comment  
on draft  
protocol
Participate in  
consultations  
during  
assessment
Submit information   
to group preparing  
assessment report
Submit information  
to group preparing  
evaluation report
Present views  
during committee 
meetings
Nominate clinical and/or  
patient experts to make  
oral presentation  
to committee
Attend  
committee  
meeting
Comment on  
report and/or draft  
recommendations
Appeal  
recommendations   
or decisions
Austria •   Association of  
Austrian Social  
Security institutions  
(decisions)55
•   Pharmaceutical  
Evaluation Board  
(recommendations)56
Yes n/A n/A n/A n/A no no no no no Yes
Belgium •   Minister of Social  
Affairs (decisions)
•   Drug Reimbursement 
Committee  
(recommendations)9,60
Yes n/A n/A n/A n/A no no no no Yes Yes
Czech  
Republic
•   State institute for  
Drug Control 
(decisions)65,176
Yes n/A n/A n/A n/A no information  
found
no information  
found
no information  
found
no information  
found
no information  
found
Yes
Denmark •   Danish Medicines  
Agency (decisions)68,69,121
•   Reimbursement  
Committee 
(recommendations)68,121
Yes n/A n/A n/A n/A no no no no Yes, if  
recommendation  
is negative
Yes
Estonia •   Ministry of Social  
Affairs (decisions)72
•   Pharmaceuticals  
Committee  
(recommendations)72
Yes n/A n/A n/A n/A no information  
found
no information  
found
no information  
found
no information  
found
no information  
found
no information  
found
Finland •   Pharmaceuticals  
Pricing Board 
(decisions)73,74,76
•   Pharmaceuticals  
Pricing Board  
Expert group  
(recommendations)75
Yes n/A n/A n/A n/A no no no no Yes, if  
recommendation  
is negative
Yes
France •   Ministry for health  
and Social  
Security  
(decisions)20,78
•   French national  
Authority for health  
(recommendations)78
Yes Yes (multiple  
technology  
appraisals) 
n/A (single  
technology  
appraisals)
no Yes (multiple  
technology  
appraisals) 
n/A (single  
technology  
appraisals)
no (multiple  
technology appraisals) 
n/A (single  
technology appraisals)
no no no no Yes Yes
germany •   Federal Joint  
Committee 
(decisions)19
•   institute for  
Quality and Efficiency  
in health Care  
(recommendations)19
no Yes Yes no Yes no no no no Yes Yes (decisions only)
greece •   Transparency  
Committee in the  
Reimbursement and  
Medicinal Products  
(makes decisions)85
Yes n/A n/A n/A n/A no information  
found
no information  
found
no information  
found
no information  
found
no information  
found
no information 
found
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Table 8 Comparison of the role of manufacturers in centralized reimbursement processes
Country Centralized  
reimbursement  
review/decision- 
making body (role)
Refer technology  
topics for  
reimbursement 
consideration
Participate in  
defining scope  
and/or protocol  
of assessment
Comment  
on draft  
protocol
Participate in  
consultations  
during  
assessment
Submit information   
to group preparing  
assessment report
Submit information  
to group preparing  
evaluation report
Present views  
during committee 
meetings
Nominate clinical and/or  
patient experts to make  
oral presentation  
to committee
Attend  
committee  
meeting
Comment on  
report and/or draft  
recommendations
Appeal  
recommendations   
or decisions
Austria •   Association of  
Austrian Social  
Security institutions  
(decisions)55
•   Pharmaceutical  
Evaluation Board  
(recommendations)56
Yes n/A n/A n/A n/A no no no no no Yes
Belgium •   Minister of Social  
Affairs (decisions)
•   Drug Reimbursement 
Committee  
(recommendations)9,60
Yes n/A n/A n/A n/A no no no no Yes Yes
Czech  
Republic
•   State institute for  
Drug Control 
(decisions)65,176
Yes n/A n/A n/A n/A no information  
found
no information  
found
no information  
found
no information  
found
no information  
found
Yes
Denmark •   Danish Medicines  
Agency (decisions)68,69,121
•   Reimbursement  
Committee 
(recommendations)68,121
Yes n/A n/A n/A n/A no no no no Yes, if  
recommendation  
is negative
Yes
Estonia •   Ministry of Social  
Affairs (decisions)72
•   Pharmaceuticals  
Committee  
(recommendations)72
Yes n/A n/A n/A n/A no information  
found
no information  
found
no information  
found
no information  
found
no information  
found
no information  
found
Finland •   Pharmaceuticals  
Pricing Board 
(decisions)73,74,76
•   Pharmaceuticals  
Pricing Board  
Expert group  
(recommendations)75
Yes n/A n/A n/A n/A no no no no Yes, if  
recommendation  
is negative
Yes
France •   Ministry for health  
and Social  
Security  
(decisions)20,78
•   French national  
Authority for health  
(recommendations)78
Yes Yes (multiple  
technology  
appraisals) 
n/A (single  
technology  
appraisals)
no Yes (multiple  
technology  
appraisals) 
n/A (single  
technology  
appraisals)
no (multiple  
technology appraisals) 
n/A (single  
technology appraisals)
no no no no Yes Yes
germany •   Federal Joint  
Committee 
(decisions)19
•   institute for  
Quality and Efficiency  
in health Care  
(recommendations)19
no Yes Yes no Yes no no no no Yes Yes (decisions only)
greece •   Transparency  
Committee in the  
Reimbursement and  
Medicinal Products  
(makes decisions)85
Yes n/A n/A n/A n/A no information  
found
no information  
found
no information  
found
no information  
found
no information  
found
no information 
found
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Country Centralized  
reimbursement  
review/decision- 
making body (role)
Refer technology  
topics for  
reimbursement 
consideration
Participate in  
defining scope  
and/or protocol  
of assessment
Comment  
on draft  
protocol
Participate in  
consultations  
during  
assessment
Submit information   
to group preparing  
assessment report
Submit information  
to group preparing  
evaluation report
Present views  
during committee 
meetings
Nominate clinical and/or  
patient experts to make  
oral presentation  
to committee
Attend  
committee  
meeting
Comment on  
report and/or draft  
recommendations
Appeal  
recommendations   
or decisions
hungary •   Ministers of health  
and Finance
•   national health  
insurance Fund  
Administration  
(recommendations)88
Yes n/A n/A n/A n/A no information  
found
no information  
found
no information  
found
no information  
found
no information  
found
Yes
ireland •   health Service  
Executive  
(decisions)91,92,147
Yes n/A n/A n/A Yes no no no no Yes Yes
italy •   italian Medicines  
Agency Technical  
Scientific Committee  
(decisions)94
•   italian Medicines  
Agency Pricing and  
Reimbursement  
Committee  
(recommendations)95
Yes n/A n/A n/A no Yes no no no Yes no
norway •   norwegian Medicines 
Agency (decisions)98
•   Department of  
Pharmacoeconomics  
(recommendations)98
Yes n/A n/A n/A no information  
found
no information  
found
no information  
found
no information  
found
no information  
found
no information  
found
Yes
Poland •   Ministry of health  
(decisions)99,166
Yes n/A n/A n/A no information  
found
no information  
found
no information  
found
no information  
found
no information  
found
no information  
found
no information 
found
Portugal •   Ministry of health  
(decisions)
•   inFARMED 
(recommendations)36,44
Yes n/A n/A n/A no information  
found
no information  
found
no information  
found
no information  
found
no information  
found
no information 
found
Yes
Scotland •   national health  
Service Scotland  
(decisions)30
•   Scottish Medicines  
Consortium  
(recommendations)
Yes n/A n/A n/A no Yes no no no Yes Yes
Slovakia •   Ministry of health  
(decisions)
•   Reimbursement  
Committee for  
Medicinal Products  
(recommendations)105–107
Yes n/A n/A n/A no information  
found
no information  
found
no information  
found
no information  
found
no information  
found
no information  
found
no
Spain •   Ministry of health  
Directorate general  
of Pharmacy and  
health Products;  
inter-Ministerial  
Pricing Commission  
(decisions)21,108
no no no Yes Yes no no no no no no
Sweden •   Dental and  
Pharmaceutical  
Benefits Board  
Expert Board  
(decisions)10,104,105
Yes n/A n/A n/A n/A Yes Yes no no Yes Yes
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Country Centralized  
reimbursement  
review/decision- 
making body (role)
Refer technology  
topics for  
reimbursement 
consideration
Participate in  
defining scope  
and/or protocol  
of assessment
Comment  
on draft  
protocol
Participate in  
consultations  
during  
assessment
Submit information   
to group preparing  
assessment report
Submit information  
to group preparing  
evaluation report
Present views  
during committee 
meetings
Nominate clinical and/or  
patient experts to make  
oral presentation  
to committee
Attend  
committee  
meeting
Comment on  
report and/or draft  
recommendations
Appeal  
recommendations   
or decisions
hungary •   Ministers of health  
and Finance
•   national health  
insurance Fund  
Administration  
(recommendations)88
Yes n/A n/A n/A n/A no information  
found
no information  
found
no information  
found
no information  
found
no information  
found
Yes
ireland •   health Service  
Executive  
(decisions)91,92,147
Yes n/A n/A n/A Yes no no no no Yes Yes
italy •   italian Medicines  
Agency Technical  
Scientific Committee  
(decisions)94
•   italian Medicines  
Agency Pricing and  
Reimbursement  
Committee  
(recommendations)95
Yes n/A n/A n/A no Yes no no no Yes no
norway •   norwegian Medicines 
Agency (decisions)98
•   Department of  
Pharmacoeconomics  
(recommendations)98
Yes n/A n/A n/A no information  
found
no information  
found
no information  
found
no information  
found
no information  
found
no information  
found
Yes
Poland •   Ministry of health  
(decisions)99,166
Yes n/A n/A n/A no information  
found
no information  
found
no information  
found
no information  
found
no information  
found
no information  
found
no information 
found
Portugal •   Ministry of health  
(decisions)
•   inFARMED 
(recommendations)36,44
Yes n/A n/A n/A no information  
found
no information  
found
no information  
found
no information  
found
no information  
found
no information 
found
Yes
Scotland •   national health  
Service Scotland  
(decisions)30
•   Scottish Medicines  
Consortium  
(recommendations)
Yes n/A n/A n/A no Yes no no no Yes Yes
Slovakia •   Ministry of health  
(decisions)
•   Reimbursement  
Committee for  
Medicinal Products  
(recommendations)105–107
Yes n/A n/A n/A no information  
found
no information  
found
no information  
found
no information  
found
no information  
found
no information  
found
no
Spain •   Ministry of health  
Directorate general  
of Pharmacy and  
health Products;  
inter-Ministerial  
Pricing Commission  
(decisions)21,108
no no no Yes Yes no no no no no no
Sweden •   Dental and  
Pharmaceutical  
Benefits Board  
Expert Board  
(decisions)10,104,105
Yes n/A n/A n/A n/A Yes Yes no no Yes Yes
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Country Centralized  
reimbursement  
review/decision- 
making body (role)
Refer technology  
topics for  
reimbursement 
consideration
Participate in  
defining scope  
and/or protocol  
of assessment
Comment  
on draft  
protocol
Participate in  
consultations  
during  
assessment
Submit information   
to group preparing  
assessment report
Submit information  
to group preparing  
evaluation report
Present views  
during committee 
meetings
Nominate clinical and/or  
patient experts to make  
oral presentation  
to committee
Attend  
committee  
meeting
Comment on  
report and/or draft  
recommendations
Appeal  
recommendations   
or decisions
Switzerland •   Swiss Federal Office of 
Public health  
(decisions)
•   Federal Drug  
Commission 
(recommendations)113,114
Yes n/A n/A n/A n/A no information  
found
no information  
found
no information  
found
no information  
found
no information  
found
Yes
The  
netherlands
•   Ministry of health,  
Welfare and Sport  
(decisions)
•   Dutch healthcare  
insurance Board  
Committee of the  
Dutch healthcare  
insurance Board  
(recommendations)31
Yes n/A n/A n/A n/A no no no no no Yes
United  
Kingdom
•   national institute for  
health and Clinical  
Excellence (decisions)
•   Technology  
Appraisals Committee  
(recommendations)7
Yes Yes (multiple  
technology  
appraisals) 
n/A (single  
technology  
appraisals)
no (multiple  
technology 
appraisals) 
n/A (single  
technology  
appraisals)
no (multiple  
technology  
appraisals) 
n/A (single  
technology  
appraisals)
Yes (multiple  
technology appraisals) 
n/A (single  
technology appraisals)
Yes (single technology  
appraisals) 
n/A (single technology  
appraisals)
no Yes no Yes Yes
Wales •   Ministry for health  
and Social Services  
(decisions)
•   All Wales Medicines  
Strategy group  
(recommendations)120
Yes n/A n/A n/A n/A Yes no no Yes Yes Yes
processes and an improved sense of legitimacy to decisions. 
Nevertheless, there remains a lack of transparency around 
critical elements, such as how multiple factors or criteria are 
weighed during committee deliberations. Further, empirical 
studies evaluating the extent to which centralized reimburse-
ment systems with advisory as opposed to decision-making 
authority are able to reduce inequities in access to new 
technologies within jurisdictions appear sparse.
Given the rapid pace with which new technologies that 
appear promising are now entering the market and the need 
to work alongside broader government industrial policies for 
encouraging innovation in an economic climate that demands 
prudent use of strained health care resources, the adoption of 
AED schemes by reimbursement systems seems inevitable. 
However, until more information on the outcomes of initia-
tives such as flexible pricing in the UK becomes available, 
their implementation should be approached with caution.
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